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Abstract 
The induction of pain states is known to involve changes in gene expression in DRGs 
and spinal dorsal horn. These changes lead to plasticity in both peripheral and central 
pathways in the form of peripheral and central sensitisation, which contribute to the full 
manifestation of pain states. 
 
Strong evidence exists to implicate the regulation of pain states by epigenetic 
mechanisms.  Histone modification contributes to long-term plasticity and modulation of 
gene expression and histone modifying enzymes have been shown to regulate memory 
formation, a process thought to require neural activity similar to central sensitisation. 
Specifically, both neural processes engage the same molecular events such as 
extracellular signal-regulated kinase (ERK) activity, which induces the histone 
modification phosphorylation of histone H3 at serine 10 (PH3S10) via the nuclear 
mitogen and stress-activated protein kinase (MSK1).  
 
MSK1 has been implicated in various animal models of neural plasticity and PH3S10 is 
a known marker of transcriptional activation, but neither has been investigated 
following noxious stimulation. The aim of this thesis was to use the rat formalin model, 
which induces a biphasic nocifensive behavioural response reflective of peripheral 
nociceptor activation followed by central sensitisation maintained by ongoing peripheral 
input, to investigate the role of histone modifications, in particular PH3S10, in pain 
processing. 
 
This thesis demonstrated using immunohistochemistry that hindpaw formalin 
stimulation caused induction of PMSK1 and PH3S10 in the ipsilateral dorsal horn. 
PH3S10 peaked at 30 minutes and colocalised with markers of the pain pathways 
PERK, NK1, c-Fos, and Zif268. Formalin-induced PMSK1 and PH3S10 were prevented 
by inhibition of upstream ERK activity with the MEK inhibitor SL327. Moreover, 
intrathecal delivery of the MSK1 inhibitor SB747651A prevented full expression of 
PH3S10, and attenuated both phases of the formalin response. These findings are the 
first to elucidate key players involved in ERK/MAPK regulation of pain processing, and 
suggest that histone phosphorylation plays a crucial role in the response to injury.  
 
Graphical Abstract 
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Graphical Abstract 
 
Main findings in this thesis. Box A) Expression of molecular targets investigated in the dorsal horn under naïve, injured, and injured-5-HT-ablated conditions. 
Red box indicates area of investigation. Box B) Percentage colocalisation of formalin-induced PH3S10 population with markers of the pain pathways. Box C) 
Pharmacological inhibition of ERK/MAPK signalling by SL327 led to a reduction in formalin-induced PERK, PMSK1, and PH3S10. In a separate experiment, 
inhibition of MSK1 by SB747651A reduced PH3S10 and prevented the full expression of pain states. Horizontal arrows indicate no change in injury-induced 
expression of molecular targets following drug treatment. Black inhibitory symbols indicate reduction in injury- induced expression of target following 5,7-DHT 
ablation or drug treatment.  
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RSK2 ribosomal s6 kinase/ p70S6K 
RVM rostral ventromedial medulla 
RT room temperature 
SAHA suberoyl anilide hydroxamic acid  
SDS-PAGE sodium dodecyl sulfate - polyacrylamide gel electrophoresis 
SGK1 serum- and glucocorticoid-inducible kinase 1 
SP substance P  
SP-SAP substance P- saporin 
SST somatostatin 
TPH tryptophan hydroxylase 
TRK tyrosine kinase receptor 
TRP transient receptor potential  
TSA trichostatin A 
TSA tyramide signal amplification 
TTBS triton- tris buffered saline 
TTX tetrodotoxin 
VPL ventral posterolateral nucleus (of the thalamus) 
VPM ventral posteromedial nucleus (of the thalamus) 
WT wild type 
 
 
N.B. There is a lack of consistency regarding the nomenclature used for the 
abbreviation of histone modifications. In this thesis the nature of the modification is 
listed first, followed by the specified histone tail, followed by the specific residue and 
position. For example, Phosphorylation of histone H3 at serine 10 would be PH3S10. 
Likewise, Acetylation of histone H4 at lysine 8 would be referred to as AcH4K8.  
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Pain is a complex and subjective experience encompassing both sensory and 
affective-motivational components that are contextually dependent. The International 
Association for the Study of Pain (IASP) describes pain as ‘an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described 
in terms of such damage.’ Somewhat counter-intuitively, pain is ultimately protective, 
and the physiological processes underlying the pain response have in fact been proven 
to have an evolutionarily advantageous outcome in organism survival (Crook et al., 
2014). The generation of unpleasant sensations associated with pain manifest in a 
complex behavioural response that serves as a warning to promote the avoidance of 
further potentially dangerous encounters, in addition to preventing further damage to 
the original site of injury to promote tissue healing. While the inability to feel pain might 
seem enticing, the importance of having an intact pain response is easily highlighted 
through cases of individuals bearing genetic mutations that prevent them from 
appropriately sensing and responding to harmful stimuli, which can lead to a lifetime of 
severe injuries (Cox et al., 2006; Goldberg et al., 2007). 
Negative societal associations/perceptions of pain are not unwarranted as pain can 
adopt a pathological form when it becomes no longer protective and can be extremely 
debilitating. Behaviourally, pain can manifest as touch-evoked pain (allodynia) and/or 
as an exaggerated response to noxious stimulation (hyperalgesia), which can spread 
beyond the original site of injury. Pain can persist beyond the point at which the injury 
has healed, illustrating one example in which pain is not purely sensory-driven as it can 
be experienced even in the absence of obvious tissue damage (Latremoliere and Woolf, 
2009; Scholz and Woolf, 2002). In maladaptive/pathological pain states, pain can arise 
spontaneously and is often chronic in nature. Chronic pain- lasting 3 months or longer- 
is a major problem, with 1 in 5 individuals in Europe having reported moderate to 
severe pain at some point in their lives (Breivik et al., 2006). Furthermore, many of 
these individuals (40%) also report an inadequate management of their pain. Severe 
consequences arise due to the lack of suitable treatments, including compromised 
quality of living and well-being, in addition to economic burden on society (Breivik et al., 
2006; Reid et al., 2011). Thus, a clear and progressive understanding of the 
neurobiological processes underlying normal and aberrant nociceptive processing 
remains ever crucial. In particular, epigenetic mechanisms have been identified as 
potential targets for the regulation of pain processing, because they are required for 
long-term synaptic plasticity and the regulation of gene expression; key characteristics 
necessary for the full expression of persistent pain states. 
The contents of this General Introduction will firstly illustrate the classification of pain 
types and underlying neurobiology and neurophysiology of pain processing. 
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Subsequently, the field of neuroepigenetics will be introduced and a case for 
neuroepigenetic regulation of pain states will be made. 
 
1.1 Classification of pain types 
It is useful to understand the different types of pain that exist. Pain can be separated 
into three categories (Scholz and Woolf, 2002; Woolf, 2010), described below.  
Nociceptive pain 
Nociception is the ability of the nervous system to encode noxious stimuli (International 
Association for the Study of Pain). Nociceptive pain describes the normal, protective 
response to intense, high-threshold noxious stimuli that elicits a physiological response 
(i.e. withdrawal reflex, unpleasant sensory and emotional sensation) which serves as a 
warning system to limit further damage to the body.  
Inflammatory pain 
Inflammatory pain concerns hypersensitivity as a result of tissue damage, which is 
mediated by the immune response-driven release of inflammatory mediators, also 
collectively called the ‘inflammatory soup’ (Basbaum et al., 2009; Julius and Basbaum, 
2001). Inflammation is an attempt to initiate repair at the site of injury, and inflammatory 
pain is considered an adaptive, protective pain. If inflammatory pain is persistent 
following tissue injury, it can become maladaptive in nature. 
Maladaptive/pathological pain 
When pain no longer serves a protective function it adopts a maladaptive/pathological 
state, indicating aberrant nociceptive processing and a ‘disease state of the nervous 
system’ (Woolf, 2010). Pathological pain can occur following injury (i.e. neuropathic 
pain), but also in the absence of any obvious injury or noxious stimuli (i.e. fibromyalgia, 
irritable bowel syndrome).  
1.2 Nociceptive pathways 
The nociceptive pathways involve a network of peripheral and central nervous system 
relay components, which can demonstrate extensive plasticity in response to noxious 
input (Figure 1.1). The peripheral and central mechanisms of nociception and pain 
processing are described below; plasticity-related sensitisation processes are 
described subsequently in 1.3. 
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Figure 1.1 Nociceptive pathways. Information encoding noxious stimulation is relayed from 
the periphery (skin, viscera, and joints) to the central nervous system (spinal cord, brain).  
 
1.2.1 Nociceptors  
A subset of sensory fibres responsible for the signal transduction of noxious stimuli, 
called nociceptors, originate from soma housed in DRG or trigeminal ganglion and 
have free endings that innervate peripheral tissues including skin, joints and visceral 
tissue, as well as a central terminus in the dorsal horn. First identified by Sherrington 
(1906, 1903), the primary role of nociceptors is to transduce and relay information 
regarding the nature of noxious stimuli to the spinal cord. The abundance of studies 
that have followed in the past century has determined that primary afferent nociceptors 
have different properties and respond to different modalities.  
The majority of nociceptors are small diameter (0.4-1.2m) unmyelinated C-fibres, 
which have a conduction velocity of <2m/s (Woolf and Fitzgerald, 1983). The majority 
of C-fibres are polymodal (73% rat hairy skin), that is, they respond to a variety of 
noxious stimuli- typically mechanical, thermal and chemical stimuli (Bessou and Perl, 
1969; Lynn and Carpenter, 1982).  
A smaller proportion of nociceptors are A-fibres, including both larger diameter (2-5m) 
myelinated Aδ-fibres (conduction velocity of 12-30m/s) (Burgess and Perl, 1967; 
Lawson and Waddell, 1991), as well as myelinated A-fibres (5-14m). Although often 
overlooked due to the fact that there are no distinctive differences in conduction 
velocities between Aδ and A-fibres, in the rat, A-fibres have been reported to 
comprise more than 50% of A-fibre nociceptors, and 20% of the A-fibre population are 
nociceptors (Djouhri and Lawson, 2004). Functionally, A-fibre nociceptors can be 
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classified by their response to mechanical and thermal stimulation. Some A-fibre 
nociceptors are high threshold mechanoreceptors (20% in rat hairy skin), although the 
majority respond to noxious thermal stimulation as well (Djouhri and Lawson, 2004; 
Lynn and Carpenter, 1982). In primates, heat-responsive A-fibre nociceptors can be 
separated into two groups defined by action potential firing in response to noxious heat, 
specifically, Type I-mechano-heat Aδ and A-fibres (low mechanical, higher heat 
thresholds), and type II-mechano-insensitive Aδ-fibres (higher mechanical, lower heat 
thresholds; mediate first response to heat) (Treede et al., 1998). A group of capsaicin-
insensitive Type I fibres and A-fibre high threshold mechanoreceptors are primarily 
responsible for pinprick pain, and central sensitisation occurring from this peripheral 
input underlies mechanical secondary hyperalgesia (Magerl et al., 2001). 
The remaining majority of non-nociceptive Aδ-fibres are low-threshold 
mechanoreceptors (also called D-hair), although there are a small minority that are low-
threshold thermoreceptors (Djouhri and Lawson, 2004). The majority of non-
nociceptive A-fibres respond to tactile low-threshold mechanical stimuli such as touch 
(also called A-LTMRs) (Menétrey et al., 1977) and also play an important role in 
pathological pain states (Lu et al., 2013; Torsney and MacDermott, 2006). There is also 
a group of C-LTMR which respond to low intensity, slow moving tactile stimulation, and 
play a role in mechanical hypersensitivity following injury (Bessou et al., 1971; Seal et 
al., 2009).  
Due to myelination and conduction properties, Aδ-fibres are responsible for initial fast, 
sharp (pricking) pain, whereas C-fibres are responsible for the slow, dull pain that 
follows (Handwerker and Kobal, 1993). C-fibres respond to noxious mechanical 
stimulation at higher discharge frequencies compared to A-fibres; the latter is thought 
to encode the quality or nature of stimulation whereas the former is thought to encode 
stimulus intensity (Garell et al., 1996).  
In the nociceptive response, the first important function of the nociceptor is the 
transduction of high-intensity noxious stimuli in response to noxious stimulation or 
tissue damage. Transduction of sensory stimuli occurs via a variety of transducer 
ligand-gated ion channels and G-protein coupled receptors (GPCRs) in the surface of 
the peripheral terminal, and lead to influx of calcium upon activation (Figure 1.2). The 
inward current generated by transducer activation may be sufficient to generate action 
potential firing, which initiates the relay of the nociceptive response to the central 
nervous system and encodes information about the activating stimulus. Importantly, the 
specific distribution of ion channels and GPCRs are responsible for the sensory 
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modality specificity of nociceptors, for example noxious heat, mechanical, or chemical 
stimuli (Ramsey et al., 2006).  
There are a family of nine voltage gated sodium channels (Nav1.1-1.9) that have been 
shown to play a crucial role in nociceptive signalling (Raouf et al., 2010) (Figure 1.2). 
Sufficient activity-driven membrane depolarisation due to transducer activation causes 
voltage gated sodium channels to activate, which in turn conduct the flow of Na+ ions 
into the neuron, leading to the depolarisation upstroke of the action potential. The use 
of genetically modified mice in particular have contributed to the proven role of sodium 
channels in pain processing; Mice deficient in Nav1.7 (SCN9A) in peripheral 
nociceptors have impairments in acute mechanical and heat nociception, and 
inflammatory pain (Nassar et al., 2004). Behavioural responses to neuropathic pain, 
however, are unaffected (Minett et al., 2012). Interestingly, deletion of SCN9A in 
sympathetic as well as sensory neurons leads to a pain-free phenotype, indicating an 
important role for Nav1.7-expressing sympathetic neurons in neuropathic pain 
conditions (Minett et al., 2012). Similarly, mice genetically deficient for the TTX-
resistant sodium channel Nav1.8 exhibit altered responses to noxious mechanical and 
thermal stimuli, and show delayed onset of inflammatory hyperalgesia (Abrahamsen et 
al., 2008; Akopian et al., 1999; Papadatos et al., 2002). In humans, loss-of-function 
mutations in SCN9A can lead to pain insensitivity and thus severe injuries due to the 
inability to detect harmful stimuli (Cox et al., 2006; Goldberg et al., 2007). Conversely, 
SCN9A gain-of-function mutations are associated with pain syndromes such as 
paroxysmal extreme pain disorder or erythromelalgia, the latter of which is often 
characterised by a burning sensation of the limbs (Bennett and Woods, 2014). Due to 
their importance in nociception, sodium channels in particular Nav1.7, have been of 
interest as pharmacological targets for the treatment of inflammatory and neuropathic 
pain (England and de Groot, 2009; Lee et al., 2014; McCormack et al., 2013; Nardi et 
al., 2012; Yang et al., 2013).  
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Figure 1.2 Activity of the nociceptor. Adapted from Neuron, Vol 55, Woolf C.J. and Ma Q., 
Nociceptors- Noxious Stimulus Detectors, pp. 353-364, Copyright (2007), with permission from 
Elsevier. A variety of ligand-gated ion channels in the peripheral terminal mediate the 
transduction of noxious stimuli. The transient-receptor-potential (TRP) channels are a group of 
non-selective cation channels with polymodal activation properties that mediate the response to 
noxious heat, pressure, or specific molecules/chemicals. TRPV1 has polymodal properties, it is 
the receptor for capsaicin and allicin among other molecules and is also activated by noxious 
heat (above 42˚C) and plays a role in inflammation and thermal hyperalgesia (Caterina et al., 
2000, 1999; Davis et al., 2000). TRPV2, TRPV3, and TRPV4 mediate the nociceptive response 
to heat (Dhaka et al., 2006). TRPM8 mediates innocuous cooling, or cooling by agents such as 
menthol (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007). TRPA1, expressed in a 
subgroup of unmyelinated peptidergic TRPV1-expressing nociceptors, is activated by noxious 
cold (<17C) although this is controversial (Bandell et al., 2004; Bautista et al., 2006; Fajardo et 
al., 2008; Karashima et al., 2009; Kwan et al., 2009, 2006; Story et al., 2003). TRPA1 is also 
polymodal in activation, and responds to allyl isothiocyanate and allicin, among other agents, 
and mechanotransduction. Additional ligand gated ion channels mediating the transduction of 
noxious stimuli include acid-sensing ion channels (ASICs), activated by protons released in 
tissue acidosis following injury (Deval et al., 2010), and P2X receptors that activate in response 
to binding of ATP which is abundant in tissues post-injury (Chizh and Illes, 2001; Ding et al., 
2000). The more recently identified mechanically activated PIEZO ion channels also play a key 
role in mechanosensory nociception (Coste et al., 2013, 2010; Kim et al., 2012), as well as 
nerve injury-induced mechanical allodynia (Eijkelkamp et al., 2013). PIEZO is also found in 
merkel cells and plays a key role in the slowly adapting merkel cell mediated response to non-
noxious touch mechanosensation (Woo et al., 2014).  
 
Classification by signalling molecules used in central neurotransmission  
Propagation of an action potential along the axon of the nociceptor and its entry into 
the central terminal will lead to calcium influx into the terminal and subsequent 
neurotransmitter release into the dorsal horn (Neher and Sakaba, 2008). Glutamate is 
the main fast excitatory neurotransmitter used by all primary afferents, although other 
signaling molecules are released in addition, depending on fibre type.  
Quite usefully, nociceptors can be neurochemically grouped by the type of peptide 
neurotransmitters that they release at their central terminals. In particular, nociceptors 
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can be separated into two groups, peptidergic and non-peptidergic, which indicate that 
one group of nociceptors synthesize peptide molecules such as substance P (SP) and 
calcitonin-gene related peptide (CGRP) as signaling molecules (Hunt and Rossi, 1985; 
Nagy and Hunt, 1982). Importantly, the peptidergic and non-peptidergic categories of 
nociceptors differ in their expression patterns of ion channels and receptors (Chen et 
al., 2006; Woolf and Ma, 2007), and have different patterns of peripheral and central 
terminal target innervation (Braz et al., 2005; Zylka et al., 2005). Specifically, non-
peptidergic C-fibres are localised superficially in peripheral target innervations, 
terminating in the epidermis of the skin, while peptidergic C-fibres, including some 
peptidergic Aδ fibres (Lawson et al., 1997), terminate in deeper tissues (Todd, 2010). 
The identity of these fibres is determined in embryonic development [E12.5-P14]. In 
particular, TrkA-positive peptidergic neurons go on to express neuropeptides SP and 
CGRP (Chen et al., 2006), undergo downregulation of Runx1 and require NGF for 
survival. The receptor tyrosine kinase RET appears to downregulate TrkA in the non-
peptidergic neurons, and survival of the non-peptidergic population depends on glial 
cell line-derived neurotrophic factor (GDNF) signaling (Molliver et al., 1997). 
Importantly, the non-peptidergic nociceptor population can be identified 
immunohistochemically by the ability to bind isolectin B4 (IB4) (Plenderleith and Snow, 
1993), and when characterised by their electrophysiological properties are functionally 
distinct from non-IB4 positive nociceptors (Stucky and Lewin, 1999). It is important to 
note that roughly 75% of all IB4 positive neurons also express the mas-related G-
protein coupled receptor member D (Mrgprd) (Dong et al., 2001), which is particularly 
useful for genetic targeting of the non-peptidergic, unmyelinated C-fibre population 
(Cavanaugh et al., 2009; Shields et al., 2010; Zhang et al., 2013). The selective 
ablation of Mrgprd results in the loss of noxious mechanical but not thermal sensitivity 
(Cavanaugh et al., 2009; Zhang et al., 2013).  
1.2.2 Spinal cord: first central hub of nociceptive activity modulation  
Primary afferent nociceptors project to the dorsal horn of the spinal cord, the first key 
synapse of the pain pathway. The dorsal horn is a crucial site of the pain pathway, and 
a key structure where incoming nociceptive activity is modulated by a complex network 
of synaptic circuits. It is from the dorsal horn that transmission of nociceptive activity to 
the brain occurs, where pain is ultimately experienced. Dorsal horn activity is also 
subject to modulation by descending activity from the brain, which will be described 
later (see 1.2.3).  
1.2.2.1 Central termination of primary afferents and dorsal horn circuitry 
The grey matter of the dorsal horn is organised in a laminar fashion with a total of ten 
layers, originally described by Rexed in cat spinal cord (1954, 1952) (Figure 1.3). This 
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organisation is conserved in the rat (Molander et al., 1989, 1984), and includes a 
somatotopic distribution which relates to peripheral innervations of primary afferent 
fibres (Molander and Grant, 1986; Swett and Woolf, 1985). The majority of primary 
afferents terminate in the dorsal horn ipsilaterally, although some may project 
contralaterally (Culberson et al., 1979).  
Central terminals of Aδ and C-nociceptors terminate in the most superficial layers of 
the dorsal horn, laminae I-II. Peptidergic C and Aδ-fibres terminate in laminae I-II outer 
(IIo), while non-peptidergic IB4 positive C-fibres, the majority of which can also be 
identified as Mrgprd positive, terminate primarily in inner lamina II (Iii) (Lorenzo et al., 
2008; Snider and McMahon, 1998; Todd, 2010).  SP-expressing nociceptors terminate 
within lamina I and IIo. Additionally, a small subset of unmyelinated C-fibres conveying 
tactile cutaneous sensory input, called C low-threshold mechanoreceptors (LTMR) 
have been identified, and terminate in lamina II (Liu et al., 2007; Seal et al., 2009). 
Deeper laminae IIi-V are primarily occupied by LTMR arborisations; specifically, A 
tactile and hair follicle afferents primarily terminate within laminae III-V, and Aδ hair 
follicle afferents terminate within laminae Iii-III (Brown et al., 1981; Light and Perl, 1979; 
Shortland et al., 1989; Todd, 2010) (Figure 1.3). The majority of cells in lamina V are 
wide-dynamic range neurons that receive polymodal input and respond to all 
somatosensory modalities including mechanical, thermal and chemical stimuli (Mendell, 
1966). 
 
Figure 1.3 Termination of primary afferent fibres in the dorsal horn of the spinal cord. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience, Vol 11, 
Todd, A.J., Neuronal circuitry for pain processing in the dorsal horn, pp. 823–836, copyright 
(2010). 
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Interneurons 
The majority of primary afferents synapse onto interneurons, which have local dendritic 
arborisations and axon projections within dorsal horn laminae I-III (Todd, 2010). 
Interneurons are either inhibitory or excitatory depending on their main 
neurotransmitter, which is glycine and/or GABA, or glutamate, respectively. In the rat 
spinal cord, GABA is present in 25 and 30% of lamina I and II neurons, respectively 
(Polgár et al., 2003), and glycinergic neurons in laminae I-II predominantly co-express 
with the GABAergic population (Polgár et al., 2003; Todd and Sullivan, 1990). Due to 
the complexity of spinal cord circuitry, it is likely that all spinal cord neurons receive 
primary afferent input, as well as input from both inhibitory and excitatory interneurons 
(Todd, 2010).  
Interneurons constitute the majority of neurons in lamina I and III, and nearly all of the 
neurons in lamina II. Indeed, lamina II interneurons have been the most extensively 
studied. Lamina II interneurons can be categorised based on their neurochemical 
identity, dendritic morphology (islet, radial, central, vertical neurons), or 
electrophysiological properties in response to stimuli (Grudt and Perl, 2002; Todd, 
2010). Islet and central cells are innervated primarily by C-fibres; radial and vertical 
cells are innervated by C and Aδ-fibres. While there are correlations between 
interneuron dendritic morphology and neurotransmitter identity (GABA/Glycinergic, 
Glutamatergic), this is not completely straightforward. Further, there is little correlation 
between dendritic morphology and firing patterns; firing pattern is more closely 
correlated with neurotransmitter (Todd, 2010); for example, Kv4 mediated A-type 
potassium currents can be found exclusively in glutamatergic interneurons (Yasaka et 
al., 2010).  
When using immunohistochemistry to identify interneurons, it is difficult to achieve 
immunostaining for GABA or glutamatergic cell bodies. Therefore, recent studies have 
taken to identifying interneurons using a neurochemical approach. Neuropeptide Y 
(NPY), galanin, parvalbumin (PV), and nNOS are four neurochemical markers known 
to label GABAergic interneurons, with the latter two also labelling cotransmitting GABA 
and glycinergic interneurons (Laing et al., 1994; Polgár et al., 2011; Sardella et al., 
2011; Tiong et al., 2011). The appeal of using these four markers is that they are easily 
identifiable using IHC, and are non-overlapping populations with some functional 
distinctiveness in response to stimuli (Polgár et al., 2013).  Conversely, the proteins 
somatostatin (SST), neurotensin, calretinin, SP, NKB, and for the most part calbindin 
and PKC can be used to label glutamatergic excitatory interneurons. PKC in 
particular is expressed by a set of neurons in lamina II inner and lamina III; these cells 
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receive input from low threshold mechanoreceptors (Lu et al., 2013; Malmberg et al., 
1997; Miraucourt et al., 2007; Neumann et al., 1996). 
Lamina I interneurons are less well-studied, although they have also been identified by 
morphology (fusiform, pyramidal, multipolar) (Han et al., 1998; Lima and Coimbra, 
1986). Notably, however, this classification does not distinguish interneurons from the 
very important lamina I projection neuron population (Todd, 2010).   
 
Projection Neurons 
Activity from the dorsal horn is relayed supraspinally via projection neurons, many of 
which have axons that cross the midline and project rostrally through the spinal white 
matter to key brain areas involved in pain processing. The majority of lamina I 
projection neurons respond to noxious stimulation, although a few respond to 
innocuous cooling (Andrew, 2009; Bester et al., 2000; Han et al., 1998; Willis et al., 
1974; Zhang and Giesler, 2005). 
Lamina I contains a higher density of projection neurons than that observed in any 
other laminae of the spinal cord expressing projection neurons (III-VI) (Todd, 2010). 
However, to gain perspective of this limited population of neurons, it has been shown 
that only 5% of all lamina I neurons are projection neurons (Bice & Beal 1997b; Bice & 
Beal 1997a; Spike et al. 2003; Al-Khater & Todd 2009).  
Neurochemically, the neurokinin-1 receptor (NK1) has long been of interest due to the 
fact that 80% of lamina I projection neurons are known to express this receptor. NK1 
however, is not restricted to projection neurons and is found to also label excitatory 
interneurons albeit to a lesser degree than projection neurons (Al Ghamdi et al., 2009; 
Littlewood et al., 1995). Importantly, toxin-conjugated ablation techniques have 
revealed that NK1 positive projection neurons are known to play a key role in 
neuropathic and inflammatory pain processing (further discussed in Chapter 4) (Mantyh 
et al., 1997; Nichols et al., 1999). NK1 projection neurons are also present in laminae 
III-IV, and have dendrites that project superficially into lamina I (Naim et al., 1997; Todd 
et al., 2000)  
A class of NK1 negative projection neurons, called giant cells, are sparse in existence 
(1-2% of lamina I projection neurons) and are predominantly spinothalamic (Polgár et 
al., 2008; Puskár et al., 2001). Supraspinal targets of projection neurons will be 
discussed below in 1.2.2.2. 
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Inputs to Projection Neurons  
Studies have found that lamina I NK1 positive projection neurons receive monosynaptic 
glutamatergic C and Aδ-fibre input (Torsney and MacDermott, 2006) from peptidergic 
primary afferents, the majority of which contain SP (Lawson et al., 1997; Naim et al., 
1997; Todd et al., 2002) (Figure 1.4). Importantly, after peripheral inflammation, 
monosynaptic Aδ-fibre input is increased, contributing to C-fibre-induced 
heterosynaptic facilitation at lamina I NK1 positive neurons, and potentially underlying 
states of hypersensitivity (Torsney, 2011).  
NK1 negative lamina I giant cell projection neurons do not receive much direct input 
from peptidergic primary afferents. They do however, have a high density of both 
glutamatergic and GABAergic synapses, labelled by the vesicular glutamate 
transporter 2 (VGLUT2) and nNOS/GABA, respectively (Polgár et al., 2008), supporting 
the finding that lamina I neurons are under permanent GABAergic interneuron control 
(Dahlhaus et al., 2005; Seagrove et al., 2004). 
 
Figure 1.4 Inputs to projection neurons. Although describing only a limited picture of dorsal 
horn circuitry, the figure above indicates the major inputs to lamina I and III NK1 projection 
neurons (~80% of lamina I projection neurons are NK1 positive). The great majority of input to 
non-NK1 projection neurons is from polysynaptic Aδ- and A-fibres (not pictured) (Torsney and 
MacDermott, 2006). Red boxes indicate projection neurons. Adapted by permission from 
Macmillan Publishers Ltd: Nature Reviews Neuroscience, Vol 11, Todd, A.J., Neuronal circuitry 
for pain processing in the dorsal horn, pp. 823–836, copyright (2010). 
 
Chapter 1 General Introduction 
 
 32 
1.2.2.2 Ascending projections/pathways and supraspinal centres 
Projection neurons can be identified using the injection of retrograde tracers into 
supraspinal targets, a technique first utilised by Trevino and Carstens (1975) and 
currently along with anterograde tracing, the most reliable way to confirm a neuronal 
projection neuron identity. Importantly, experiments identifying lamina I projection 
neurons using the retrograde tracer technique have shown that there are roughly 400 
projection neurons on each side of the spinal cord within the lumbar L4 segment (Al-
Khater and Todd, 2009). In general, the ascending circuits originating in lamina I 
projection neurons differ from those originating in deeper laminae III-V (Gauriau and 
Bernard, 2002).  
A major target of lamina I projection neurons is the lateral parabrachial area (LPb), 
which contains neurons that subsequently project to the amygdala and hypothalamus 
of the limbic system. In the rat, 95% of lamina I projection neurons in the lumbar L4 
region terminate in the LPb (Al-Khater et al., 2008; Spike et al., 2003; Todd et al., 
2000). Additionally, the other main targets of lamina I projection neurons, include the 
caudal ventrolateral medulla (CVLM), nucleus of the solitary tract (NTS), the 
periaqueductal grey matter (PAG), and lateral thalamus/thalamic nuclei including the 
ventral posterior nuclei (including VPL, VPM), which project to the somatosensory and 
insular cortices (Al-Khater et al., 2008; Gauriau and Bernard, 2004) (Figure 1.5). 
Projection neurons in deeper laminae III-IV have also been found to project to the 
thalamus, primarily to the central lateral nucleus in the medial (anterior) thalamus which 
subsequently sends projections to the anterior cingulate cortex (ACC) (Gauriau and 
Bernard, 2004; Marshall et al., 1996; Naim et al., 1997). The majority (>90%) of lamina 
III projection neurons in L4 have been found to project to the contralateral reticular 
nuclei, and a little more than half to the LPb (Todd et al., 2000). The range of 
supraspinal projection neuron targets indicates the diversity of structures involved in 
the pain response, including those responsible for emotional/affective processing 
(limbic structures amygdala, hypothalamus, insular cortex) and sensory/discriminative 
processing (somatosensory cortex). Moreover, tracer studies of projection neurons 
have indicated that ascending projections to the brain exhibit extensive collateralisation, 
meaning that each fibre projects to more than one target (Al-Khater and Todd, 2009). 
The majority of these projections project contralaterally, although some do project 
bilaterally (Spike et al., 2003).  
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Figure 1.5 Supraspinal pathways to and from the dorsal horn.  
 
Supraspinal centres 
Dorsal horn projection neurons allow activity generated by nociceptive transmission to 
reach the brain, where perception of the pain experience occurs. Studies utilising 
human functional neuroimaging techniques have greatly enhanced our knowledge of 
brain structures activated during noxious stimulation. In particular, nociceptive 
stimulation has been found to elicit activity from a network of structures, including the 
primary and secondary somatosensory (S1/S2), insular, anterior cingulate (ACC), and 
prefrontal (PFC) cortices, and thalamus (Apkarian et al., 2005; Tracey and Mantyh, 
2007; Treede et al., 1999) (Figure 1.5). Many studies have implicated the existence of 
a ‘pain matrix,’ a group or signature of structures specific to processing of noxious 
stimuli (Tracey and Mantyh, 2007). However, it has been shown that these structures 
demonstrate activity in response to a variety of sensory modalities rather than 
exclusively to nociceptive somatosensory stimulation (Mouraux et al., 2011). Thus, a 
more recent theory has proposed that the cortical areas activated during noxious 
stimuli represent the recognition of a general threat occurrence to ‘any behaviourally 
relevant or salient stimulus,’ including important responses such as nociception, rather 
than a network specifically attributed for a nociceptive specific response alone (Iannetti 
and Mouraux, 2010; Legrain et al., 2011; Mouraux et al., 2011). Moreover, evidence 
also indicates that the increased activity of brain areas observed during a nociceptive 
event is contextually dependent, and that perceived pain intensity can be dissociated 
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from the magnitude of brain response activity, which further supports the role of brain 
responses that are less tuned to sensory modality but to the response generated in the 
presence of potential harm (Iannetti and Mouraux, 2010); for example, stress and 
arousal.  
1.2.3 The descending pathway and pain modulation 
The existence of an endogenous inhibitory pain modulation system has long been 
observed, with some of the earliest studies indicating that affective components such 
as stress or anxiety had an effect on the degree of pain reported, necessity for pain 
relief, or latency to report pain following injury (Beecher, 1946; Melzack et al., 1982). It 
is now generally accepted that a top-down modulation of pain exists in the form of a 
number of descending circuits from the brain to the spinal cord, which has provided a 
mechanism through which the brain can enhance or suppress dorsal horn activity and 
the overall pain response (Figure 1.5). In particular, one example that has provided 
evidence for the top-down modulation of the pain response is the activation of cortical 
structures during placebo (Petrovic et al., 2002). The inhibitory system in particular is 
activated by situations inducing stress, primarily through the endogenous opioidergic 
system (Siegfried et al., 1990; Terman et al., 1984).  
The majority of the descending circuits in the brain converge upon the periaqueductal 
grey matter (PAG) (Figure 1.5). In particular, the PAG receives input from the ACC, 
amygdala, and hypothalamus. Rather than sending direct projections to the spinal cord, 
the majority of output from the PAG projects to the rostral ventromedial medulla (RVM) 
(Hunt and Mantyh, 2001). Historically, the role of the PAG in pain modulation was first 
identified through the specific injection of opiates [morphine] into the PAG, an action 
that produced antinociceptive effects in the rabbit (Tsou and Jang, 1964). Further 
studies indicated that direct electrical stimulation of the PAG produced profound 
analgesia in the rat (Reynolds, 1969), and importantly, the application of naloxone 
reversed the effect of stimulation-produced analgesia which indicated the presence of 
an endogenous inhibitory system mediated by opioids (Hosobuchi et al., 1977). Not 
surprisingly, the PAG is an important pharmacological target for opiate-mediated 
analgesia (Herz et al., 1970; Yaksh et al., 1976).  
The RVM is inclusive of the nucleus raphe magnus (NRM) and the nucleus reticularis 
gigantocellularis (GiA), and projects a descending modulatory influence upon the spinal 
cord (Basbaum and Fields, 1979; Fields et al., 1977). The delivery of lidocaine in the 
RVM temporarily reverses allodynia and hyperalgesia induced  as a result of nerve 
injury, and has been implicated in the maintenance but not induction of neuropathic 
pain (Burgess et al., 2002; Vera-Portocarrero et al., 2006). Importantly however, the 
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RVM can have bidirectional inhibitory and facilitatory descending influences on spinal 
nociception (Urban and Gebhart, 1999), activity which has been observed during direct 
electrical stimulation applied to the RVM. In general, low intensities of electrical 
stimulation have been shown to facilitate spinal nociception, while high intensities have 
an inhibitory effect (Urban and Gebhart, 1997; Urban and Smith, 1993; Zhuo and 
Gebhart, 1997, 1992).  
Crucially, the importance of the spino-bulbo-spinal circuit has been highlighted in 
nociception through studies indicating that projection neurons are essential to the full 
activation of molecular pathways in the superficial dorsal horn, via activation of 
descending regulatory controls (Géranton et al., 2008; Suzuki et al., 2002). 
Furthermore, more recently, the activation of descending inhibition has been shown to 
be engaged following nerve injury, and may be an explanation for understanding why 
nerve injury develops into chronic pain in certain subjects (De Felice et al., 2011). 
Descending modulation will also be discussed in Chapter 5. 
1.3 States of sensitisation 
The nervous system is extremely plastic and can undergo many functional changes as 
a result of persistent activity. These activity-induced changes can contribute to a range 
of processes, including cognitive processes such as memory formation and abnormal 
psychiatric states such as depression, schizophrenia, as well as neural function related 
to sensory processes such as visual cortical development (Espinosa and Stryker, 2012; 
Kandel et al., 2014; Tsankova et al., 2007). Activity-induced plasticity of neural function 
also occurs in nociceptive processing (Kuner, 2010; Latremoliere and Woolf, 2009; 
Scholz and Woolf, 2002; Woolf and Ma, 2007; Woolf and Salter, 2000).  
Importantly, the protection provided by nociceptive processing is enhanced by a 
process called sensitisation. Specifically, plasticity of the nociceptive system manifests 
in peripheral and central components, which occurs following repeated or intense 
stimulation, and leads to a reduction in nociceptive thresholds, amplified neural signal, 
and subsequent behavioural hypersensitivity (Latremoliere and Woolf, 2009; Woolf and 
Salter, 2000). Sensitisation is thus an adaptive response and also a key hallmark of the 
nociceptive process; in normal nociceptive processing it can be long-lasting but only 
through to the point of injury healing. Importantly, sensitisation also underlies diseased 
or pathological pain states, such as chronic inflammatory or neuropathic pain, and is 
also responsible for pain states persisting following injury healing or without any 
apparent injury, such as fibromyalgia. 
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1.3.1 Peripheral sensitisation  
Nociceptor plasticity occurs as a result of activity resulting from peripheral inflammation 
or tissue damage. This phenomenon is called peripheral sensitisation, associated with 
a reduction in nociceptor activation threshold which leads to increased excitability and 
enhanced firing to a stimulus of the same intensity, typically in C-fibres. Importantly, 
peripheral sensitisation contributes to the development of both inflammatory and 
neuropathic pain (Hucho and Levine, 2007; Reichling et al., 2013; Reichling and Levine, 
2009); it primarily plays a key role in heat hyperalgesia, not mechanical hyperalgesia, 
the latter of which is a key hallmark of chronic pain conditions. 
A number of inflammatory mediators are released by damaged tissue and immune 
cells, which bind to respective receptors at the nociceptor peripheral terminals and act 
to lower the threshold of the nociceptor and enhance the magnitude of nociceptive 
response. In particular, the ‘inflammatory soup’ released by damaged tissue includes 
peptides (bradykinin), lipids (prostaglandins), neurotransmitters (ATP, 5-HT) and 
trophic factors (NGF, GDNF), as well as protons released due to tissue acidosis (Julius 
and Basbaum, 2001; Woolf and Ma, 2007). Furthermore, the activation of immune 
system leukocytes includes the production of the cytokines tumour necrosis factor α 
(TNFα), interleukins (IL-1, IL-6), and chemokines, as well as the enzyme 
cyclooxygenase-2 (COX-2).  
The binding of inflammatory mediators activates intracellular signalling cascades which 
play an important role in nociceptor hyperexcitability by allowing a cell to respond 
quickly to various extracellular stimuli (Reichling and Levine, 2009; Woolf and Ma, 
2007). Signalling kinases are capable of directly modulating transducer receptor 
subunits on peripheral terminals, activity which can lead to the enhancement of 
sensory stimuli signal transduction. For example, a key mechanism is NGF-induced 
TRPV1 phosphorylation mediated by kinase activity, which can lead to increased 
receptor subunit trafficking and changes in  channel kinetics (Chuang et al., 2001; Ji et 
al., 2002b; Zhang et al., 2005). Importantly, it has been shown that the molecular 
events leading to persistent chronic hyperalgesia are due to a switch in intracellular 
kinase signalling, from protein kinase A (PKA) signalling in acute nociception, to both 
PKA and protein kinase C (PKC) signalling in states of chronicity. Joint signalling 
activity thus maintains a ‘primed’ state of the nociceptor which underlies an 
enhancement of the hyperalgesic response during subsequent injury (Reichling and 
Levine, 2009) 
Peripheral sensitisation can also result in long-term changes due to gene transcription 
at the DRG cell body. Such changes involve the synthesis of neurotransmitters to 
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either enhance central transmission (i.e. BDNF) (Mannion et al., 1999), or the novel 
synthesis of neurotransmitters normally not expressed, for example, a phenotypic 
switch involving the synthesis of SP (Neumann et al., 1996). Alterations in ion channel 
synthesis can also lead to hyperexcitability, such as the increase in voltage gated 
calcium channels, which play a crucial role in regulating the release of 
neurotransmitters at the central terminal (Bourinet et al., 2014; Dolmetsch et al., 2001; 
Ghosh and Greenberg, 1995), or BDNF-induced decrease in potassium channel 
transcription post-nerve injury (Waxman and Zamponi, 2014).  
The reduced threshold and hyperexcitable state of the nociceptor means that normally 
non-noxious stimuli are able to activate what are normally high threshold nociceptors. 
Increased sensitivity for activation can manifest as increases in spontaneous pain, and 
in rats, increased spontaneous lifting of the affected limb (Djouhri et al., 2006). 
Interestingly, spontaneous lifting has been attributed mechanistically to peripheral 
processes as lifting correlates with C-fibre activity, but not with allodynia, which is 
associated with central sensitisation, discussed below. The importance of peripheral 
activity cannot be ignored, and studies have crucially indicated that local anaesthesia is 
capable of attenuating hyperalgesia associated with central sensitisation in various 
pain models (Reichling and Levine, 2009).  
1.3.2 Central sensitisation  
Central sensitisation was first identified by Woolf (1983), and can be understood as 
“increased responsiveness of nociceptive neurons in the central nervous system to 
their normal or subthreshold afferent input” (Sandkühler, 2009). While peripheral 
sensitisation contributes to the initiation of central pathway sensitisation, it is restricted 
to fibres innervating the injured area, and maintenance typically requires ongoing 
peripheral input or injury. Certain aspects of pain such as secondary hyperalgesia, 
allodynia, and pain that is uncoupled to stimulus presence, intensity, or duration 
(including pain without apparent injury) cannot be accounted for by peripheral 
mechanisms alone (Latremoliere and Woolf, 2009). Central sensitisation recruits novel, 
normally non-nociceptive input to contribute to hypersensitivity associated with pain 
states. Central sensitisation occurs following repeated and sustained intense 
stimulation, and can be maintained with or without apparent injury/cause, leading to an 
abnormal state of responsiveness of the nociceptive system (Woolf, 1983; Woolf and 
Salter, 2000).  
The cellular processes underlying central sensitisation can be identified as increased 
membrane excitability, facilitation of synaptic strength, and disinhibition of nociceptive 
circuits (Latremoliere and Woolf, 2009).  
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1.3.2.1 Induction of central sensitisation 
Central sensitisation via post-synaptic mechanisms occurs as a result of noxious C-
fibre stimulation that leads to the activity of a number of cell-surface receptors in dorsal 
horn neurons, including ionotropic AMPAR, NMDAR, and kainate receptors, as well as 
metabotropic glutamate receptors (mGlu), all of which are activated by glutamate which 
is released at central terminals of nociceptors. One of the most important 
consequences of postsynaptic activation is the influx of Ca2+, a crucial step to the 
induction of intracellular signalling events.  
Activation of the NMDA receptor is vital to the induction of central sensitisation (Woolf 
and Thompson, 1991). NMDAR in the dorsal horn are composed of mainly NR1 and 
NR2A/B subunits (Nagy et al., 2004). Upon sufficient membrane depolarisation 
resulting from central neurotransmitter-mediated activation of post-synaptic receptors, 
the voltage-sensitive Mg2+ ion normally blocking the NMDAR pore is displaced and 
allows for the influx of Ca2+ into the neuron, which subsequently leads to the activation 
of a number of intracellular signalling pathways that mediate the development of the 
sensitised state (see 1.3.2.3)  (Mayer et al., 1984). Notably, intrathecal (i.t.) delivery of 
NMDAR antagonists (Ma and Woolf, 1995a; Woolf and Thompson, 1991), and the 
deletion of NR1 have been shown to prevent the development of acute (formalin) 
central sensitisation (South et al., 2003). Other sources of synaptic activity-induced 
Ca2+ include L-type voltage-dependent calcium channels and mGluR-IP3 mediated 
release of Ca2+ stores (Fagni et al., 2000; Hagenston and Bading, 2011). Additionally, 
SP-NK1 activity has been shown to play a major role in central sensitisation, and has 
been shown to have sustained effects in dorsal horn activity (Henry, 1976; Khasabov et 
al., 2002; Mantyh et al., 1997; Ma and Woolf, 1995b). The ablation of NK1 expressing 
dorsal horn neurons has been shown to prevent the development of central 
sensitisation induced by capsaicin as observed using behavioural and 
electrophysiological methods (Khasabov et al., 2002; Mantyh et al., 1997; Suzuki et al., 
2002). 
It should be noted that dorsal horn central sensitisation can also occur as a result of 
presynaptic mechanisms. Luo et al. (2012) genetically targeted presynaptically 
localised protein kinase G-1 (PKG-1), a type I cGMP kinase crucial to intracellular 
signalling, which prevented the development of sensitisation in spino-PAG dorsal horn 
neurons. Notably, the presynaptic deletion of PKG-1 also significantly attenuated CFA-
induced mechanical and thermal hypersensitivity, as well as formalin nocifensive 
behaviours, most likely due to regulation of the presynaptic neurotransmitter release 
from nociceptor central terminals.  
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1.3.2.2 LTP and Central Sensitisation 
Similarities have been highlighted between the induction of central sensitisation- the 
neural correlate of plasticity underlying the generation of persistent pain states- and 
early long-term potentiation (LTP), a lasting increase in synaptic strength and a 
substrate for learning and memory processes. Both LTP and central sensitisation are 
key mechanisms of neural plasticity. 
There is an ongoing debate regarding the use of nociceptive spinal LTP vs. central 
sensitisation terminology (Latremoliere and Woolf, 2009; Sandkühler, 2010). This is 
particularly due to the generally accepted homosynaptic nature of LTP observed in the 
brain (Bliss and Collingridge, 1993; Lee et al., 2009), whereas heterosynaptic 
facilitation has been cited as one of the distinguishing features of spinal cord LTP 
(Figure 1.6). Recently, both homo and heterosynaptic potentiation have been 
suggested to occur at GABAergic and C-fibre synapses in the dorsal horn (Fenselau et 
al., 2011), as well as in lamina I NK1 neurons (Torsney, 2011). Importantly, Torsney 
(2011) has shown that inflammation can induce heterosynaptic facilitation of silent Aδ-
fibre monosynaptic input to these key lamina I NK1 neurons, many of which project 
supraspinally (Torsney, 2011). Indeed, homosynaptic potentiation in the dorsal horn 
could contribute to primary hyperalgesia (Ikeda et al., 2006, 2003), but two major 
features of the behavioural pain response include secondary hyperalgesia and 
allodynia, both of which require heterosynaptic facilitatory mechanisms. It should be 
noted that both homo and heterosynaptic potentiation of cortical synapses has also 
been observed, and it has been suggested that LTP can be induced at most, if not all 
synapses in the CNS (Sandkühler and Gruber-Schoffnegger, 2012). Interestingly, 
although dendritic spine remodelling associated with inflammation-induced 
hypersensitivity has been observed in the dorsal horn (Simonetti et al., 2013), it does 
not appear to occur to the same extent as the high density of dendritic spines often 
promoted by hippocampal LTP (Bosch and Hayashi, 2012; Cingolani and Goda, 2008), 
which could perhaps influence the nature of synaptic potentiation. 
While there are indeed differences in the location, and nature (synaptic-i.e. 
excitatory/inhibitory; potentiation-i.e. homo or heterosynaptic) of LTP observed in the 
CNS, the long-term persistence of increased synaptic strength is a common feature. 
Importantly, studies have indicated that one major similarity between central 
sensitisation and early-LTP are the post-synaptic signalling events involved in their 
induction and maintenance. In particular, central sensitisation and LTP share the same 
post-translational regulation of AMPA and NMDA receptors and intracellular signalling 
cascades such as the p44/42 extracellular signal-regulated kinase/mitogen-activated 
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protein kinase (ERK/MAPK) pathway leading to transcription of immediate early gene 
programmes such as Zif268 and CREB (Ji et al., 2003). Moreover, it has been 
suggested that the molecular events underlying the synaptic plasticity observed in 
nociception and memory formation are evolutionarily conserved (Rahn et al., 2013).  
 
Figure 1.6 Homo vs. heterosynaptic facilitation. Central sensitisation in the dorsal horn is 
primarily due to heterosynaptic facilitation (right); following activity-dependent activation (red 
synapse), facilitation can spread to nearby synapses (green) which can also demonstrate 
enhanced response. Homosynaptic facilitation (left) prevails in hippocampal LTP. Reprinted 
from The Journal of Pain, Vol 10, Latremoliere A. and Woolf C.J., Central Sensitization: A 
Generator of Pain Hypersensitivity by Central Neural Plasticity, pp. 895-926, Copyright (2009), 
with permission from Elsevier. 
 
1.3.2.3 Molecular mechanisms of central sensitisation 
A number of post-synaptic molecular events are involved in developing the key 
attributes of neural activity in central sensitisation, which can be distinguished 
temporally by short-term and long-term changes. Similarly to peripheral sensitisation, 
short-term immediate effects involve largely post-translational alterations, whereas 
evidence of gene transcription is indicative of long-term changes. 
Intracellular signalling 
Ca2+ influx is particularly important for the activation of cytoplasmic kinase signalling 
events involved in central sensitisation, such as the activation of calcium calmodulin 
dependent kinase II (CaMKII), PKA, PKC, and extracellular signal-regulated kinase 
(ERK) (Fagni et al., 2000; Pezet et al., 2008).  
Activation of kinase signalling molecules leads to the post-translational modification of 
membrane receptors which increase the excitability of the post-synaptic neuron. 
Specifically, PKA phosphorylates the GluR1 subunit of the α-Amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR), and PKC phosphorylates residues 
of the GluR1, GluR2, and NR1 subunits (Carvalho et al., 2000; Chen and Roche, 2007) 
which can lead to subunit turnover, trafficking of new subunits, and ultimately structural 
and functional changes in the receptor (Carvalho et al., 2000; Lau and Zukin, 2007). 
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Studies have shown that after acute inflammatory injury, a switch occurs in the dorsal 
horn for the preferential expression of AMPAR GluR1 subunits in place of GluR2, to 
permit the influx of Ca2+ which is not possible in the presence of the Ca2+ impermeable 
GluR2 subunit (L. Fang et al., 2003; Li Fang et al., 2003; Larsson and Broman, 2008; 
Vikman et al., 2008). Moreover, the AMPAR GluR1 subunit is also targeted post-
translationally by CaMKII. PKA, PKC, and CaMKII signalling are known to converge 
upon ERK, which causes increased excitability of dorsal horn neurons (Hu et al., 2003; 
Ji et al., 2009). ERK activity is required for the phosphorylation of the NR1 subunit of 
NMDAR following capsaicin or direct application of BDNF (Slack et al., 2004; Zou et al., 
2000). ERK has also been shown to mediate the phosphorylation of the potassium 
channel Kv4.2 in the dorsal horn, which leads to increased excitability by inhibiting A-
type K+ currents and decreasing K+ efflux which typically regulates action potential 
firing (Hu et al., 2007). 
ERK/MAPK signalling for longer-term changes in nuclear activity 
The p44/42 extracellular signal-regulated kinase (ERK) is one of three members of the 
mitogen-activated protein kinase (MAPK) family, and regulates a multitude of cellular 
functions including growth, differentiation, apoptosis, and very importantly, gene 
expression (Widmann et al., 1999). ERK comes in two forms: ERK1 (p44) and ERK2 
(p42), which are similarly activated and are often described together as ERK. 
Canonical ERK signalling occurs as a result of extracellular growth factor activation of 
Ras G-protein-coupled receptor tyrosine kinases. Downstream of the Ras, Raf, and 
MEK kinases, ERK is activated (phosphorylated) at threonine 202 and tyrosine 204 
residues (Figure 1.7).  
PERK regulates downstream signalling that can result in nuclear activity leading to 
gene transcription and the synthesis of new protein. Translocation of PERK into the 
nucleus is essential to the activity of nuclear proteins including the phosphorylation of 
the nuclear mitogen and stress-activated protein kinase 1 (PMSK1) (Deak et al., 1998), 
and cAMP response element-binding protein (PCREB) in dorsal horn neurons following 
noxious stimulation, particularly in NK1 positive neurons (Anderson and Seybold, 2000; 
Ji and Rupp, 1997; Kawasaki et al., 2004). CREB is a well-known transcription factor 
that binds to regulatory CRE-binding sites embedded within specific genes, and is a 
key regulator of long-term neural plasticity (Impey et al., 1996; Lonze and Ginty, 2002). 
In the case of nociception, CREB regulates the activity-induced expression of 
immediate early genes (IEG) such as Zif268, Arc, and c-Fos, as well as late-response 
genes key to nociception and maintenance of central sensitisation, such as those 
encoding NK1, prodynorphin, or TrkB (Ji et al., 2002a). Importantly, PERK is widely 
used as a marker of neuronal activation by noxious stimuli in the spinal cord and brain 
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(Gao and Ji, 2009; Ji et al., 2009, 1999), and its role in nociception will be discussed in 
Chapter 3. 
Notably, activation of the canonical ERK/MAPK cascade is not the only means of 
transducing synaptic activity to the nuclear compartment. Elevated Ca2+ can 
alternatively activate CaMKI or CaMKIV kinases, which are capable of CREB 
phosphorylation. It has been demonstrated that CREB-dependent transcription 
(inclusive of canonical ERK-CREB transcription) requires activation of its co-
transcription factor, CREB binding protein (CBP). This can only be accomplished via 
generation of nuclear Ca2+ signalling, which is mediated by CaMKIV (Chawla et al., 
1998; Hardingham et al., 1999; Impey et al., 2002). Notably, nuclear Ca2+ activity has 
been shown to regulate inflammation-induced gene transcription in the dorsal horn 
(Simonetti et al., 2013).  
 
Figure 1.7 Diagram of signalling events leading to CREB-mediated gene transcription, 
including ERK/MAPK. Adapted from Brain Research Reviews, Vol 60, Ji R.R., Gereau R.W., 
Malcangio M.,  Strichartz G.R., MAP kinase and pain, pp. 135-148, Copyright (2009), with 
permission from Elsevier. 
 
ERK/MAPK and neuronal plasticity  
It is well established that ERK signalling plays an important role in neural plasticity, and 
PERK is used as a marker of neural plasticity and activation in the CNS (Impey et al., 
1999). Physiology and behavioural studies investigating the role of ERK in neuronal 
signalling have made great advances due to the synthesis of the MEK inhibitor 
compounds PD98059, U0126 and SL327. English and Sweatt were the first to 
implicate a role for ERK/MAPK in neural plasticity through the use of PD980589 to 
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block NMDA-activated hippocampal long-term potentiation (LTP) (English and Sweatt, 
1997). The group were subsequently the first to establish a behavioural role for 
ERK/MAPK in long-term memory formation using both cued and contextual fear 
conditioning paradigms (Atkins et al., 1998). Perhaps not surprisingly, studies have 
subsequently highlighted the importance of ERK/MAPK signalling in nociceptive 
plasticity, and the aforementioned MEK inhibitors have also been used toward the 
attenuation of injury-induced nociceptive hypersensitivity (Ji et al., 2009). For further 
information on the role of ERK/MAPK in nociceptive plasticity, please refer to 3.1.2. 
1.4 Animal models of pain   
Measuring pain in humans- particularly chronic pain- is incredibly complex because it is 
not simply limited to alterations in sensory thresholds, but also characterised by 
spontaneous pain and includes a substantial emotional-affective component (Tappe-
Theodor and Kuner, 2014). Moreover, understanding human pain is often most reliable 
through personal communication and self-reporting, a measurement which is largely 
subjective and obviously, unattainable in animals (Mogil, 2009). The translational 
applicability of animal studies to better understanding human pain has been debated 
(Langley et al., 2008); in particular, considerations of ethics, and the applicability of 
both assay (i.e. applicability to human aetiology of pain) and behavioural 
measurements utilised have been highlighted (Mogil, 2009). However, due to the broad 
similarities in nociceptive processing in human and rodents (Mogil, 2009), animal 
models represent a crucial first step toward basic understanding of the underlying 
mechanisms of human pain. Specifically, animal models allow for investigation into the 
causal or correlative links between neurobiology and measures of nociceptive 
behaviour. Although there are nociceptive, inflammatory, neuropathic, and idiopathic 
pain assays, only inflammatory assays were utilised in this thesis. 
1.4.1 Inflammatory pain assays 
The generation of inflammation is used to study inflammatory pain, typically by injecting 
agents into the cutaneous tissue of the animal hindpaw which activate primary afferent 
fibres that project to the lumbar region of the dorsal spinal cord, in particular L4-L6 (Le 
Bars et al., 2001). 
Commonly injected compounds include agents that activate the immune response such 
as Complete Freund’s Adjuvant (CFA) and carrageenan (Honoré et al., 1995; Stein et 
al., 1988), which produce longer-lasting inflammatory hypersensitivity that can persist 
for days. Alternatively, some short-term cutaneous inflammatory models include direct 
injection of endogenous inflammatory molecules such as prostaglandin, bradykinin, or 
cytokines (Dina et al., 2008; Ferreira et al., 1978). Other less clinically relevant but 
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widely used models to generate hindpaw inflammation includes injection of a dilute 
solution of formalin, a cross-linking fixative (Dubuisson and Dennis, 1977), or capsaicin 
(Gilchrist et al., 1996), to directly activate TRPV1 receptors. Although a variety of 
inflammatory agents exists, they are chosen primarily because they generate thermal 
and mechanical hypersensitivity, as well as other measurable nocifensive behaviours. 
1.4.2 Formalin 
The formalin stimulus is described as ‘moderate, continuous pain generated by injured 
tissue’ that induces ‘tonic’ pain which manifests a set formalin response-related 
behaviours (Tjølsen et al., 1992). Moreover, formalin-induced injury involves 
components of peripheral inflammatory as well as spinal dorsal horn central nervous 
system mechanisms (Tjølsen et al., 1992). However, considering its working function 
as a tissue fixative, formalin as a noxious stimulus is probably not mediated by a 
specific receptor, although it does act as an agonist for TRPA1 (McNamara et al., 
2007).  
For the great majority of experiments in this thesis (with the exception of Experiment 2, 
Chapter 3) I chose to use the rat formalin model of acute inflammation, for a number of 
reasons. At higher concentrations (2.5% vs. 0.5%) formalin is known to cause broad 
activation of all primary afferents including A, Aδ and C-fibres in the first phase 
response (Puig and Sorkin, 1996). This aspect could be considered advantageous 
compared to the capsaicin model which selectively activates C-nociceptors. Moreover, 
the time course of the formalin model is short in duration (1h) and ideal for quick 
screening of therapeutic compounds. One final main advantage of the formalin model 
is that it generates a biphasic response of nocifensive behaviours which include 
spontaneous behaviours licking, flinching, and lifting (Dubuisson and Dennis, 1977). 
While the exact mechanisms of formalin-induced behaviour and molecular targets are 
still not entirely known, it is of general agreement that the first phase (first 10min) of the 
response is a result of peripheral nociceptor activation, while the second phase (20-
60min) is indicative of central sensitisation in spinal cord circuits following on from 
peripheral nociceptor sensitisation (Coderre and Melzack, 1992; Dickenson and 
Sullivan, 1987) maintained by sustained Aδ and C-fibre activity (Dubuisson and Dennis, 
1977; Puig and Sorkin, 1996; Tjølsen et al., 1992). Chapters 3 and 6 will address the 
formalin assay in-depth. 
1.4.3 Measuring nociceptive behaviour 
Importantly, a number of pain-related nociceptive animal behaviours can be measured, 
including evoked reflexive measures, spontaneous, operant, and complex affective 
behaviours (i.e. stress, anxiety, social interaction) (Mogil, 2009).  
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Importantly, considering that human pain is not limited to the testing of evoked sensory 
thresholds, it has been suggested that measurement of voluntary and spontaneous 
behaviours should be investigated in addition to stimulus-dependent evoked behaviour 
(i.e. traditional mechanical or thermal threshold testing such as using von Frey hairs or 
Hargreaves method). A focus on spontaneous behaviours is particularly important due 
to the fact that human chronic pain conditions are often characterised by ongoing pain 
which can manifest in spontaneous episodes. In particular, spontaneous 
measurements such as gait analysis/ weight bearing, flinching, guarding, licking, and 
lifting are considered to be simple reflexes that, although laborious, are the most 
reliable and objective to quantify (Mogil, 2009). Furthermore, slightly more complex 
operant measures such as conditioned place preference/avoidance can be utilised to 
measure ongoing states of pain (Vierck et al., 2008). 
Finally, animal behaviours that reflect quality of life have increasingly received attention, 
and include measures related to pain-related affective states such as anxiety, 
depression or social interaction (Blackburn-Munro, 2004). These tests can include 
measurements in activity, such as home cage behaviours or paradigms such as open 
field, wheel running, burrowing, and measures of social interaction (Tappe-Theodor 
and Kuner, 2014). Although it is not often realistic to measure all aspects of pain-
related behaviours, observation across a range of relevant animal behaviours, 
particularly in addition to the most often utilised evoked measurement of 
hypersensitivity, is ideal. 
1.5  Neuroepigenetics 
The term epigenetics literally refers to molecular events occurring above or upon (‘epi’ 
in greek) the DNA sequence. Conrad Waddington was the first to introduce the 
‘epigenetic landscape’ to illustrate the genome-environment interactions leading to 
phenotypic variation. Specifically, epigenetics proposed a solution to the conundrum of 
how a diversity of cell-types (i.e. muscle cell vs neuron) could arise from a single cell 
during development (Waddington, 1942). Today, the word epigenetics is commonly 
used to describe phenotypic differences between individuals that are independent from 
their genetic code. A very good example of this concept is the case of genetically 
identical twins that over a lifetime can show different vulnerability to diseases. 
At the molecular level, epigenetic mechanisms are responsible for a set of 
modifications that regulate the structure of chromatin- the combination of DNA, 
histones, and other proteins that make up chromosomes (Figure 1.8 A). These 
modifications lead to the dynamic remodelling of chromatin, which affects the 
differential expression of genes without altering the DNA sequence itself. Epigenetic 
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mechanisms manifest as chemical marks (i.e. DNA methylation, histone modification), 
the sum of which are referred to as the epigenome. Although originally discovered as 
mechanisms regulating cell division and development, it is now widely accepted that 
epigenetic mechanisms can be engaged by environmental experience, such as stress, 
learning, or addiction (Borrelli et al., 2008; Renthal and Nestler, 2008; Weaver et al., 
2004), indicating that activity-dependent experiences can be imprinted onto the fixed 
DNA sequence in the form of the epigenome (Day and Sweatt, 2011; Lester et al., 
2011; Sweatt, 2013). Consequently, the emerging field of ‘neuroepigenetics’- also 
called ‘behavioural epigenetics’, refers to epigenetic mechanisms and processes that 
allow experience-dependent regulation of the epigenome specifically in neurons (Day 
and Sweatt, 2011; Sweatt, 2013) and has important implications for post-mitotic neural 
function in the central nervous system. Importantly, epigenetics is a means of refining 
neural activity according to experience, and allows for life-long biological changes in 
both gene expression and behaviour as a result of environmental influence. 
1.5.1 Epigenetic mechanisms 
Epigenetic regulation involves a variety of mechanisms including histone modification, 
DNA methylation, non-coding RNA activity (i.e. microRNAs) and retrotransposable 
elements (Landry et al., 2013; Rajasethupathy et al., 2012; Sweatt, 2013). This thesis 
is only focused on histone modifications, which are described below. Histone 
modifications and DNA methylation are well-known to interact, and therefore DNA 
methylation will be briefly introduced. 
1.5.1.1 Histone modifications 
The nucleosome is the basic building block of chromatin, and is composed of 147 base 
pairs of DNA wrapped around an octamer of histone proteins, which contains two 
copies each of H2A, H2B, H3 and H4 (Figure 1.8 B). The N-terminal tails of histones 
protrude from the nucleosome, and are highly accessible and subject to post-
translational modifications, such as lysine acetylation (Ac), serine/threonine 
phosphorylation (P), lysine/arginine methylation (single methyl = Me, dimethyl = Me2, 
trimethyl = Me3), histone ubiquitination and ADP-ribosylation. These modifications are 
particularly abundant at sites on histones H3 and H4 (Figure 1.8). Histone 
modifications and their catalysing enzymes have been the subject of many reviews 
(Cheung et al., 2000; Kouzarides, 2007; Strahl and Allis, 2000; Zhou et al., 2011).  
Histone modifications regulate a significant amount of control over chromatin dynamics, 
in particular due to the presence of electronegative acetyl or phospho groups, which 
decrease the affinity between histone proteins and negatively charged DNA. This 
activity contributes to the overall relaxation of chromatin and thus increased access of 
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transcriptional machinery leading to active transcription (Figure 1.8 B). In general, 
phospho and acetyl modifications serve as indicators of active gene transcription, while 
many methylated histone marks indicate transcriptional silencing (Figure 1.9). However, 
histone methylation is not entirely straightforward as it can also indicate active gene 
expression, for example Me3H3K4 is a marker of gene activation, whereas Me2H3K9 
and Me3H3K9 are markers of silencing. Furthermore, the interpretation of histone 
marks is not straightforward since the presence of both active and repressive marks 
can leave certain parts of DNA in a ‘poised’ state, susceptible to subsequent activity-
induced changes. Finally, some histone marks are known to participate in ‘crosstalk’ 
(Molina‑Serrano et al., 2013) and the combinatorial sum of DNA methylation and 
histone modifications can jointly affect recruitment and binding of chromatin binding 
complexes (such as RNA Pol II) (Jenuwein and Allis, 2001; Meaney and Ferguson-
Smith, 2010).  
 
Figure 1.8 A diagram of epigenetic mechanism involved in the regulation of chromatin 
structure. A) N-terminal histone tails are subject to covalent modification which plays a key role 
in epigenetic regulation of chromatin remodelling. Histone modifications also participate in 
cross-talk with DNA methylation. B) The sum of epigenetic marks, particularly histone 
modification, aid in the relaxation and condensation of chromatin. Image from Géranton and 
Tochiki (In press). 
 
Histone modifying enzymes 
There are specific enzymes dedicated to imparting and removing histone modifications 
(Figure 1.9). Histone acetyltransferases (HATs) are responsible for the addition of 
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histone acetyl marks, a process of transferring an acetyl group from acetyl coenzyme A 
to histone tail lysine residues (Lee and Workman, 2007). Histone acetylation is 
negatively regulated by histone deacetylases (HDACs), of which there are four classes, 
including zinc-dependent classes I, II, and IV, and the nicotinamide adenine 
dinucleotide (NAD)- dependent class III (also called sirtuins) (Haberland et al., 2009). 
HDACs have gained much attention as pharmacological targets of inhibition, 
particularly due to the fact that deregulation of epigenetic processes, including histone 
modifications, has been associated with a broad spectrum of neurological disorders 
(Akbarian, 2010; Deutsch et al., 2008; Qureshi and Mehler, 2010). Although HDAC 
inhibition is largely non-specific to histones, the overall aim of HDAC inhibitors 
(HDACis) is to increase the transcription of ‘favourable’ genes to battle disease. 
Furthermore, deregulation of histone acetylation is a hallmark of cancer and HDACis 
have received significant attention in cancer drug development (Wee et al., 2014). 
Traditionally, HDACis have been used to hyper-acetylate histones and favour 
transcription of tumour suppressor genes.  
Signalling to histone modifications 
Modulation of histone modifications occurs via the activation of surface-to-nucleus 
signalling cascades such as MAPK and NFkB (Riccio, 2010; Suganuma and Workman, 
2012; Zhou et al., 2013), which specifically target the enzymatic machinery responsible 
for chromatin modification, by either inducing phosphorylation of specific regulators or 
by modulating their interactions (i.e. transcription factor complexes). For example, 
activation of MSK1 via ERK/MAPK leads to histone H3 phosphorylation, a mechanism 
important for synaptic activity-induced chromatin remodelling in neurons (Arthur et al., 
2004; Soloaga et al., 2003).  
Understanding histone modifications and histone modifying enzymes are only a single 
aspect of the complex interaction that occurs across all epigenetic mechanisms (i.e. 
histone-DNA methylation interaction, transcription factor binding complexes) upon the 
genomic sequence. It is therefore important to not over-interpret the meaning of histone 
modifications (Meaney and Ferguson-Smith, 2010).  
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Figure 1.9 A few of the most common histone marks and their enzymes. Histone tails on 
H3 and H4 are the most extensively modified. The numbers on the histone tails indicate the 
residue position; acetylation and methylation most often occur at lysine (K) residues, 
phosphorylation occurs at serine (S) residues. Histone modifying enzymes are listed in grey 
boxes. The majority of acetylated and phosphorylated residues are markers of transcriptional 
activation, whereas histone methylation, which can occur in mono, di, or tri methylated states, 
can indicate both silencing and activation. Adapted by permission from Macmillan Publishers 
Ltd: Neuropsychopharmacology, Vol 37, Day J.J. and Sweatt J.D., Epigenetic Treatments for 
Cognitive Impairments, pp. 247-260, copyright (2012). 
 
1.5.2 Epigenetic Mechanisms: Learning and Memory studies 
Substrates for lifelong memories have long been investigated, and understandably 
include histone modifications and the enzymes responsible for these experience-
dependent marks upon the epigenome. Although the rationale for epigenetic regulation 
of pain states is strong, the current pool of studies is very limited. It is therefore 
essential to draw from extensive evidence showing that epigenetic processes are 
engaged in and required for memory formation (Barrett and Wood, 2008; Borrelli et al., 
2008; Day and Sweatt, 2011, 2010; Gräff and Tsai, 2013; Peixoto and Abel, 2013).  
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Given the similarities of central sensitisation and LTP (see 1.3.2.2), key studies 
identifying the epigenetic mechanisms underlying the plasticity of memory formation 
are particularly relevant, and are presented below.  
1.5.2.1 Histone modifications in memory formation 
It is well established that the expression of histone modifications is altered during 
memory formation, but it is important to note that these marks vary spatiotemporally 
and by learning paradigm (Gräff and Tsai, 2013).  
David Sweatt’s group were the first to identify upregulation of transcriptionally 
permissive histone modifications on histone H3 (PH3S10, AcH3K14, and phospho-
acetyl S10/K14 ) in the hippocampus during the consolidation phase of contextual fear 
conditioning (Chwang et al., 2006; Levenson et al., 2004) (Figure 1.10).  
Subsequent experiments identified that these same marks (PH3S10, AcH3K14) in 
addition to others (AcH4K5, Me3H3K36 active transcription mark) were again 
upregulated in the hippocampus 10min-24h following  a different paradigm, novel-
object recognition learning (Gräff et al., 2012b). Additionally, AcH3K14, AcH4K5 and 
Me3H3K36 were also increased with delayed expression in the prefrontal cortex, and 
persisting for up to 7d, implicating an important role for these marks in remote memory 
formation (Gräff et al., 2012b). Notably, acetylation of histone H3 (AcH3K9) has also 
been shown to act as a cortical ‘tag’ for remote olfactory memories (Lesburgueres et al., 
2011). 
Furthermore, studies have used chromatin immunoprecipitation (ChIP, whereby a 
DNA-associated protein of interest is selected and its associated gene sequence 
probed) and ChIP-sequencing to identify promoter-specific increases of 
transcriptionally active histone marks at pro-memory formation genes such as Bdnf, 
Zif268, and Homer1 following memory formation paradigms (Gupta et al., 2010, 2010; 
Lubin et al., 2008; Mahan et al., 2012).  
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Figure 1.10 Examples of cognitive behavioural correlates of histone H3/H4 modifications 
(rodent models). 
 
1.5.2.2 Antagonising histone modifications 
Crucially, the correlation of histone marks with learning behaviour does not imply that 
these marks are necessary to memory formation. In order to understand the role of 
histone modifications in such processes, it is necessary to target these marks and 
observe the resulting effect on animal behaviour. While largely unspecific, targeting the 
enzymes responsible for imparting or removing key histone modifications (HATs or 
HDACs) has been the main method of approach. In particular, many studies have 
targeted HDAC activity with the aim to improve cognitive function by overexpression of 
pro-memory forming genes (Gräff and Tsai, 2013). As highlighted in 1.5.2.1, histone 
acetylation has been observed in various brain areas during memory formation, and 
inhibiting HDAC activity, or genetic manipulation of HDAC expression has been the 
focus of many of these studies. 
Genetic modification: HDACs 2 and 3 
The role of Class I HDACs 2 and 3 have been the most extensively studied, using 
either genetic or pharmacological approaches. The experimental use of genetically 
modified knockout mice has identified HDAC2 and HDAC3 as negative regulators of 
memory (Guan et al., 2009; McQuown et al., 2011). 
HDAC2 was upregulated in the hippocampi of mice exhibiting memory deficits due to 
aging, or induced neurodegeneration (CK-P25 mice) when compared with control 
animals (Castellano et al., 2012; Gräff et al., 2012a). In the latter case, HDAC2 was 
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associated with promoter regions of genes crucial to memory formation, indicating that 
they were silenced (Gräff et al., 2012a). Finally, knockdown of HDAC2 with virally 
transfected shRNA in the hippocampus and PFC has also been shown to improve 
memory deficits (Gräff et al., 2012a).  
Use of pharmacological HDAC inhibitors  
In general, the systemic or localised (i.e. hippocampal infusion) delivery of HDACis 
such as sodium butyrate (NaB), trichostatin A (TSA) and valproate (VPA) have been 
shown to enhance normal cognitive function when given during the memory 
consolidation phase shortly after training (Bredy and Barad, 2008; Fischer et al., 2007; 
Guan et al., 2009; Gupta et al., 2010; Levenson et al., 2004; Lubin et al., 2008; Mahan 
et al., 2012; Roozendaal et al., 2010; Stefanko et al., 2009; Vecsey et al., 2007). These 
inhibitors have been shown to act predominantly by increasing histone acetylation 
globally, as well as at gene-specific promoter regions. 
Moreover, HDACis have also been shown to reversibly recover deficits in memory 
formation. For example, chronic intraperitoneal (i.p.) NaB re-established access to 
long-term memory in memory-impaired neurodegenerating mice, which also increased 
AcH3K14 and AcH4K5 levels, as well as the expression of synaptic proteins (Fischer et 
al., 2007). Furthermore, hippocampal infusion of suberoyl anilide hydroxamic acid 
(SAHA) reinstated AcH4K12 expression and reversed cognitive deficits in aged (16 
month old) mice (Peleg et al., 2010).  
While the use of HDACis could be expected to affect the expression of a very large 
number of genes, a gene array study has found that non-selective HDACis in vitro 
upregulated only 10-15% of all genes analysed (Tabuchi et al., 2006). As this value 
might be expected to be higher, a 10-15% increase potentially indicates some 
specificity of genes targeted by HDACis. 
1.5.3 Pain and neuroepigenetics studies 
Investigation into the epigenetic regulation of pain states is a relatively new field; 
however, the number of studies produced around the subject has increased rapidly in 
the past few years. Pain studies have focused on injury-induced changes to the 
epigenome, and have also targeted the marks on the epigenome, particularly with the 
goal of regulating nociception by pre-emptively treating or reversing existing pain states 
(Bai et al., 2014; Denk and McMahon, 2012; Géranton, 2011; Géranton and Tochiki, In 
press; Rahn et al., 2013b; Stone and Szyf, 2013).  
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1.5.3.1 Injury induced changes in epigenetic modifications and modifying 
enzymes 
A number of studies have investigated the presence of marks comprising the 
epigenome at different locations along the pain pathways (Géranton and Tochiki, In 
press). Thus far changes have been reported in the sciatic nerve, DRGs, dorsal horn 
and brain (the nucleus raphe magnus- NRM- and the frontal cortex). Many studies 
have focused on histone acetylation levels, either globally, or at gene-specific promoter 
areas, including genes relevant to nociception MeCP2, Bdnf, Gad2, Hdac1, and 
CXCR2 (Denk et al., 2013; Kiguchi et al., 2013, 2012; Liang et al., 2013; Matsushita et 
al., 2013; Sun et al., 2013; Zhang et al., 2011; Zhu et al., 2014). Although the majority 
of reports have shown increased levels in histone acetylation following injury, indicating 
activation of gene transcription, this information is far from conclusive as both 
increases and decreases in histone acetylation have been reported in the promoter 
area of pro-nociceptive genes. Such variation is not entirely surprising and likely to 
differ by the nature of injury (i.e. inflammatory, neuropathic) (Sun et al., 2013); however, 
it is an important consideration when targeting epigenetic mechanisms for pain relief. 
Additionally, examining global histone acetylation levels of a particular anatomical 
region may not necessarily be reflective of locus-specific gene changes. In particular, 
global H3 acetylation was increased in the NRM following CFA stimulation, but in fact 
H3 acetylation was decreased specifically at the promoter area of the Gad2 gene 
(Zhang et al., 2011).  
The expression of a number of epigenome modifying enzymes are also altered in the 
dorsal horn and DRGs in pain states, including MeCP2 (Tochiki et al., 2012; Wang et 
al., 2011), the HAT, p300 (Zhu et al., 2014, 2012), and several of the DNA-
methyltransferases (DNMTs) and HDACs (Bai et al., 2010; Qi et al., 2013; Tochiki et al., 
2012; Zhang et al., 2013). The studies, however, looked at different pain models and 
there was no obvious agreement in terms of time scale or direction of the changes. 
Please see Figures 7.1 and 7.2 for a detailed summarisation of the aforementioned 
studies. 
1.5.3.2 Antagonising histone modifications to improve injury- induced 
hypersensitivity: HDACs and HATs 
Pharmacological inhibition of HDACs to alter nociception in animal models has so far 
been the most frequently utilised approach in pain studies. The administration of 
HDACis MS-275 and SAHA has generally had overall positive outcomes in attenuating 
pain behaviours, both inflammatory and neuropathic.  
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The administration of the HDACi SAHA has been shown to attenuate both the second 
phase of formalin response and intraplantar CFA -induced hypersensitivity (Bai et al., 
2010; Chiechio et al., 2009; Zhang et al., 2011), albeit via different proposed 
mechanisms. Chiechio et al. (2009) attributed the effect of the HDACis on formalin 
behaviour to an upregulation of mGlu2 metabotropic glutamate receptors in the DRG 
and spinal cord, a receptor known to produce analgesic effects in inflammatory and 
neuropathic pain states. Due to the non-specificity of HDACi, the authors found 
hyperacetylation of the p65 transcription factor, a regulator of NFκB genes including 
mGlu2. However, no injury-induced changes in acetylation were reported in this study. 
Zhang et al. (2011) showed that NRM infusions of TSA and SAHA could improve 
injury-induced reduction of tail flick latency by targeting impaired presynaptic 
GABAergic synaptic function (Zhang et al., 2011). HDACi attenuation of nociceptive 
behaviour was found to be associated with increased histone H3 acetylation at the 
Gad2 promoter. 
HDACis have also been used to attenuate hypersensitivity in neuropathic pain models. 
Intrathecal infusion of MS-275 reduced thermal and mechanical hyperalgesia by 50% 
in including nerve injury models, as well as neuropathy induced by the antiretroviral 
drug, d4T (Stavudine) (Denk et al., 2013). The authors concluded that MS-275 acted 
specifically via spinal HDAC1 and caused increase in spinal cord AcH3K9 levels. 
However, when given after injury, MS-275 was unable to reverse hypersensitivity. 
Moreover, C-fibre hypoesthesia induced by neuropathic injury was also prevented by 
systemic TSA and valproate, and can be reversed by SAHA (Matsushita et al., 2013). 
The underlying mechanism of neuropathic C-fibre hypoesthesia- silencing of Nav1.8 
due to the binding of transcription factor NRSF/REST- is prevented by HDACi due to 
hyperacetylation of histone H3/H4 at the NRSE (binding sequence for NRSF) within the 
Nav1.8 gene in the DRG (Matsushita et al., 2013; Uchida et al., 2010). The 
NRSF/REST silencing mechanism also occurs within the Kv4.3 gene following nerve 
injury (Uchida et al., 2010).  Another study by the same group used chromatin 
immunoprecipitation to reveal hyperacetylation of histone H3 and H4 at the exon I 
transcript of the Bdnf gene in primary afferent nociceptors, which might be responsible 
for the pronociceptive role of BDNF in the development of neuropathic pain states. 
Crucially however, the authors never fully investigated the behavioural consequences 
of targeting these epigenetic targets (Uchida et al., 2013).   
Further highlighting the complexity of the epigenetic contribution to pain behaviours, 
HDACis have been found to exacerbate hypersensitivity induced by the skin incision 
model (Sun et al., 2013) and chronic opioid use (Liang et al., 2013). As expected, HAT 
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inhibitors (anacardic acid (AA) and curcumin, respectively) significantly attenuated the 
hypersensitivity associated with these models. 
A detailed breakdown of the main studies investigating epigenetic mechanisms in pain 
processing can be found in the General Discussion (Figure 7.1, Figure 7.2).  
1.6 Hypothesis and aim of this thesis 
It is well-established that histone modifications play an important role in neural plasticity 
and changes in gene expression (Borrelli et al., 2008). Plasticity-related changes in 
gene expresion are known to occur following both noxious stimulation (Géranton et al., 
2007) and memory acquisition (Day and Sweatt, 2011). The initial conception of 
experiments in this thesis follows on primarily from learning and memory studies (see 
1.5.2) identifying increases in hippocampal acetylation and phosphorylation at specific 
histone residues 30-60 minutes following memory acquisition (Chandramohan et al., 
2008; Fischer et al., 2007; Peleg et al., 2010). These studies have clearly identified 
histone modification as a key molecular event regulating learning and memory by 
altering changes in gene expression through use of pharmacological or animal 
knockout methods (Day and Sweatt, 2011; Gräff and Tsai, 2013; Peixoto and Abel, 
2013).The similarity of molecular events involved in the induction and maintenance of 
LTP, the proposed underlying neural correlate of memory formation, and central 
sensitisation (Ji et al., 2003), indicate that these similarities may also be inclusive of 
epigenetic modifications such as histone modification.  
 
More recently, studies have emerged that have directly investigated a role for spinal 
histone acetylation in the full expression of neuropathic behaviour (Bai et al., 2010; 
Denk et al., 2013). While injury-induced histone phosphorylation has not yet been 
investigated in the dorsal horn, it is of particular interest as it is known to occur 
downstream of ERK signalling, a key event in the development of nociceptive plasticity.  
 
The global aim of this thesis was to use a model of inflammatory pain to investigate the 
role of spinal dorsal horn histone modification in the development and regulation of 
central sensitisation and injury-induced nociceptive behaviour. Specifically, the aims of 
this thesis were to: 
1. Identify specific histone modifications displaying altered expression in the 
spinal dorsal horn following peripheral noxious stimulation (PH3S10) 
(Chapter 3). 
 
2. Use the formalin model to investigate the overlap/expression of the formalin-
induced PH3S10 population with markers of the pain pathways (Chapter 4). 
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3. Investigate the role of descending serotonergic activity on the expression of 
formalin-induced PH3S10 (Chapter 5). 
 
4. Elucidate the molecular signalling events upstream of PH3S10 (ERK, 
MSK1) using pharmacological inhibitors, to determine if preventing PH3S10 
by targeting MSK1 can regulate formalin-induced nocifensive behaviour and 
central sensitisation (Chapter 6). 
 
 
 
 
 
Chapter 2 Materials and Methods 
 
57 
 
 
 
 
 
Chapter 2  Materials and Methods 
  
Chapter 2 Materials and Methods 
 
58 
 
This section describes general methods used throughout this thesis. Experimental 
design (i.e. n numbers) as well as the specifics of some methods is addressed in-detail 
within the Methods section of each Results chapter. For solution recipes, please refer 
to the Appendix. 
2.1 Animals 
All procedures were licensed under the Animals (Scientific Procedures) Act 1986. 
Experiments were performed using adult male Sprague-Dawley rats at 200-230g at the 
beginning of the experiment and bred by the UCL Biological Services Unit. For 
experiments where animals required intrathecal surgery (Chapter 5, Chapter 6 
Experiment 2) all subjects were between 170-185g.  Animals were housed four 
maximum to a cage, with a 12h light-dark cycle (lights on beginning at 08:00) and 
access to food and water provided ad libitum.  
2.2 Model of acute pain  
2.2.1 Injections 
Acute inflammation was induced with an intraplantar hindpaw injection of 50µl, 2% 
formalin under isoflurane anaesthesia (5% for induction and 2.5% for maintenance 
under nose cone combined with 100% O2, 2L/min) or 20µl, 5% formalin without 
anaesthesia using a 1ml syringe and disposable 30G ½ inch needle. For the latter, the 
animal was lightly restrained in a leather glove during injection. Animals injected under 
anaesthesia were returned to a recovery box until regaining consciousness. Sham-
anaesthetised animals were subject to the same anaesthesia as the formalin injected 
animals but received no injection, while sham-non-anaesthetised animals had 
handling/restraint and no injection.  
In this thesis, with the exception of Chapter 6, Experiment 2, all animals were injected 
with formalin (50µl, 2%) under isoflurane anaesthesia. The requirements of Chapter 6 
Experiment 2, Does inhibition of MSK1 activity block formalin-induced PH3S10 and c-
Fos expression, and attenuate formalin behaviour? necessitated the injection of 
formalin without anaesthesia in order to monitor behaviour immediately following 
injection. Due to Home Office licence limitations, rats injected without anaesthesia had 
to be given a smaller volume but higher concentration of formalin (20µl, 5%). 
Importantly, it should be noted that the two formalin doses deliver the same amount of 
formalin but in different volumes. The purpose of Chapter 6, Experiment 3: Are there 
any differences in spinal PERK expression following two different conditions of i.pl. 
formalin injection? was to serve as a control experiment to investigate any differences 
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in PERK activation between the slightly different conditions of formalin injections used 
in this thesis. Please also refer to 6.2.1.3. 
The survival time following formalin or sham stimulation ranged from 5min to 4h 
depending on the experiment. 
2.2.2 Scoring of formalin behaviour 
Animals were recorded for 60min in an 11 x 17 cm perspex box with a Panasonic SDR-
H100 video camera following injection. Formalin behaviour was scored and quantified 
as the length of time spent licking and flinching, or the number of total flinches in 5min 
bins across the 60min following injection. All scoring was done with the experimenter 
blind to treatment. 
2.3 Drugs and method of delivery  
Table 2.1  Drugs. DMSO, dimethyl sulfoxide; EtOH, ethanol. 
Drug Company 
Cat # 
Delivery Solvent Amount 
delivered 
Vehicle 
equivalent 
Desipramine 
(Chapter 5) 
Sigma 
D3900 
i.p. 0.9% Saline 25mg/kg - 
5,7-DHT 
(Chapter 5) 
Sigma 
37970 
i.t. 0.9% Saline 60µg in 10µl 0.9% Saline 
SL327 
(Chapter 6) 
Tocris 
1969 
i.p. DMSO 50mg/kg 
 
100% 
DMSO 
SB747651A 
(Chapter 6) 
Tocris 
4630 
i.t. 10mg/200 µl 
EtOH + 2ml 
0.9% saline 
(10.49mM) 
 433ng 
(10µM,10µl)    
or                  
4.33ng      
(1µM, 10µl) 
0.0086% 
EtOH/saline 
 
2.3.1 Intrathecal surgery 
Intrathecal surgery was performed under isoflurane anaesthesia (5% for induction and 
2.5% for maintenance under nose cone combined with 100% O2, 2L/min). The head of 
the animal was shaved and the animal secured in a stereotaxic frame. Following 
sterilisation of the shaved area, an incision was made using a no. 22 blade from the top 
of the head to the base of the skull/first vertebra. The muscle was parted to reveal the 
atlanto-occipital membrane, which was carefully pierced and a small opening cleared to 
allow insertion of a polyethene tube (diameter 0.28mm) attached to a 50µl Hamilton 
syringe containing either drug or vehicle solution (see Table 2.1).  The tubing was 
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carefully inserted into the subarachnoid space and guided to a predetermined location 
identifying the L4/L5 spinal cord region and 10µl of solution delivered.  The tube was 
inserted without resistance and care was taken not to damage the spinal cord or dorsal 
roots. Once the tube was removed, the overlying muscle was sutured once using 5-0 
mersilk, and the wound subsequently closed with three 11x2mm suture clips. The 
animal was then placed into a temperature controlled recovery chamber and monitored 
closely for signs of locomotor impairment or distress once awake. Animals receiving 
5,7-DHT were also monitored over the 6 day period for any weight loss (Chapter 5). 
2.4 Tissue collection 
Following formalin stimulation, animals were sacrificed and spinal cords dissected out 
either fresh or fixed with paraformaldehyde for western blot or immunohistochemistry, 
respectively. 
2.4.1 Fresh Tissue 
Animals were sacrificed using carbon dioxide (CO2) asphyxiation by steady flow of CO2 
into a chamber until unconscious and not breathing. A cervical dislocation was 
subsequently performed to ensure death. The spinal cord was quickly dissected on ice. 
The ipsilateral and contralateral (to the injected hindpaw) dorsal horn of L4-L6 
(weighing roughly 10mg each) were cut out and placed in separate tubes and 
immediately frozen on dry ice. Tissue was stored at -80˚C until processing. 
2.4.2 Perfusion 
Animals were deeply anaesthetised first with isoflurane and subsequently with 
pentobarbital (Euthatal, typically 0.8ml/animal, i.p.). After breathing stopped and the 
animal failed to exhibit eyelid reflex, a transcardial perfusion was performed first with 
heparinsed saline (5000IU/litre 0.9% saline) followed by 4% paraformaldehyde 
(PFA)/0.1MPB for 7min, using a pump and 18 gauge cannula delivering the fixative at 
30ml/min.  The PFA solution contained 0.2% (w/v) sodium fluoride (NaF), a 
phosphatase inhibitor. 
The spinal cord was then post-fixed for 2.5-3h in the same PFA solution and 
subsequently stored at 4˚C in 30% sucrose/0.1M PB/0.02% (w/v) azide for 
cryoprotection for at least 48h before further processing. 
2.5 Immunohistochemistry 
Immunohistochemistry was used to visualise antigens of interest within spinal cord 
tissue sections using antigen-specific generated antibodies. The antibodies were 
visualised with either fluorescent or chromogenic methods and typically the signal was 
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amplified using principles of avidin-biotin affinity (see 2.5.4.1 below). The specifics of 
antibody combinations used for colocalisation are located in the Methods section of 
relevant Results chapters. For solution recipes please see the Appendix. 
2.5.1 Tissue Sectioning 
The L4 to L6 region of the perfused spinal cord was identified using L4 and L5 roots, 
and isolated for sectioning on a Leica SMR2000R freezing microtome. 40µm coronal 
sections were taken serially in six sets and stored in 5% sucrose/0.1M PB/0.02%(w/v) 
azide until staining.  
2.5.2 Blocking of non-specific antigens 
All staining of tissue was done free floating in volumes of 1ml solutions with gentle 
rocking agitation unless otherwise stated. 3 x 10min washes in 0.1M PB were 
performed after incubation with all solutions except after incubation with blocking 
solution. Washes were done in excess of 1ml.  
In some cases, an antigen retrieval step was required (see asterisk, Table 2.2). 
Sections were acid pretreated with 2N hydrochloric acid (HCl) for 30min followed 
directly by a neutralisation step of 0.1M Boric acid for 10min prior to serum block.  
Tissue sections were blocked for 1h in 3% normal goat or horse serum depending on the 
host of the secondary antibody (Vector, UK,  
Table 2.3) and 0.3% triton X-100 in 0.1M PB to minimise non-specific binding of 
secondary antibodies. For chromogenic staining, 2% H2O2 was added to the blocking 
solution to quench endogenous peroxidase activity and minimise background. 
Following removal of the blocking solution, primary antibody was added either 
overnight (O/N) at room temperature (RT) or over 3d at 4˚C in Triton-Tris-buffered 
saline (TTBS). See Table 2.2 for further antibody information. 
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2.5.3 Antibodies- Immunohistochemistry 
 
Table 2.2 Primary antibodies (immunohistochemical experiments) Asterisk indicates acid 
pretreatment antigen retrieval was required prior to the blocking step (see 2.5.2). Rb, 
rabbit; Ms, mouse. 
Antibody Host Company Cat. No Concentration Incubation 
time and 
temperature 
Detection or 
amplification 
method 
5-HT Rat Chemicon MAB352 1:75 3d, 4˚C Biotin 
Amplification 
AcH3K9 Rb Upstate 06-942 1:1000 O/N, RT Direct Alexa 
AcH3K14 Rb Cell 
signalling 
4318 1:1000 O/N, RT TSA* 
AcH4K5 Rb Millipore 17-211 
06-759 
- - - 
AcH4K8 Rb Millipore 17-211 
06-760 
1:1000 O/N, RT Direct Alexa* 
AcH4K12 Rb Millipore 17-211 
06-761 
1:1000 O/N, RT Direct Alexa 
AcH4K16 Rb Millipore 17-211 
06-762 
1:1000 O/N, RT Direct Alexa 
APC CC1 Ms Calbiochem OP-80 1:100 O/N, RT Direct Alexa 
Calbindin Ms Sigma C8666 1:1000 O/N, RT Direct Alexa 
c-Fos Rb Calbiochem PC38 1:10,000  
1:20,000 
O/N, RT 
O/N, RT 
DAB         
TSA 
GFAP Rb Dako Z0334 1:4000 O/N, RT Direct Alexa 
NK1 Rb Millipore AB5060 1:20,000 3d, 4˚C TSA 
NeuN Ms Chemicon MAB377 1:1000 O/N, RT  Direct Alexa 
nNOS Rb Cell 
signalling 
4231S 1:1000 O/N, RT TSA 
Parvalbumin Rb Swant PV28 1:1000 O/N, RT Direct Alexa 
PERK 
(Thr202/ 
Tyr204) 
Rb Cell 
signalling 
9101 1:250         
1:500 
O/N, RT  
O/N, RT 
TSA        
Direct Alexa 
and DAB 
PH3S10 Ms Abcam ab14955 1:10,000   
1:5,000    
1:500 
3d, 4˚C     
O/N, RT 
O/N, RT 
TSA        
DAB 
Direct Alexa* 
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PH3S10/ 
AcH3K14 
Rb Millipore 07-081 1:20,000 3d, 4˚C     TSA 
PMSK1 
(Thr581) 
Rb Cell 
signalling 
9595 1:500 3d, 4˚C TSA 
Zif268   
(Egr-1) 
Rb Santa Cruz sc-189 1:10,000 O/N, RT TSA 
 
 
Table 2.3 Secondary antibodies (immunohistochemical experiments). Ch, chicken; Gt, 
goat; Hs horse. 
Secondary      
antibody 
Host Company Cat. No Concentration Incubation time 
(all RT) 
Biotinylated 
anti-Rb IgG 
Gt Vector BA-1000 1:400              
1:500 
1.5h, TSA                       
2h,  DAB 
Biotinylated 
anti-Ms IgG 
Hs Vector BA-2001 1:400              
1:500 
1.5h, TSA                       
2h,  DAB 
Biotinylated 
anti-Rat IgG 
Gt Vector BA-9400 1:400              
1:500 
1.5h, TSA                       
2h,  DAB 
Alexa 594 
anti-Ms IgG 
Gt Invitrogen A11072 1:500 O/N 
Alexa 594 
anti-Rb IgG 
Gt Invitrogen A11037 1:500 O/N 
Alexa 488 
anti-Ms IgG 
Gt Invitrogen A11001 1:500 O/N 
Alexa 488 
anti-Rb IgG 
Ch Invitrogen A21441 1:500 O/N 
 
2.5.4 Fluorescent immunohistochemical methods 
After incubation with primary antibody, typically two fluorescent immunohistochemical 
methods were used to visualise primary antibodies, either:  
1. Tyramide signal amplification (using fluorescein isothiocyanate FITC avidin), or  
2. Direct detection (using Alexa fluorophore-conjugated secondary antibody) 
These methods were either used singly or combined in sequence if a colocalisation 
study was conducted. Under a fluorescent microscope beam, FITC avidin and Alexa 
488 fluoresce green when excited at a wavelength of 488nm, and Cy3 Streptavidin and 
Alexa 594 fluoresce red when excited at 594nm. Using two fluorochromes that have 
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non-overlapping excitation/emission wavelengths is particularly useful when visualising 
two different antigens on the same tissue (Figure 2.4) (Figure 2.6).  
2.5.4.1 Tyramide signal amplification (TSA) 
Amplification of antibody signal using TSA allows for the antibody to be used at a low 
concentration. This is particularly useful if the antibody is in limited supply, or if a 
double stain is desired with an antibody of the same host species. Biotinylated-
tyramide is activated by the enzyme horseradish peroxidase (HRP) and deposited at 
electron-rich regions at HRP binding sites. In this case HRP is conjugated to an avidin-
biotin complex (ABC) aggregate and maximises the number of sites for binding with 
avidin-conjugated fluorochrome (FITC avidin). Avidin and biotin have an extremely high 
affinity for one another, with every avidin glycoprotein having four identical subunits 
that bind one biotin each. (Figure 2.1). 
Following incubation with primary antibody, a respective biotinylated secondary 
antibody (Vector, UK) was subsequently applied at a dilution of 1:400 in TTBS for 1.5h, 
followed by 30min in ABC solution diluted to 1:250 of each Vectastain A and Vectastain 
B solutions (Vector, UK).  A further amplification step was completed using a dilution of 
1:75 biotinylated tyramide in amplification diluent in 0.25ml only (Perkin Elmer, UK) for 
7min.  Sections were then incubated with FITC avidin (Vector, UK), 1:600 in TTBS for 
2h in a dark box.  
If colocalisation with another antigen was desired, the tissue was subsequently 
incubated with a second primary antibody of interest in TTBS and left to incubate O/N 
in the dark at RT (see Table 2.2 Primary antibodies (immunohistochemical 
experiments) Asterisk indicates acid pretreatment antigen retrieval was required prior 
to the blocking step (see 2.5.2)  The following day, the antibody was detected with an 
Alexa-conjugated secondary as described below (see 2.5.4.3). If no colocalisation was 
desired, sections were mounted from 0.01M PB onto gelatinised slides. It should be 
noted that where a double stain was completed with two antibodies of the same host, a 
negative control eliminating the second primary confirmed no cross reactivity of 
secondary antibodies. Once dry, slides were coverslipped with Fluoromount (Sigma, 
UK) to minimise fluorescent fading. 
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Figure 2.1 Tyramide signal amplification (TSA). 1) The tissue is incubated with primary 
antibody overnight or over 3d; the primary antibody binds to the antigen of interest. 2) The 
primary antibody is detected by a secondary antibody conjugated to biotin (B). 3) The high 
affinity avidin (red X)-biotin (B) aggregate binds to the biotinylated secondary antibody. 4) The 
avidin-biotin aggregate is conjugated to HRP (not shown), which catalyses (blue arrow) the 
deposition of biotinylated tyramide (BT). 5) FITC (green star) conjugated avidin (red X) binds to 
biotinylated tyramide, completing the amplification signal of the primary antibody. FITC is 
visualised under the fluorescent microscope. 
 
2.5.4.2 Biotin amplification 
A biotin amplification does not amplify signal strength to the same extent as TSA but 
more so than direct detection with an Alexa-conjugated secondary (see 2.5.4.3). Biotin 
amplification was used for the antibody 5-HT only and cannot be combined with TSA. 
Following incubation with the 5-HT antibody, a goat anti-rat biotinylated secondary 
antibody (Vector, UK) was subsequently applied at a dilution of 1:500 in TTBS for 1.5h, 
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followed by 45min in Cy3 streptavidin 1:4000 in TTBS (Jackson Immunoresearch, 
Europe).  Tissue was mounted and once dry, slides were coverslipped with 
Fluoromount (Figure 2.2) 
 
Figure 2.2 Biotin amplification. 1) The tissue is incubated with primary antibody overnight or 
over 3d; the primary antibody binds to the antigen of interest. 2) The primary antibody is 
detected by a secondary antibody conjugated to biotin (B). 3) Cy3 (red star)-conjugated 
streptavidin (red X) binds to the biotinylated secondary antibody. Cy3 is visualised under the 
fluorescent microscope. 
 
2.5.4.3 Direct detection with Alexa 
Sections were incubated in a dark box O/N in Alexa Fluor conjugated secondary 
antibody at 1:500 (see  
Table 2.3 Secondary antibodies (immunohistochemical experiments). The next day 
they were mounted from 0.01M PB onto gelatinsed slides and coverslipped with 
Fluoromount (Figure 2.3) 
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Figure 2.3 Direct Alexa detection of primary antibody. 1) The tissue is incubated with 
primary antibody overnight; the primary antibody binds to the antigen of interest. 2) The primary 
antibody is detected by an Alexa fluor (488 or 594)-conjugated secondary antibody. Alexa 488 
or 594 is visualised under the fluorescent microscope. 
 
Figure 2.4 Combining TSA and Direct Alexa methods to ‘double stain’ for two different 
antigens. Combination of protocols in Figure 2.1 and Figure 2.3.  
 
2.5.5 Chromogenic immunohistochemical methods: 3,3’-Diaminobenzidine 
(DAB) reaction 
In some cases, particularly for quantification of cell counts, a 3,3’-diaminobezidine 
(DAB) reaction was employed. Amplification of antibody signal using DAB is similar to 
TSA, again utilising the affinity of the ABC complex. DAB is a chromogenic electron 
donor which deposits a brown polymer in the presence of H2O2 and HRP. 
Following incubation for 1h in blocking solution (see 2.5.2) respective biotinylated 
secondary antibody was subsequently applied at a dilution of 1:500 in TTBS for 2h, 
followed by 1h in ABC solution diluted to 1:1000 of each Vectastain A and Vectastain B 
solutions.  Sections were then developed using a DAB kit (Vector, UK) for 5-7min 
under constant visualisation using a stereoscopic microscope. The reaction was 
terminated by transferring the sections into dH20 followed by 0.1M PB (5min each). 
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Sections were mounted from 0.01M PB and left to dry O/N before dehydration in EtOH 
of increasing concentration (10s in dH20 followed by 2 x 1min in each 70% EtOH, 95% 
EtOH, 100% EtOH, Histoclear (National Diagnostics, UK). Slides were coverslipped 
directly from histoclear with DPX mountant (VWR, UK) (Figure 2.5). 
 
Figure 2.5 3,3’ Diaminobenzidine (DAB) amplification. 1) The tissue is incubated with 
primary antibody overnight or over 3d; the primary antibody binds to the antigen of interest. 2) 
The primary antibody is detected by a secondary antibody conjugated to biotin (B). 3) The high 
affinity avidin (red X)-biotin (B) aggregate binds to the biotinylated secondary antibody. 4) The 
avidin-biotin aggregate is conjugated to HRP (not shown), which catalyses (blue arrow) the 
deposition of DAB polymer (brown circle). The DAB signal is visualised under the light 
microscope. 
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Figure 2.6 Immunohistochemical methods used in this thesis: degrees of amplification. 
TSA and DAB are the protocols yielding the highest amount of amplification of primary antibody; 
Direct Alexa is the lowest degree of amplification. 
 
2.5.6 Imaging 
Images of DAB staining were captured using a Nikon Coolpix E4500 digital camera 
attached to a Nikon Eclipse E800 microscope. Images of fluorescent stains and some 
DAB stains (Chapter 6, Figure 6.13) were captured using a Hamamatsu CCD C4742 
digital camera attached to a Leica DMR microscope using the software Volocity 
(PerkinElmer, Waltham MA, USA). In some images of fluorescent staining, confocal 
microscopy was employed using a Leica TCS SPE Laser scanning microscope. A 
single focal plane was used for any colocalisation images presented using confocal 
microscopy as well as when determining colocalisation under the Leica DMR 
microscope. 
2.5.7 Quantification of immunohistochemistry 
Immunopositive cells for all sections were counted manually with experimenter blind to 
treatment using a Leica DMR fluorescent microscope. The immunopositive cells were 
separated by laminae I-II and III-V. Once all sections were counted, per animal, five 
sections with the maximum response (ipsilateral) were used and the average taken on 
the ipsilateral and, if necessary, contralateral side of the dorsal horn. The average of 
the treatment group was then calculated along with the standard error of each group 
mean (SEM). 
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2.6 Western Blot 
For recipes of Western Blot solutions, please see the Appendix. 
2.6.1 Tissue homogenisation and histone extraction (TX Buffer or CHAPS 
extraction) 
Two extraction methods were used: a whole-cell lysate extraction (CHAPS, 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate) and a nuclear lysate which is 
designed specifically for the extraction of histones (TX Buffer). The CHAPS extraction 
worked well for only one antigen of interest, AcH4K8. All other Western Blots used a 
specific nuclear fraction lysate obtained with TX Buffer extraction. 
2.6.1.1 TX Buffer extraction 
Fresh tissue samples (see 2.4.1) were kept on dry ice until the last possible moment, 
and homogenised using a FastPrep Biopulverisier (MP Biomedicals, France), twice at a 
speed of 9.5 for 10 seconds each, in 200µl of TX Buffer with 12-15 beads of lysing 
matrix D (MP Biomedicals, France) per tube. The lysate was briefly spun down and 
transferred to a 1.5ml Eppendorf on ice for 15min. Samples were then centrifuged at 
2,000rpm, 4˚C for 10min. The supernatant was discarded and the pellet washed in TX 
Buffer. The pellet was resuspended in 50µl TX Buffer + 0.2M HCl and left on ice for 
30min to lyse the nuclei. Samples were centrifuged at 10,000rpm, 4˚C for 10min. The 
supernatant was recovered and stored at -20˚C until bicinchoninic acid (BCA) or 
immunoblot.  
2.6.1.2 CHAPS extraction 
In the AcH4K8 blot, the CHAPS protein extraction was used.  Tissue samples were 
homogenised using the FastPrep Biopulveriser method as mentioned above, but 
instead with 200µl of CHAPS buffer. Following homogenisation, the lysate was 
transferred to a 1.5ml Eppendorf on ice and left for 2h. The samples were centrifuged 
at 12,000rpm, 4˚C for 15min.  The supernatant was kept and stored at -20˚C until BCA 
Assay and immunoblot. 
2.6.2 BCA Assay 
Total protein concentration was measured using a BCA protein assay kit (Pierce, UK). 
Six protein standards of known concentration were loaded into a 96-well plate in 
duplicate and experimental samples also added in duplicate to the plate. BCA and 
copper sulphate was added to all wells and left to incubate at 37 ˚C for 30min. The 
samples were then measured using a spectrophotometer at 570nm.   
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2.6.3 Gel run and transfer  
Samples were prepared with 4x NuPage LDS loading sample buffer (Life Technologies, 
UK) to a volume of 18µl and 8 or 10µg of protein. After boiling for 5min, 15µl of 
prepared sample was loaded into a 12% gel for sodium dodecyl sulfate- polyacrylamide 
gel electrophoresis (SDS-PAGE) (Bio-Rad, UK) set in a chamber containing 3-(N-
Morpholino)propanesulfonic acid, 4-Morpholinepropanesulfonic acid (MOPS) running 
buffer. 5µl of Kaleidoscope Precision Plus Protein ladder was also loaded in the gel 
(Bio-Rad, UK). The gel was run at 160V for 1h. Proteins were subsequently 
electrophoretically transferred from the gel to a polyvinylidine difluoride (PVDF) 
membrane in a chamber containing transfer buffer and an ice pack to prevent 
overheating at 100V for 1h (Bio-Rad, UK). The PVDF membrane had been activated 
prior to transfer by soaking for 10min in 100% methanol. After the transfer, the 
membrane was removed and blocked in 0.24% iBlock (Tropix/Applied Biosystems, UK) 
for 1h and left in a tube on a roller O/N at 4˚C in primary antibody in iBlock (see Table 
2.4 Primary Antibodies (Western Blot)). 
2.6.4 Immunoblotting 
All washes were done 6 x 5min with PBS-Tween on a rocker. The PVDF membrane 
was washed and incubated in the respective HRP-conjugated secondary antibody (see 
Table 2.5 Secondary Antibodies (Western Blot) for 50 min at 1:2000/iBlock. HRP 
activity was reacted with SuperSignal West Pico, a chemiluminescent substrate (Pierce, 
UK) and visualised either a Chemi Doc XRS or Chemi Doc MP (Bio-Rad, UK). Signal 
intensity was measured using Quantity One software or Image Lab (Bio-Rad, UK).  
2.6.4.1 Housekeeping genes and normalisation 
After probing the membrane for the protein of interest the membrane was washed, and 
subsequently incubated O/N in the nuclear housekeeping gene product calnexin or 
histone H4, both at 1:1000/iBlock. For the AcH4K8 immunoblot which utilised whole-
cell CHAPS extracted lysate, the cytoplasmic housekeeping gene product 
glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used at 1:2000/iBlock. 
The following day, detection and visualisation of calnexin was completed the using the 
same protocol mentioned above (see 2.6.4) 
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2.6.4.2 Antibodies- Western Blot 
Table 2.4 Primary Antibodies (Western Blot) 
Antibody M.W. Host Company Cat. No Concentration 
AcH3K9 17kDa Rb Upstate 06-942 1:500 
AcH3K14 17kDa Rb Cell signalling 4318 1:1000 
AcH4K5 14kDa Rb Millipore 17-211       
06-759 
- 
AcH4K8 10kDa Rb Millipore 17-211      
06-760 
1:1000 
AcH4K12 14kDa Rb Millipore 17-211      
06-761 
1:1000 
AcH4K16 10-
14kDa 
Rb Millipore 17-211      
06-762 
1:500 
Calnexin 90kDa Rb BioVision 3811-100 1:1000 
GAPDH 38kDa Ms Millipore MAB374 1:2000 
H3 17kDa Rb Millipore 06-755 - 
H4 10kDa Rb Millipore 07-108 1:1000 
PH3S10 17kDa Ms Abcam ab14955 1:1000 
 
 
Table 2.5 Secondary Antibodies (Western Blot) 
Antibody Host Company Cat. No Concentration 
HRP anti-Mouse IgG Gt Santa Cruz sc2302 1:2000 
HRP anti-Rabbit IgG Gt Santa Cruz sc2301 1:2000 
 
Antibody Controls- specificity of phospho-site for PH3S10 antibody 
It should be noted that the antibody for phospho-histone H3 serine 10 (PH3S10) in 
future will require a control experiment to confirm the specificity of the antibody for the 
phosphorylated epitope beyond the use of a blocking peptide. To confirm the antibody 
specificity for a phosphorylated epitope, tissue sections or protein homogenate should 
be treated with phosphatases prior to IHC or Western blot. Subsequent completion of 
the IHC or Western blot protocol using the PH3S10 antibody should indicate no 
detection of antigen. 
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Additionally, it is worth noting that PH3S10 is not the only phosphorylated histone 
residue on H3 (Figure 1.9), which also includes phosphorylation at serine 28 (PH3S28). 
Notably, PH3S10 and PH3S28 have the same amino acid sequence preceding the 
serine phospho-site (arginine, lysine, serine), which may cause some concerns over 
antibody specificity for PH3S10. Although lack of specificity would seem unlikely in this 
case as the antibody was purchased from a reputable source (ChIP-grade mouse 
monoclonal, Abcam, UK), it would be interesting to see if IHC detection using PH3S28 
would reveal a different pattern of staining in the dorsal horn following formalin 
stimulation. 
2.7 Statistical analysis 
All statistical analyses were performed using IBM SPSS PC+ (Chicago IL, USA) or 
Microsoft Excel (Redmond WA, USA). Analyses were performed using independent t-
tests or univariate Analysis of Variance (ANOVA). Data was checked for normal 
distribution using the Shapiro-Wilk analysis, and homogeneity of variance using 
Levene’s test prior to performing parametric analyses. If the data violated the 
assumptions required to perform parametric analyses, a log10 transformation was done 
to achieve a normal distribution (Chapter 6 Behaviour, Figure 6.11). Data was checked 
for sphericity using Mauchley’s test of sphericity and where violated, the Greenhouse-
Geisser correction was used.  For all experiments a statistical significance of p<0.05 
was used. For more details regarding analysis please see the relevant Methods section 
of each chapter. 
2.7.1 Quantification and analysis of IHC 
In Chapters 5 and 6, cell counts were compared between treatment groups. 
Comparison was analysed using independent t-test or univariate ANOVA, with 
‘treatment’  as the between-subjects factor, and ‘side’ (ipsilateral vs. contralateral) as 
the within-subjects factor. 
2.7.2 Quantification and analysis of western blots 
The signal from the protein of interest was normalised with the intensity of the 
respective housekeeping protein signal from the same blot. This provided a 
protein/housekeeping gene ratio which was expressed as a percentage change from 
the mean control group (sham anaesthesia only) value. The mean of the value for 
control animals was arbitrarily set to 100%.  Normalised signals were averaged for 
each treatment group and expressed as mean ± SEM, and were compared in sham 
(control), treated-ipsilateral, and treated-contralateral animals by univariate ANOVA in 
IBM SPSS PC+ (Chicago IL, USA). 
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2.7.3 Quantification and analysis of behaviour 
In Chapter 6, Formalin-induced nociceptive behaviour was compared in animals 
receiving Vehicle and animals receiving drug. Data was analysed using a repeated 
measures ANOVA, with ‘treatment’ as the between-subjects factor, and ‘time’ as the 
within-subjects factor. A significant main effect of treatment or significant interaction led 
to post-hoc analysis by least significant difference (LSD) and Bonferroni tests.  
To determine the degree of drug treatment effect, percentage reductions in formalin-
induced nocifensive behaviour were calculated using the area under the curve (AUC) 
for the two formalin phases (first phase 0-10 minutes, second phase 15-60 minutes). 
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3.1 Introduction 
Studies have shown that regulation of gene expression occurs following induction of 
persistent inflammatory pain states in both DRGs and spinal cord (Géranton et al., 
2007; Griffin et al., 2007; Lacroix-Fralish et al., 2006; Valder et al., 2003; Vega-Avelaira 
et al., 2009; Xiao et al., 2002) and these changes in gene expression are believed to 
be key to the development and maintenance of central sensitisation. Crucially, it is well 
known that epigenetic mechanisms, inclusive of dynamic histone modifications, are 
required for long-term synaptic plasticity and gene regulation (Borrelli et al., 2008; 
Zocchi and Sassone-Corsi, 2010). This chapter describes experiments investigating 
expression of histone modifications in the spinal cord after noxious hindpaw stimulation. 
3.1.1 The role of histone modification in memory formation 
There are many neurobiological similarities regarding the induction of central 
sensitisation and early- LTP, the respective neural correlates underlying the 
development of pain states and learning processes (see General Introduction 1.3.2.2 
and 1.5.2). An abundance of evidence exists to indicate the involvement of epigenetic 
mechanisms in learning and memory formation (Day and Sweatt, 2011; Gräff and Tsai, 
2013; Roth and Sweatt, 2009). As there is limited albeit growing evidence for the role of 
epigenetic mechanisms in pain states, it is understandably worthwhile to look at studies 
investigating histone modifications involved in learning and memory studies. 
Importantly, the majority of studies investigating memory consolidation show that 
alteration of histone modifications, primarily upregulation of histone acetylation, occurs 
quickly and within hours of memory acquisition. In particular, hippocampal and cortical 
histone H3 and H4 acetylation associated with activity-induced gene regulation in 
learning and memory paradigms have been extensively investigated (Figure 3.1). The 
studies indicate that the expression of histone modifications varies spatiotemporally 
and is dependent on learning paradigm (Gräff and Tsai, 2013).  
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Figure 3.1 Histone modifications involved in learning and memory. From Géranton and 
Tochiki (In press). 
3.1.2 Extracellular signal-regulated kinase (ERK) in neural plasticity 
A very important and common feature between the induction of central sensitisation 
and early- LTP is ERK signalling. ERK/MAPK signalling was introduced in Chapter 1 
General Introduction (see 1.3.2.3), and plays a crucial role in neuronal plasticity (Impey 
et al., 1999). 
3.1.2.1 Nociceptive activation of ERK/MAPK in the spinal cord 
In the pain field, PERK is a widely used marker of neuronal activation by nociceptive 
stimuli in the spinal cord and brain (Gao and Ji, 2009; Ji et al., 2009). The first evidence 
for the role of ERK/MAPK in nociceptive processing came from (Ji et al., 1999) who 
showed the nociceptive-specific, intensity-dependent activation of PERK in the 
superficial dorsal horn of the spinal cord. Importantly, Ji et al. showed that pre-emptive 
blocking of PERK with i.t. delivery of PD98059 regulated pain behaviour by attenuating 
the second phase of nocifensive behaviours associated with hindpaw formalin 
stimulation by 70%.  
It is now known that persistent inflammation induced by various types of stimuli, such 
as hindpaw inflammation with formalin, CFA, capsaicin, scorpion venom, as well as 
CFA ankle joint inflammation and visceral pain hyperalgesia caused by bladder 
distention induce PERK expression in the spinal cord (Cruz et al., 2005; Ji et al., 2002, 
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1999; Lai et al., 2011). Under normal conditions, PERK requires a stimulus duration 
significant enough to induce persistent neural activity, and can be activated by high 
threshold mechanical stimulation mediated by C and Aδ-fibre activity (Gao and Ji, 
2010; Hao et al., 2005; Ji et al., 1999). Under pathological conditions however (i.e. 
inflammation, nerve injury), tactile stimulation is sufficient to induce PERK, and 
stimulation of A fibres is sufficient to induce PERK following disinhibition by GABAA 
receptor antagonists (Baba et al., 2003; Hao et al., 2005). Generally, spinal PERK 
expression peaks within five minutes and persists for no longer than an hour in the 
dorsal horn following noxious stimulation. 
Activation of PERK is known to be NMDA-dependent (Ji et al., 1999; Lever et al., 2003; 
Wei et al., 2006), and metabotropic glutamate receptor (mGlu) 1 and 5 are also 
required for PERK activation in models of inflammation (Karim et al., 2001; Kawasaki et 
al., 2004). Furthermore the activated neurokinin 1 (NK1) receptor is known to 
colocalise with PERK, although some controversy exists regarding NK1 activity 
contributing to PERK expression (Ji et al., 2002; Kawasaki et al., 2004; Lever et al., 
2003; Polgár et al., 2007; Wei et al., 2006). Not surprisingly, BDNF, the neurotrophin 
that binds to the TrkB receptor tyrosine kinase is also known to be a major contributing 
factor in PERK activation (Pezet et al., 2002).  
3.1.3 Aims 
A key study by Peleg et al. (2010) found increased expression of five of six investigated 
acetylated histone residues in the hippocampus 1h hour post- fear conditioning training, 
a time point associated with the early induction of synaptic plasticity associated with 
memory acquisition.  The modifications investigated included AcH3K9, AcH3K14, 
AcH4K5, AcH4K8, AcH4K12 and AcH4K16 which was the only acetylated residue with 
unaltered expression 1h post-fear conditioning. Furthermore, a study by Chwang et al. 
(2006) found that AcH3K14, PH3S10, and joint phosphoacetylation (PH3S10-
AcH3K14) were upregulated in the hippocampus 1h after fear conditioning training.  
The similarity of molecular events involved in the induction and maintenance of LTP, 
the proposed underlying neural correlate of memory formation, and central 
sensitisation (Ji et al., 2003), indicate that changes in histone modification may also be 
observed at early time points following injury-induced sensitisation. Furthermore, 
changes in gene expression, known to occur in the dorsal horn following noxious 
stimulation (Géranton et al., 2007), are preceded by and require histone modifying 
events. 
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The experiments in this chapter investigate eight specific histone modifications 
implicated in the studies by Peleg et al. (2010) and Chwang et al. (2006). Specifically, 
the aim of this chapter was to: 
1. Use Western blot and IHC to screen for any alterations in histone modification 
levels in the spinal cord following noxious formalin stimulation at early time 
points (1h) known to be key to the induction of central sensitisation.  
 
2. Investigate the effect of selective activation of C-fibre nociceptors on histone 
modification in the dorsal horn following i.pl. capsaicin. 
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3.2 Materials and Methods 
Please also see Chapter 2 for General Materials and Methods.  
3.2.1 Experimental Protocol 
There are 2 separate experiments in this chapter: 
3.2.1.1 Experiment 1: The preliminary analysis of various histone modifications in the 
spinal cord following noxious formalin stimulation 
There were 2 treatment groups: 
1. Formalin with anaesthesia 
2. Sham anaesthesia only 
All animals were sacrificed for fresh tissue (n=6 each group) or perfusion (n=1 each 
group) 1h following stimulation for western blot or immunohistochemistry (IHC) analysis, 
respectively.  
3.2.1.2 Experiment 2: Histone modification in the spinal cord following noxious 
capsaicin stimulation 
There was 1 group: 
1. Capsaicin with anaesthesia 
All animals were sacrificed for perfusion 1h following stimulation for IHC (n=4). There 
was no separate control group as the previous experiment established a very low level 
of PH3S10 nuclei in sham anaesthesia animals. Expression of PH3S10 in the 
contralateral dorsal horn corresponding to the non-stimulated hindpaw was so low that 
it was used as an internal control but not quantified here.  
3.2.2 Formalin stimulation 
Under isoflurane anaesthesia animals were given intraplantar formalin, 50µl 2% (see 
2.2). Sham animals were given general anaesthesia only. 
3.2.3 Capsaicin stimulation 
Intraplantar capsaicin, 25µl, 1% was given under isoflurane anaesthesia (see 2.2).  
3.2.4 Immunohistochemistry 
All staining done in this chapter were single stains done using either fluorescent IHC 
with TSA or Direct Alexa (see 2.5). Note that for this chapter PERK and PH3S10 were 
detected with TSA. See Table 2.2 and 2.3 for primary and secondary antibody 
concentrations.  
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Table 3.1 IHC experiments completed in Chapter 3. All investigations 1h post-stimulation. 
Asterisk indicates use of acid pretreatment antigen retrieval step (see 2.5.2). 
Immunostain Method of detection 
PERK TSA 
PH3S10 TSA 
PH3S10-AcH3K14 TSA 
AcH3K9 Direct Alexa 
AcH3K14 TSA* 
AcH4K8 Direct Alexa* 
AcH4K12 Direct Alexa 
AcH4K16 Direct Alexa 
 
3.2.4.1 Immunohistochemistry- Image acquisition 
Images of fluorescent IHC in this chapter were taken on the Leica TCS SPE Laser 
scanning confocal microscope using an air 10x optic lens, or a Hamamatsu CCD 
C4742 digital camera attached to a Leica DMR microscope using the software Volocity 
(PerkinElmer, Waltham MA, USA). Images of DAB staining were captured using a 
Nikon Coolpix E4500 digital camera attached to a Nikon Eclipse E800 microscope 
3.2.5 Western blot  
Ipsilateral and contralateral (to the injected hindpaw) dorsal horn tissue of L4-L6 (see 
2.4.1) was taken fresh and processed for histone extraction and western blot (see 2.6) 
(n=6 each group).  
3.2.5.1 Tissue homogenisation and histone extraction 
The nuclear-lysate TX Buffer extraction method (see 2.6) was used for the AcH3K9, 
AcH3K14, AcH412, AcH4K16, PH3S10 immunoblots. The lysate used for the AcH4K8 
immunoblot was homogenised and extracted using whole-cell lysate CHAPS extraction 
(see 2.6). See Tables 2.4 and 2.5 for primary and secondary antibody concentrations.  
3.2.5.2 Housekeeping gene products used for normalisation 
Due to the nature of the CHAPS extraction, on the AcH4K8 immunoblot, GAPDH was 
used as the internal housekeeping gene. For the AcH3K9, AcH3K14, AcH412, and 
AcH4K16 blots, Calnexin was used. For the PH3S10 blot, H4 was used. Calnexin and 
H4 are nuclear housekeeping gene products, suitable for use with the nuclear lysate-
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specific TX-buffer extraction, while GAPDH is a whole cell-lysate housekeeping gene 
product suitable for CHAPS extracted tissue samples. 
3.2.5.3 Western blot- Image acquisition  
Immunoblots were visualised using either a Chemi Doc XRS or Chemi Doc MP (Bio-
Rad, UK). Signal intensity was measured using Quantity One software or Image Lab 
(Bio-Rad, UK). 
3.2.5.4 Western blot- Quantification 
For the western blots in Experiment 1, the signal from the protein of interest was 
normalised with the intensity of the respective housekeeping protein signal from the 
same blot. This provided a protein/housekeeping gene ratio which was expressed as a 
percentage change from the mean control group (sham-anaesthesia only) value. The 
mean of the value for control animals was arbitrarily set to 100%.  Normalised signals 
were averaged for each treatment group and expressed as mean ± SEM. 
3.2.6 Statistical analysis 
Please also see 2.7 for full details of statistical analysis. 
3.2.6.1 Western blots 
Group means as calculated above (3.2.5.4) were analysed by univariate ANOVA with 
treatment (sham, treated- ipsilateral, and treated-contralateral) as the between-subjects 
factor. 
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3.3 Results 
3.3.1 Quantification of 6 different histone modifications in the dorsal horn 
indicates no significant changes following formalin stimulation 
Western blot was used to screen six different histone residues in ipsilateral and 
contralateral dorsal horn of formalin-stimulated and sham animals. Quantification of 
western blots did not show any significant formalin-induced changes in PH3S10, 
AcH3K9, AcH3K14, AcH4K8, AcH4K12, or AcH4K16 expression although a trend 
towards increased expression of PH3S10 was seen. (Figure 3.2). It should be noted 
that while the aim was to investigate the 8 aforementioned histone modifications by 
western blot, the experiment for AcH4K5 was unsuccessful as the antibody could not 
identify protein at the correct position on the gel. Moreover, PH3S10-AcH3K14 was not 
investigated by western blot.  
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Figure 3.2 Western blot analysis indicates no significant change in histone acetylation or 
phosphorylation in the dorsal horn of the spinal cord 1h post-intraplantar formalin 
stimulation. (n=5/6) 
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3.3.2 Immunohistochemistry suggests that histone phosphorylation is 
upregulated in the superficial dorsal horn 1h following formalin 
stimulation 
Although no significant formalin-induced changes in histone modification were 
observed in the dorsal horn with western blot analysis, additional preliminary screening 
was completed using IHC in order to observe the localisation of the histone 
modifications in dorsal horn tissue of formalin animals. There was no apparent 
difference between contralateral and sham expression as indicated by western blot, 
therefore only IHC from formalin stimulated tissue is shown. 
The majority of stains indicated that histone acetylation (AcH3K9, AcH3K14, AcH4K8, 
AcH4K12, AcH4K16, and co-occuring PH3S10-AcH3K14) was nuclear in expression 
and very densely expressed throughout both the ipsilateral and contralateral dorsal 
horn of formalin stimulated and sham animals (Figure 3.3). There were no visible 
differences between ipsilateral and contralateral expression in stimulated animals, and 
manual quantification would have been difficult due to the ubiquitous nature of positive 
staining. 
Remarkably, IHC suggested that histone phosphorylation at serine 10 (PH3S10) was 
the only histone residue to show a visible and obvious upregulation in the ipsilateral 
medial superficial dorsal horn following formalin stimulation and with low resting levels 
of activation. PH3S10 was upregulated in a small but distinct population of cells, and 
this upregulation was not observed in contralateral or sham ipsilateral tissue (Figure 
3.3). The upregulation of PH3S10 in the ipsilateral dorsal horn displayed a distribution 
pattern similar to the expression of PERK at 30min post-formalin (Figure 3.3, shown for 
comparison).  
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Figure 3.3 IHC screen of 7 histone modifications (at 1h) post-formalin. Preliminary screen 
suggests ipsilateral upregulation of histone H3 phosphorylation (PH3S10) but no change in 
histone H3 or H4 acetylation in the superficial dorsal horn 1h post-formalin. Scale bar 100µm. 
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3.3.3 PH3S10 is upregulated in the superficial dorsal horn following selective 
stimulation of C-fibres by capsaicin  
After preliminary IHC screening suggested that PH3S10 was upregulated in the dorsal 
horn following formalin stimulation, a full investigation into noxious stimulation-induced 
upregulation of PH3S10 was completed using i.pl. stimulation with capsaicin. In 
contrast to formalin which is capable of activating all primary afferents (see Discussion 
3.4), capsaicin selectively stimulates TRPV1- expressing C-fibre nociceptors. At 1h, 
capsaicin-induced PH3S10 was diffusely distributed across laminae I-II of the dorsal 
horn (10.0±1.0 nuclei/40µm section, n=4) (Figure 3.4). 
 
Figure 3.4 PH3S10 is upregulated in the ipsilateral superficial dorsal horn following 
intraplantar capsaicin stimulation. Scale bar 50µm. White line indicates border between 
lamina I and white matter. 
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3.4 Discussion 
It is well-established that key histone modifications indicative of active gene 
transcription are involved in models of neural plasticity, specifically in the hippocampus 
following memory formation. It is also well-known that changes in gene expression are 
essential to the full development of pain states. The main aim of this chapter was to 
identify candidate histone modifications involved in nociceptive processing, by 
investigating the expression of histone modifications in the dorsal horn following 
noxious stimulation.  A Western analysis of a number of candidate modifications failed 
to show obvious differences between stimulated and unstimulated sides of the dorsal 
horn of the spinal cord. However a follow up screen using immunohistochemistry 
confirmed high constitutive levels of most histone modifications examined but a specific 
and unique upregulation of PH3S10. 
3.4.1 Using formalin to induce acute inflammation  
Preliminary IHC experiments (Experiment 1) and results from the capsaicin study 
(Experiment 2) demonstrated that histone H3 is phosphorylated at the serine 10 
residue (PH3S10) in the dorsal horn following acute noxious stimulation. Following on 
from these results, it was decided that the rest of the experiments in this thesis would 
continue to utilise the formalin model to further investigate the role of PH3S10 in pain 
processing.  
There are many reasons why formalin is a relevant model for the purposes of this 
thesis.  The formalin stimulus is described as ‘moderate, continuous pain generated by 
injured tissue’ that generates ‘tonic’ pain which is measured across 1h of the formalin 
response (Tjølsen et al., 1992). Moreover, formalin-induced injury involves components 
of peripheral inflammatory and spinal dorsal horn central nervous system mechanisms 
(Tjølsen et al., 1992). However, considering its working function as a tissue fixative, 
formalin as a noxious stimulus may not be mediated by a specific receptor, although 
recent reports may suggest otherwise (see 3.4.1.1). While this caveat makes it difficult 
to dissect out fibre-specific contributions to behaviour and molecular targets, formalin at 
higher concentrations (2.5%) is known to cause broad activation of all primary afferents 
including A, Aδ and C fibres in the first phase response (Puig and Sorkin, 1996), and 
it has been reported that at 5% formalin induces upregulation of the nerve injury marker, 
ATF3, in both myelinated and unmyelinated fibres in the DRG (Bráz and Basbaum, 
2010). Notably, Experiment 2 confirmed that stimulation of nociceptive C-fibres alone, 
with i.pl. capsaicin was sufficient to induce PH3S10 in the dorsal horn (Caterina et al., 
1999). However, when investigating whether novel epigenetic mechanisms are 
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engaged in nociceptive processing, broad activation of primary afferent activity by 
formalin is advantageous as it includes C, Aδ, and A nociceptor activity, instead of 
selective C-fibre stimulation as is the case with capsaicin. Furthermore, the formalin 
response is an advantageous model behaviourally as it does not require stimulus-
evoked measurements to calculate changes in nociceptive threshold, but rather is 
characterised by spontaneous pain behaviours, a dominant clinical feature of chronic 
pain conditions (Tappe-Theodor and Kuner, 2014). Finally, for the purposes of Chapter 
6, the time course of the formalin model is short in duration (1h) and ideal for quick 
screening of therapeutic compounds. 
3.4.1.1 Mechanisms and effects of formalin concentration 
While the exact mechanisms of formalin-induced behaviour and molecular targets are 
still not entirely known, it is of general agreement that the first phase (first 10min) of the 
response is a result of peripheral nociceptor activation, while the second phase (20-
60min) is partly mediated by central sensitisation in spinal cord circuits following on 
from peripheral nociceptor sensitisation maintained by sustained Aδ and C-fibre activity 
(Dubuisson and Dennis, 1977; Fischer et al., 2014; Puig and Sorkin, 1996; Tjølsen et 
al., 1992). These findings have been elucidated by modulating the first phase of activity 
with pharmacological agents and looking at the second phase response. Both local 
hindpaw anaesthetic as well as brief spinal anaesthesia during the first phase response 
are sufficient to attenuate behavioural and neuronal characteristics observed during the 
second phase response (Coderre et al., 1990; Dickenson and Sullivan, 1987a, 1987b; 
Haley et al., 1990).  
More recently, it has been shown that at low concentration of formalin (0.5%), i.t. 
ablation of TRPV1 primary afferent central terminals using capsaicin attenuates the first 
10 minutes of nociceptive behavioural response seen after formalin stimulation (Shields 
et al., 2010). TRPV1-expressing unmyelinated neurons contain a small subset of 
TRPA1-expressing fibres which may account for these observations (Kobayashi et al., 
2005; Story et al., 2003) as it has been shown that low doses of formalin (0.5%) directly 
interact with the non-specific cation channel TRPA1 (Macpherson et al., 2007; 
McNamara et al., 2007). Interestingly, double ablation of the majority of C-fibres by 
targeting TRPV1-expressing nociceptors and Mrgprd, the G-protein coupled receptor 
that is expressed on the majority of non-peptidergic C-fibres, increased the latency to 
onset of formalin response (2min) but did not attenuate total nocifensive behaviour in 
either phase of formalin response generated with a higher dose of formalin (2%) 
(Shields et al., 2010). Although TRPV1/Mrgprd ablation did indeed lead to a reduction 
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in spinal cord c-Fos expression, Shields et al. suggest that the few remaining C-fibres 
after ablation as well as larger untouched myelinated Aδ afferents are sufficient to 
generate a full formalin response at the 2% formalin dose. However, the lack of 
behavioural differences seen may also be accounted for by different factors used in 
scoring of the formalin response (i.e. intensity vs. duration).   
3.4.2 Histone acetylation, HDACs, and HDAC inhibitors in the spinal cord after 
noxious stimulation 
It was somewhat surprising to find no global changes in formalin-induced histone 
acetylation in the spinal cord by western blot analysis (Experiment 1). Given that global 
HDAC levels in the dorsal horn are indeed altered during CFA-induced persistent pain 
states in mice and rats (Bai et al. 2010; Tochiki et al. 2012), it would seem logical to 
also expect changes in histone acetylation levels. Bai et al. showed an increase in 
dorsal horn expression of class IIa HDACs 4, 5, 7, and 9 up to 6 hours following 
intraplantar CFA inflammation.  The same study also found that pre-emptive i.t. delivery 
of HDAC inhibitors suberoyl anilide hydroxamic acid (SAHA), valproic acid (VPA), 
trichostatin A (TSA), 4-phenyl butyrate (4-PB), and LAQ-824 delayed the onset of 
thermal hyperalgesia, which was shown to cause an increase in spinal cord AcH3K9 
levels.  Tochiki et al. (2012) reported bilateral upregulation of class I/IIa HDACs 1 and 5 
mRNA in the dorsal horn 7d after CFA ankle joint injection. However, it is important to 
note that while Bai et al. showed attenuation of thermal hypersensitivity with Class I 
and Class IIa HDAC inhibitors (with the exception of MS-275), the authors never 
indicated whether injury lead to changes in histone acetylation per se. This is an 
important consideration due to the fact that HDAC inhibitors can act on substrates 
other than histones. 
Moreover, although western blot analysis in Experiment 1 showed no global changes in 
formalin-induced acetylation levels, i.p. delivery of the class I HDAC inhibitor, MS-275, 
as well as class II inhibitor SAHA have been previously shown to attenuate the second 
phase of the formalin response (Chiechio et al., 2009). Due to the non-specificity of 
HDAC inhibitors, Chiechio et al. found hyperacetylation of the p65 transcription factor, 
a regulator of NFκB genes including the mGlu2 receptor, which increased in DRG and 
spinal cord after HDAC inhibition. However, again, no injury-induced changes in 
acetylation were reported in this study. 
It is worth mentioning that changes in global acetylation can easily overlook locus-
specific changes in acetylation levels. Indeed, the majority of pain studies concerning 
histone modification have investigated acetylation levels linked to specific transcription 
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factor or gene targets such as transcription factors p65 and REST, Bdnf and Nav1.8 in 
the DRG, KC (ligand for CXCR2) and CXCR2 in the spinal cord, and Gad2 in the NRM 
(Chiechio et al., 2009; Matsushita et al., 2013; Sun et al., 2013; Uchida et al., 2010; 
Uchida et al., 2010; Uchida et al., 2013; Zhang et al., 2011). Furthermore, results in this 
chapter indicated that basal levels of histone acetylation in sham animals were much 
higher and more ubiquitously expressed in comparison to that of PH3S10, which may 
have made it difficult to detect any significant changes in expression after stimulation. It 
also suggests that the obvious increase in spinal cord PH3S10 may indicate that 
histone phosphorylation is more specific to nociception than histone acetylation. 
The initial studies in the pain epigenetics field were quick to investigate the effects of 
HDAC inhibitors on behavioural hypersensitivity in inflammatory and neuropathic pain 
models. While the studies showed that global or locus-specific histone acetylation 
levels expectedly increased after delivery of HDACi (Bai et al., 2010; Chiechio et al., 
2009; Denk et al., 2013; Matsushita et al., 2013; Sun et al., 2013; Zhang et al., 2011), 
only Matsushita et al., Sun et al., and Zhang et al. rightly established first that 
acetylation is in fact deregulated following induction of a pain state (Nerve injury-
induced hypoacetylation of H3/H4 at Nav1.8 in the DRG, incision-induced AcH3K9 in 
the spinal cord, and hypoacetylation of H3 at Gad2 in the NRM, respectively).  
The literature conclusively indicates that histone acetylation plays a role in various 
types of pain states, and IHC results in this chapter also indicate that histone 
phosphorylation is engaged and upregulated after noxious stimulation. 
3.4.3 Technical limitations  
PH3S10 western blot vs. immunohistochemistry 
Although the IHC screen of histone modifications completed in Experiment 1 (Figure 
3.3) was not exhaustive (i.e. insufficient number of animals), preliminary results 
revealed a ubiquitous distribution of acetylated histone residues in the spinal cord. 
There were no obvious visible formalin-induced differences in histone acetylation, 
which was confirmed by western blot. It should be noted that distribution of histone 
acetylation as indicated by IHC was ubiquitous and extremely variable (i.e. patchy), 
which would have made manual quantification difficult. Thus, no further attempts were 
made toward the investigation of these residues.  
Interestingly, the upregulation of PH3S10 nuclei in the ipsilateral dorsal horn visible by 
IHC was not confirmed by results from the western blot. While this is disappointing, it is 
not surprising as the quantified PH3S10 population was roughly 20 labelled nuclei at 
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the 1h time point. It is likely that a western blot might not be sensitive enough of a 
technique to detect such a limited population size. Furthermore, the spinal cord 
dissection used here included the entire dorsal half of the spinal cord rather than a 
laminae I-II specific sampling and therefore may have resulted in a dilution of any 
changes in expression. However, it should be noted here that Denk et al. (2013) were 
able to detect differences in histone acetylation (AcH3K9) in dorsal ipsilateral vs. 
contralateral segments in the d4T (stavudine, anti-retroviral drug known to cause 
neuropathy) and spinal nerve transection models of neuropathic pain. The IHC results 
from this Experiment 1 and Experiment 2 suggested that IHC was the best method 
forward for investigating the PH3S10 population.  
Western blot housekeeping gene products 
Total H3 was an additional candidate as a housekeeping gene product for 
normalisation of histone modifications investigated, but the antibody did not detect 
protein at the correct position on the gel and thus could not be used. 
 
3.5 Conclusions 
In summary, preliminary IHC results indicated that noxious stimulation by both formalin 
and capsaicin caused an increase in histone modification in the ipsilateral superficial 
dorsal horn. Upregulation following noxious stimulation was specific to histone 
phosphorylation (PH3S10), as no changes in histone acetylation were observed. 
Furthermore, expression of PH3S10 was highly specific and restricted to a small 
population of neurons, and upregulation at the 1h time point correlated with the 
induction phase of pain states. 
Following on from these results, the next aim was to use IHC to further investigate the 
PH3S10 population after noxious formalin stimulation, and in particular, examine the 
expression of PH3S10 within the pain pathway.  
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4.1 Introduction 
Findings in Chapter 3 indicated that histone phosphorylation (specifically PH3S10) was 
upregulated in the superficial dorsal horn following hindpaw formalin and capsaicin 
stimulation. Studies have indicated that PH3S10 is a marker of active gene 
transcription (Crosio et al., 2003; Mahadevan et al., 1991; Thomson et al., 1999), and 
is induced after both pharmacological and experience-dependent activity in the brain, 
specifically the hippocampus (Borrelli et al., 2008; Riccio, 2010; Sweatt, 2009; Zocchi 
and Sassone-Corsi, 2010). However, PH3S10 has never been studied in the spinal 
cord. This chapter describes experiments aimed at further investigating the expression 
and cellular profile of PH3S10 in the dorsal horn after noxious stimulation. 
4.1.1 PH3S10: A marker of gene transcription  
Mahadevan et al. were the first to correlate activity-induced PH3S10 expression with 
the IEGs c-Fos and c-jun, subsequently setting the scene for PH3S10 as a marker of 
active gene transcription in both non-neural and neural cells (Crosio et al., 2003; 
Mahadevan et al., 1991; Thomson et al., 1999). Along with other histone modifications, 
PH3S10 plays an important role in chromatin remodelling, in particular the 
decondensation of tightly-wrapped chromatin to allow transcription factor access to 
DNA. Levels of PH3S10 are known to correlate with synaptic activity-induced increases 
in nuclear infolding, with high infolding of the nucleus being indicative of increased 
gene transcription (Wittmann et al., 2009). Furthermore, histone phosphorylation is 
engaged in various forms of activity-induced neuronal activity, namely memory 
formation, drug addiction, and visual processing (Chandramohan et al., 2007; Chwang 
et al., 2006; Ciccarelli et al., 2013; Crosio et al., 2000; Kumar et al., 2005; Putignano et 
al., 2007; Rotllant and Armario, 2011). Interestingly, PH3S10 is also widely used as a 
marker of mitotic cell division, and studies conversely indicate that PH3S10 is 
correlated with chromatin condensation during this event (Prigent and Dimitrov, 2003). 
The seemingly contradicting roles for PH3S10 in chromatin remodelling indicate that 
the same modification can have separate functions depending on context (Jenuwein 
and Allis, 2001; Nowak and Corces, 2004). 
PH3S10 is regulated by ERK/MAPK signalling, primarily by the mitogen- and stress-
activated protein kinases 1 and 2 (MSK1, MSK2), which lie downstream of ERK (Deak 
et al., 1998; Soloaga et al., 2003). The fact that ERK/MAPK signalling also plays a 
crucial role in pain processing provides a strong basis for investigating PH3S10 in 
nociception. Further information on MSK1 and MSK2 will be addressed in Chapter 6, 
and ERK regulation of S10 is discussed at the end of this chapter. 
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4.1.2 PERK and immediate early gene (IEG) proteins c-Fos and Zif268: Markers 
of neuronal activation following noxious stimulation 
As previously highlighted, PERK is required for the full development of inflammatory 
pain states, and is widely used as a marker of nociceptive neuronal activation in the 
spinal cord and brain (Gao and Ji, 2009; Ji et al., 2009).  
The IEG product c-Fos is another widely used classical marker of noxious stimulation, 
c-Fos being a proto-oncogene rapidly induced following neurotransmitter release 
(Greenberg et al., 1986). Hunt et al. were the first to identify upregulation of c-Fos 
protein in the ipsilateral dorsal horn following peripheral stimulation using noxious heat 
and mustard oil (Hunt et al., 1987), and it has subsequently been found that c-Fos is 
also induced by noxious mechanical and various chemical stimuli in an intensity-
dependent manner. Similar to PERK, c-Fos can be induced by normally non-noxious 
stimuli following inflammation and nerve injury (Bester et al., 2000; Kosai et al., 2001; 
Ma and Woolf, 1996; Molander et al., 1994; Wei et al., 1999).  
The majority of c-Fos expression occurs within laminae I-II, similar to that of PERK; 
however c-Fos is nuclear in expression and has a comparatively larger population size 
(Gao and Ji, 2009). As c-Fos protein expression requires gene transcription, it is 
difficult to target unless using RNA interference. In the rodent dorsal horn, peak protein 
levels of c-Fos occur at the 1-2 hour time point after noxious stimulation, although c-
Fos mRNA is known to peak at 30 minutes (Figure 4.1). It has been shown that 
formalin-induced c-Fos occurs in both excitatory and inhibitory interneurons in the 
dorsal horn (Hossaini et al., 2010). Some controversy exists over the use of PERK vs. 
c-Fos as a marker of activation by nociceptive stimuli (Gao and Ji, 2009) due to the fact 
that certain repetitive non-noxious stimuli can induce c-Fos but not PERK, such as 
rotarod walking or brush stroking (Neumann et al., 2008). Moreover, the duration of 
noxious stimulation required to induce central sensitisation is also a factor as only 
longer lasting stimuli generating persistent lasting changes in spinal cord activity are 
capable of activating PERK (Gao and Ji, 2009). Please see Chapter 6 for discussion of 
c-Fos and PERK correlation with pain behaviour. 
Zif268 (encoded by Egr-1) has also been established in the dorsal horn as a marker of 
nociceptive stimulation (Wisden et al., 1990), although it is not as frequently used as c-
Fos. Zif268 is well characterised in the hippocampus as being necessary to the 
induction of LTP, and is generally recognised as a marker of neural plasticity 
(Beckmann and Wilce, 1997; Hughes and Dragunow, 1995; Lanahan and Worley, 
1998). Rapidly activated c-Fos and Zif268 appear to regulate a multitude of 
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downstream gene targets and the protein products themselves are inducible 
transcription factors. In nociception, hindpaw CFA- induced Zif268 peaks at 1-2 hours  
(Géranton et al., 2008) (Figure 4.1), and antisense knockdown of Zif268 upregulation 
has been shown to attenuate mechanical hyperalgesia (Rygh et al. 2006). Furthermore, 
Zif268 expression is regulated by descending serotonergic activity from the RVM, and 
ablation of these fibres leads to a reduction of both spinal c-Fos and Zif268 (Géranton 
et al., 2008). 
A final transcription factor and epigenetic “reader” that is also expressed in the 
superficial dorsal horn following noxious stimulation is phospho-methyl-CpG-binding 
protein 2 (PMeCP2) (Géranton et al., 2008, 2007). PMeCP2 is a global regulator of 
gene transcription and is known to peak in the dorsal horn 1h following noxious 
peripheral stimulation. Silencing the transcription of one of the downstream targets of 
PMeCP2, the serum and glucocorticoid kinase 1 (SGK1), delays the onset of CFA-
induced mechanical hypersensitivity. 
 
Figure 4.1 Time course of PERK, PMeCP2, and IEG product expression in the superficial 
dorsal horn following noxious peripheral stimulation. PERK is known to peak at 5 minutes 
and PMeCP2 at 1h, while IEG products c-Fos and Zif268 are not expressed before 1h.  
4.1.3 The role of NK1 projection neurons in pain processing 
The neurokinin-1 (NK1) receptor is the target for the neurotransmitter substance P (SP), 
and has long been of interest in nociception because it is selectively expressed on 
dorsal horn neurons responsive to noxious stimuli (De Koninck and Henry, 1991; Doyle 
and Hunt, 1999; Salter and Henry, 1991). In lamina I of the lumbar region, 45% of 
neurons are known to be immunoreactive for NK1 (Todd et al., 1998). While not all 
lamina I projection neurons are NK1 positive, the majority are (80%), and synapse in 
the lateral parabrachial area (95% of all projection neurons) (Al-Khater et al., 2008; 
Spike et al., 2003; Todd et al., 2000). NK1 positive projection neurons in particular are 
known to play a key role in neuropathic and inflammatory pain processing (Mantyh et 
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al., 1997; Nichols et al., 1999). Mantyh et al. were the first to demonstrate the 
importance of these neurons in nociceptive processing using SP conjugated to the 
ribosome inactivating toxin, saporin (SP-SAP). I.t. SP-SAP led to an 85% reduction of 
SP immunoreactivity 28 days following delivery, and attenuated 85% and 60% of 
capsaicin-induced mechanical and thermal hyperalgesia, respectively. Ablation of NK1 
projection neurons is also known to decrease receptive field size in deep dorsal horn 
neurons, and activity of NK1 projection neurons is thought to act via descending 
pathways from the brainstem containing 5HT (Suzuki et al., 2002). Specifically, the 
ablation of NK1-positive projection neurons prevented inflammation-induced changes 
in hypersensitivity and spinal excitability to the same degree as the ablation of the 
descending 5HT facilitatory projections to the dorsal horn from the RVM. NK1 itself is 
upregulated in the superficial dorsal horn 48 hours after intraplantar CFA stimulation 
(Abbadie et al., 1997; Ji et al., 2002). 
4.1.4 Aims 
Results from Chapter 3 established that PH3S10 upregulation induced by noxious 
stimulation was coupled with the induction phase of pain states. It is well-established 
that PH3S10 is regulated by ERK/MAPK via MSK1 and MSK2 (Deak et al., 1998; 
Soloaga et al., 2003). Due to the fact that ERK/MAPK signalling is known to play a 
crucial role in the full expression of pain states (Ji et al., 1999), it was expected that 
PH3S10 expression would occur within cells activated by nociceptive signalling.  
The aim of this chapter was to further investigate the expression of PH3S10 in the 
spinal cord after hindpaw formalin stimulation. Specifically, to use IHC to: 
1. Investigate the time course of formalin-induced PH3S10 upregulation. 
 
2. Identify the cellular specificity of PH3S10 (as identified by colocalisation with 
neuronal marker NeuN, inhibitory interneuron markers PV and nNOS, excitatory 
interneuron marker calbindin, and glial markers APC CC1, GFAP, and Iba-1) 
 
3. Investigate the colocalisation of PH3S10 with markers indicating neurons key to 
pain processing (PERK, NK1, c-Fos, and Zif268) 
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4.2 Materials and Methods 
Please also see Chapter 2 for General Materials and Methods.  
4.2.1 Experimental design 
All animals were stimulated in the hindpaw with formalin, sacrificed for perfusion, and 
spinal cord tissue used for immunohistochemistry (see 2.4.2).   
For the PH3S10 Time Course experiment: Animals had a survival time of 5min, 30min, 
1h, 2h, 4h or 6h (n=3 for all time points except 4h and 6h, n=1).  
For PH3S10 Colocalisation Studies: The survival time post- formalin stimulation 
depended on the molecular marker of interest; a time point was chosen to maximise 
the overlap of PH3S10 and the second population of interest (see Figure 4.10). All 
colocalisation investigations of PH3S10 in this chapter used the 1h time point, except 
for PH3S10/ PERK which was investigated 30min (n=3/4 each double stain) (Table 
4.1). 
4.2.2 Formalin stimulation 
All animals were given intraplantar formalin, 50µl 2% under isoflurane anaesthesia (see 
2.2.1).  
4.2.3 Immunohistochemistry 
Please refer to section 2.5 for the full immunohistochemical protocol and antibody 
information. The majority of immunohistochemistry experiments done in this chapter 
were double label stains (Table 4.1). 
 
 
 
 
 
 
 
 
 
Chapter 4  
      Cellular characterisation of PH3S10 in the dorsal horn following noxious stimulation 
 
99 
 
Table 4.1 IHC experiments completed in this chapter 
Immunostain 1
st
 primary Method of 
detection 
2
nd
 primary Method of 
detection 
Time 
point 
PH3S10 time 
course 
PH3S10 TSA - - various 
PH3S10/NeuN PH3S10 TSA NeuN Direct Alexa 
594 
1h 
PH3S10/GFAP PH3S10 TSA GFAP Direct Alexa 
594 
1h 
PH3S10/APC CC1 PH3S10 TSA APC CC1 Direct Alexa 
594 
1h 
PH3S10/Iba-1 PH3S10 TSA Iba-1 Direct Alexa 
594 
1h 
PH3S10/nNOS nNOS TSA PH3S10 Direct Alexa 
594 
1h 
PH3S10/PV PH3S10 TSA PV Direct Alexa 
594 
1h 
PH3S10/Calbindin PH3S10 TSA Calbindin Direct Alexa 
594 
1h 
PH3S10/PERK PERK TSA PH3S10 Direct Alexa 
594 
30min 
PH3S10/NK1 NK1 TSA PH3S10 Direct Alexa 
594 
1h 
PH3S10/c-Fos c-Fos TSA PH3S10 Direct Alexa 
594 
1h 
PH3S10/Zif268 Zif268 TSA PH3S10 Direct Alexa 
594 
1h 
 
Where PH3S10 was applied as a second primary, acid pretreatment was used for 
antigen retrieval prior to blocking (see 2.5.2). 
4.2.4 Immunohistochemistry- Image acquisition 
Images of fluorescent immunohistochemistry in this chapter were taken on the Leica 
TCS SPE laser scanning confocal microscope, or a Hamamatsu CCD C4742 digital 
camera attached to a Leica DMR microscope using the software Volocity (PerkinElmer, 
Waltham MA, USA). All images for colocalisation were taken in a single focal plane. 
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4.2.5 Immunohistochemistry- Quantification 
 
PH3S10 Time Course 
With the experimenter blind to treatment, immunopositive cell counts for all sections 
were quantified manually by laminae (I-II and III-V) on the ipsilateral and contralateral 
side of the dorsal horn using a Leica DMR fluorescent microscope.  
Once all sections were counted, per animal, five sections with the maximum response 
(ipsilateral) were used and the average taken. The average of the treatment group was 
then calculated along with the standard error of each group mean (SEM). 
Double Stains- population percentage overlap 
The goal was to obtain a percentage overlap of the two labelled populations of interest. 
Firstly, cells were quantified using above protocol (PH3S10 Time Course) for the 
PH3S10 population. Then, using the same tissue sections, the second population of 
interest, as well as the population of double labelled cells were quantified. The 
percentage of double labelling was then calculated for each section of tissue, and 
averaged per animal. Finally, the average percentage of double labelling for the group 
was presented as mean ± SEM.  
Because the maximal expression of two populations of interest may not occur in the 
same tissue sections, out of interest, the maximum the percentage overlap was also 
calculated by selecting the tissue sections with maximal response from the non-
PH3S10 population. Five sections with maximum response for the non-PH3S10 
population (ipsilateral) were selected. The PH3S10 counts and double labels from the 
same sections of tissue were counted. The percentage of double labelling was 
calculated for each section of tissue and averaged per animal. Finally, the average 
percentage of double labelling for the group was presented as mean ± SEM. 
All means were calculated from a 40µm section of spinal cord tissue. 
It was previously established in Chapter 3 that upregulation of PH3S10 nuclei were 
only observed in the ipsilateral dorsal horn and rarely seen in sham-only, or 
contralateral spinal cords of stimulated animals (~1 cell/40µm section in superficial 
laminae) (Figure 3.2). Thus, sham anaesthesia controls were not used in this chapter. 
Instead, the contralateral side of the spinal cord of stimulated animals was used as an 
internal control. Contralateral PH3S10 expression was only quantified in the PH3S10 
Time Course experiment.  
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4.3 Results 
4.3.1 PH3S10 time course: PH3S10 is upregulated in the spinal cord 5 minutes 
post-formalin and peaks at 30-60 minutes  
PH3S10 serves as an indicator of active gene transcription in vitro, and we investigated 
its expression following noxious stimulation.  There was a rapid expression of PH3S10 
labeled nuclei in the medial superficial dorsal horn following intraplantar formalin 
injection. The number of PH3S10 neurons was greater on the ipsilateral side compared 
to the contralateral side, where PH3S10 expression levels were extremely low (Figure 
4.2).  Expression of PH3S10 in superficial laminae I-II peaked at the 30min time point 
(mean, 20.5 ± 3.2 cells per 40µm section).  In deeper laminae III-V, expression of 
PH3S10 was maximal at 1h (mean, 13.3 ± 1.7 cells per 40µm section).  By 4 hours, 
PH3S10 levels were comparable to the counts seen in the contralateral as well as 
sham animals (data not shown). 
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Figure 4.2 PH3S10 is expressed in the ipsilateral dorsal horn after hindpaw formalin 
inflammation. A) Ipsilateral and contralateral expression of PH3S10 in laminae I-II and B) 
laminae III-V (n=3 each time point, 5 sections per animal). Values presented as group mean ± 
SEM (per 40µm section). C) Low-power representative image of PH3S10 distribution within the 
L4 dorsal horn. Arrowheads indicate expression in medial superficial dorsal horn and deeper 
laminae, respectively, at 30min. Scale bar 50µm. D) High power image of PH3S10 indicates 
that it is nuclear in distribution. Scale bar, 30µm. White lines indicate border between grey and 
white matter.  
 
4.3.2 Formalin-induced PH3S10 expression is mainly neuronal and rarely 
observed in glia 
Colocalisation of PH3S10 and the neuronal marker NeuN indicated that the great 
majority of PH3S10 was upregulated in neurons. PH3S10 was rarely seen to colocalise 
with glial cells using the astrocyte marker, glial fibrillary acidic protein (GFAP), as well 
as the oligodendrocyte precursor marker APC CC1, and Iba-1, a marker of microglial 
activation. Some colocalisation, however, was observed although primarily between 
background levels of PH3S10 and respective glial marker (Figure 4.3).  
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Figure 4.3 Formalin-induced PH3S10 is expressed in neurons and although rare, was 
found to colocalise with glial markers in the dorsal horn. A) Lineage and markers of glial 
subtypes. Image from Cunningham (unpublished). B) Double labelled stains taken in a single 
focal plane for PH3S10 with NeuN, GFAP, APC CC1, and Iba1 (Rows 1-4, respectively) in 
formalin-stimulated animals.  First column images (red) indicate positive staining for cell type 
investigated (NeuN, GFAP, APC CC1, Iba1). Second column images (green) indicate PH3S10, 
and third column images are column 1 and 2 images merged; yellow indicates colocalisation. 
Arrowheads indicate examples of colocalisation and show that almost all PH3S10 nuclei were 
NeuN positive. In merged glial images, PH3S10 represents background staining. Scale bar top 
row, 25µm, lower scale bar 40µm.  It should be noted that the above colocalisation shown of 
PH3S10 with glial markers GFAP, APC CC1, and Iba1 was rare and not representative of the 
extent of overlap. 
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4.3.3 Formalin-induced PH3S10 is not expressed in GABAergic inhibitory 
interneurons labelled with PV or nNOS  
NPY, Galanin, PV, and nNOS are known to label GABAergic interneurons, and an 
attempt was made to colocalise PH3S10 to PV and nNOS. PH3S10 did not colocalise 
with the inhibitory interneuron markers nNOS or PV as the population distributions 
were in different areas of the superficial dorsal horn. Both nNOS and PV appeared to 
localise in deeper lamina Iii, with PV distributed more laterally (Figure 4.4). An attempt 
was made to colabel PH3S10 with the markers NPY and Galanin, but it was not 
possible to identify cell bodies and colocalisation could not be observed. 
 
Figure 4.4 Formalin-induced PH3S10 does not colocalise with inhibitory interneurons 
labelled with PV and nNOS. Dorsal horn images of PV and PH3S10, and nNOS and PH3S10 
double labelling taken in a single focal plane in a formalin-stimulated animal. White lines 
indicate border between lamina I and white matter; arrowheads indicate PH3S10 and PV or 
nNOS positive cells that are clearly not overlapped. Scale bars 50µm. 
 
4.3.4 Formalin-induced PH3S10 does not appear to be expressed in 
glutamatergic calbindin positive neurons 
The calcium-binding protein calbindin is a marker labelling glutamatergic cell bodies 
(Todd, 2010), and an attempt was made to colabel PH3S10 with calbindin. PH3S10 
nuclei did not appear to colocalise with calbindin, although some colocalisation was 
observed between calbindin and background levels of PH3S10 (Figure 4.5).  
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Figure 4.5 PH3S10 does not colocalise with a population of glutamatergic cells labelled 
with Calbindin. Dorsal horn images of Calbindin and PH3S10 double labelling taken in a single 
focal plane in a formalin-stimulated animal. White lines indicate border between lamina I and 
white matter; arrowhead indicates one example of background PH3S10 staining which appears 
to colocalise with calbindin, but this was considered background staining. Scale bar 50µm. 
 
4.3.5 PH3S10 colocalises with NK1 neurons 
Excitatory NK1 positive neurons are selectively activated by noxious stimuli and 
colocalisation of PH3S10 and NK1 was investigated. Analysis of PH3S10 colocalisation 
with lamina I NK1 neurons at 1h post-formalin indicated that 17% of lamina I NK1 
expressing neurons also coexpressed PH3S10 (mean NK1 population 6.5 ± 1.5).  Due 
to the small NK1 population size, only 5% of laminae I-II PH3S10 coexpressed NK1 
(mean PH3S10 population 27.1 ± 3.8). For laminae III-V, 17% of NK1 positive cells 
colabelled with PH3S10 (mean NK1 population 6.1 ± 1.2), while only 4% of PH3S10 
colabelled NK1 (mean PH3S10 population 18.2 ± 3.6) (Figure 4.6, Table 4.2). 
Importantly, there was no difference in percentage overlap values when using 5 
sections with maximum response per animal from either the PH3S10 or NK1 
population. 
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Figure 4.6 Formalin-induced PH3S10 is partially found in lamina I NK1 neurons.  A) Dorsal 
horn images of NK1 (green) and PH3S10 (red) double labelling taken in a single focal plane in a 
formalin-stimulated animal. The final image shows a merge of the first two images; NK1 is a 
cell-surface receptor and thus colocalisation is shown as NK1 surrounding the PH3S10 labelled 
nucleus. White line indicates medial border between lamina I and white matter; arrowhead 
indicates example of colocalisation. Scale bar, 30µm. B) Venn diagram depicting overlap of 
PH3S10 and NK1 populations. Percentages indicate percentage of population not double 
labelled; values in parentheses indicate population size expressed as mean value 
(immunopositive cells per 40µm section) ± SEM (n=3, 5 sections per animal). 
 
4.3.6 PH3S10 colocalises with PERK, a marker of nociceptive activation  
PERK was used to label neurons in the dorsal horn receiving nociceptive-specific 
primary afferent input. As expected PERK showed a strong upregulation in laminae I-II 
in an area larger than where PH3S10 was expressed but still overlapping.  
Coexpression of PH3S10 and PERK populations was assessed at 30min, a time point 
used to obtain the maximum overlap of the two populations given their respective time 
course of expression following noxious stimulation (Figure 4.10).  Indeed, PERK 
expression peaks 5 minutes post-formalin but is still strongly expressed at 30 minutes. 
58% of all PH3S10-expressing cells colabelled with PERK (mean PH3S10 population 
26.3 ± 1.2), while 42% of PERK-expressing cells also expressed PH3S10 (mean PERK 
population 30.7 ± 3.7). For deeper laminae III-V, similar percentages of colocalisation 
were observed. 53% of PH3S10-expressing cells colabelled PERK (mean PH3S10 
population 10.3 ± 0.6) and 40% of PERK- expressing cells also coexpressed PH3S10 
(mean PERK population 16.6 ± 5.5) (Figure 4.7, Table 4.2). Importantly, there was no 
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difference in percentage overlap values when using 5 sections with maximum response 
per animal from either the PH3S10 or PERK population.  
 
Figure 4.7 Formalin-induced PH3S10 is partially expressed in PERK labelled neurons in 
the dorsal horn. A, C) Dorsal horn images of PERK (green) and PH3S10 (red) double labelling 
taken in a single focal plane in a formalin-stimulated animal, in laminae I-II (A) and III-V (C). The 
final image shows a merge of the first two images; colocalisation appears yellow. White line 
indicates medial border between lamina I and white matter; arrowheads indicate examples of 
colocalisation. Scale bar 30µm (A), 50µm (C). B, D) Venn diagram depicting overlap of 
PH3S10/PERK populations in laminae I-II (B) and III-V (D). Percentages indicate percentage of 
population not double labelled; values in parentheses indicate population size expressed as 
group mean (immunopositive cells per 40µm section) ± SEM (n=3, 5 sections per animal). 
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4.3.7 PH3S10 colocalises with the immediate early gene products c-Fos and 
Zif268 
c-Fos and Zif268 are IEG markers of neuronal plasticity known to have maximal 
expression in the ipsilateral dorsal horn 1-2h after noxious stimulation. Robust 
upregulation of both c-Fos and Zif268 was observed 1h post-formalin. Both populations 
had a larger and more anatomically widespread distribution compared to the PH3S10 
population. 60% of PH3S10 coexpressed c-Fos (mean PH3S10 population 19.3 ± 4.2), 
while 17% of c-Fos coexpressed PH3S10 (mean c-Fos population 38.5 ± 2.4) (Figure 
4.8, Table 4.2). 57% of the PH3S10 population of neurons coexpressed Zif268 (mean 
PH3S10 population 10.6 ± 1.1), while 12% of the Zif268 population coexpressed 
PH3S10 (mean Zif268 population 59.5 ± 6.6) (Figure 4.9, Table 4.2). Importantly, there 
were no differences in percentage overlap values when using 5 sections with maximum 
response per animal from either the PH3S10 or c-Fos/Zif268 population. 
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Figure 4.8 Formalin-induced PH3S10 colocalises with immediate early gene product and 
marker of nociceptive synaptic plasticity, c-Fos. Dorsal horn images of double labelling for 
PH3S10 and c-Fos in formalin-stimulated animals taken in a single focal plane.  A) Top row 
contains low power images and bottom row higher power images of the same region. First 
column images (green) indicate positive staining for c-Fos. Second column images (red) 
indicate PH3S10, and third column images are column 1 and 2 images merged; colocalisation 
appears yellow. White line indicates medial border between lamina I and white matter; 
arrowhead indicates example of PH3S10 nuclei not double labelled with c-Fos. Scale bar upper, 
50µm; lower, 30µm. B) Venn diagram depicting overlap of two populations. Percentages 
indicate percentage of population not double labelled; values in parentheses indicate population 
size expressed as mean value (immunopositive cells per 40µm section) ± SEM (n=4, 5 sections 
per animal). 
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Figure 4.9 Formalin-induced PH3S10 colocalises with immediate early gene product 
Zif268. Dorsal horn images of double labelling for PH3S10 and Zif268 in formalin-stimulated 
animals taken in a single focal plane.  A) Top row contains low power images and bottom row 
higher power images of the same region. First column images (green) indicate positive staining 
for c-Fos. Second column images (red) indicate PH3S10, and third column images are column 
1 and 2 images merged; colocalisation appears yellow. White line indicates medial border 
between lamina I and white matter; arrowhead indicates example of Zif268 nucleus not double 
labelled with PH3S10. Scale bar upper, 50µm; lower, 30µm. B) Venn diagram depicting overlap 
of PH3S10 and Zif268 populations. Percentages indicate percentage of population not double 
labelled; values in parentheses indicate population size expressed as mean value 
(immunopositive cells per 40µm section) ± SEM (n=4, 5 sections per animal). 
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Table 4.2 Summary of population sizes and overlap of PH3S10 with markers of the pain 
pathway in the ipsilateral dorsal horn post-formalin. Values are presented as mean ± SEM 
per tissue slice, 40µm thickness (n=3/4 animals each colocalisation; 5 tissue sections per 
animal). 
Marker Population 
Size            
(# cells) 
PH3S10 
population 
size             
(# cells) 
Double 
labelled   
(# cells) 
%          
PH3S10 
expressing 
Marker 
%            
Marker 
expressing 
PH3S10 
Time point 
investigated 
PERK 
(Lam1-2) 
PERK 
(Lam3-5) 
30.7 ± 3.7 
 
16.6 ± 5.5 
26.3 ± 1.2 
 
10.3 ± 0.6 
8.9 ± 4.1 
 
5.1 ± 1.1 
58% 
 
53% 
42% 
 
40% 
 
30 min 
NK1    
(Lam 1) 
NK1 
(Lam3-5) 
6.5 ± 1.5 
 
6.1 ± 1.2 
27.1 ± 3.8 
 
18.2 ± 3.6 
1.3 ± 0.7 
 
0.8 ± 0.4 
5% 
 
4% 
17% 
 
17% 
 
1h 
 
c-Fos 
(Lam1-2) 
38.5 ± 2.4 19.3 ± 4.2 6.2 ± 1.2 60% 17% 1h 
Zif268 
(Lam1-2) 
59.5 ± 6.6 10.6 ± 1.1 6.3 ± 1.2 57% 12% 1h 
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4.4 Discussion 
PH3S10 is a histone modification associated with transcriptional activation in neurons 
and is regulated by ERK/MAPK signalling in various forms of neuronal plasticity. In this 
chapter it was shown that PH3S10 is upregulated in the dorsal horn of spinal cord 
neurons immediately and transiently after noxious hindpaw stimulation. It was also 
shown that PH3S10 occurred within neurons expressing markers of the pain pathway, 
PERK, NK1, c-Fos, and Zif268.  
4.4.1 Intracellular signalling: linking PERK, PH3S10, and IEG events in models 
of synaptic plasticity 
PERK and c-Fos are classical markers of primary afferent nociceptive activation and 
central sensitisation (Gao and Ji, 2009). It is therefore of great interest that more than 
half of the PH3S10 population overlapped with both PERK and c-Fos populations at 
58% (30 min) and 60% (1h), respectively. No other studies had investigated PH3S10 in 
the spinal cord following noxious stimulation, but strong coupling of PERK, PH3S10, 
and c-Fos expression has been confirmed in various models of activity-induced 
synaptic plasticity in the brain (Brami-Cherrier et al., 2009; Chwang et al., 2006; 
Ciccarelli and Giustetto, 2014; Crosio et al., 2003).  
PERK and PH3S10 
It was not surprising that the majority of PH3S10 colocalised with PERK at 30 minutes, 
as PH3S10 is known to occur downstream of ERK via the mitogen- and stress- related 
kinase 1/2, MSK1/2 (Soloaga et al., 2003).  Following pharmacological activation of 
neuronal plasticity, 80% of PH3S10 nuclei colocalised with PERK in the dentate gyrus 
1 hour after glutamatergic activation with kainic acid (Crosio et al., 2003). In the same 
study, virtually all of PH3S10 nuclei expressed c-Fos mRNA, and PH3S10 expression 
always preceded that of c-Fos. Moreover, in the hippocampus PH3S10 was found to 
be regulated by ERK following PKC and PKA pharmacological activation in vitro, and in 
synaptic plasticity induced by contextual fear conditioning in vivo (Chwang et al., 2006). 
ERK regulation of activity-upregulated PH3S10-AcH3K14 in the hippocampus was also 
observed in another stress-induced behavioural learning paradigm, the forced swim 
test (Chandramohan et al., 2008, 2007). 
Interestingly, PH3S10 expression was found to be highly coexpressed (94%) with 
PERK in the lateral septum of the brain 1 hour following plasticity induced by naloxone-
precipitated morphine withdrawal (Ciccarelli et al., 2013). Regulation of synaptic 
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activity-induced PH3S10 by ERK has also been observed in visual cortical plasticity 
and drug addiction (Brami-Cherrier et al., 2009; Putignano et al., 2007). 
In this chapter, the percentage overlap of PH3S10/PERK, and PH3S10/c-Fos both 
occurred around 60%. A 60% overlap between the PH3S10 population and PERK, or 
c-Fos populations indicated that at least 20% of the PH3S10 population expressed 
both PERK and c-Fos. However, it should be noted that the percentage overlaps 
reported here may not be an exact reflection of the true co-existence between the two 
markers due to an issue of timing. PERK, PH3S10, and c-Fos are known to peak at 
different time points (Figure 4.10), and it is only feasible to examine the population 
overlap at a single time point optimal for the maximal expression of both populations 
when using IHC (Figure 4.10). Therefore, the reported percentages are reflective of a 
minimum overlap between the two populations. An alternate approach to this limitation 
would be to block PERK activity using an inhibitor and observe the subsequent 
expression of PH3S10 and c-Fos (see Chapter 6). Furthermore, it should also be taken 
into consideration that a 60% overlap could also indicate that a signalling cascade 
other than ERK/MAPK might be responsible for expression of formalin-induced 
PH3S10 or c-Fos. 
PERK and c-Fos/ Zif268 
It is difficult to deduce whether PERK and c-Fos always occurs in the same cells of the 
dorsal horn due to differences in peak expression after noxious stimulation (Figure 
4.10); however, it has been shown that ERK has signification regulation over c-Fos 
expression following nociceptive activation (Kawasaki et al., 2004). In particular, 
following c-fibre activation by intraplantar capsaicin, the majority of PERK positive cells 
colocalised with c-Fos. Furthermore, PERK colocalised substantially (89%) with the 
transcription factor PCREB, which is upregulated more rapidly than c-Fos and is known 
to bind to CRE-regulatory sequences within genes, including c-Fos and Zif268 
(Kawasaki et al., 2004). Regulation of c-Fos by ERK has also been observed in the 
striatum and nucleus accumbens in acute amphetamine administration, and other 
models of drug addiction (Brami-Cherrier et al., 2009; Rotllant and Armario, 2011). 
Less is known about ERK regulation of Zif268 in the spinal cord, however ERK 
regulation of Zif268 and c-Fos has been well established in striatal and dentate gyrus 
neurons exhibiting LTP (Davis et al., 2000; Sgambato et al., 1998). 
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Figure 4.10 Time course of marker expression in the superficial dorsal horn of the spinal 
cord after peripheral noxious stimulation.  
While the evidence linking PERK, PH3S10 and IEG expression in various models of 
neuronal plasticity is strong, care must be taken in interpreting results from other brain 
areas and plasticity-inducing paradigms. Indeed, the studies mentioned above clearly 
indicate that expression and interaction of these markers differs according to stimulus 
and region (Wisden et al., 1990). Nevertheless, other examples of neuronal plasticity 
support the results presented in this chapter indicating a strong relationship of ERK, 
PH3S10, and IEG events in the ERK/MAPK signalling cascade. A more in-depth 
discussion on the functional necessity of PERK and PMSK1/2 for PH3S10 expression 
following noxious stimulation will take place in Chapter 6.  
4.4.2 The existence of PH3S10 in a small subset of NK1 positive lamina I 
projection neurons 
In this chapter, the colocalisation of PH3S10 with NK1 was investigated because of the 
importance of NK1 projection neurons to the full development of inflammatory pain 
states (Mantyh et al., 1997; Nichols et al., 1999).   
Analysis of staining revealed a small level of colocalisation between NK1 and PH3S10 
populations. However, it cannot be said for certain whether colocalisation occurred in 
lamina I projection neurons, as retrograde labelling from main supraspinal targets (the 
CVLM and LPb) was not performed. In lamina I of the lumbar region, 45% of neurons 
are immunoreactive for NK1 (Todd et al., 1998), yet only 5% of all lamina I neurons are 
projection neurons (Bice & Beal 1997b; Bice & Beal 1997a; Spike et al. 2003; Al-Khater 
& Todd 2009). NK1 positive cells that are not projection neurons are thought to be 
excitatory interneurons, as those in lamina I are not immunoreactive for GABA (Al 
Ghamdi et al., 2009; Littlewood et al., 1995). Based on a value of 6.5 ± 1.5 NK1 
cells/40µm section quantified in this chapter, the statistics indicate that roughly 2 
cells/40µm section would have been NK1 positive projection neurons. As 17% of 
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lamina I NK1 positive neurons colabelled with PH3S10, there is a small possibility that 
PH3S10 occurred in lamina I NK1 projection neurons. 
It should be noted however, that although only 17% of NK1 positive neurons colabelled 
with PH3S10, there is a basis for underestimation of this value. Formalin-induced 
PH3S10 is localised only within the medial superficial dorsal horn, while retrograde 
tracing has indicated that lamina I projection neurons are concentrated in the middle 
(mediolateral) of lamina I (Todd, 2010). Therefore, only 50% of the NK1 neurons 
quantified fall into the region of PH3S10 expression. Thus a value of 17% represents a 
diluted value and colocalisation should actually be higher (potentially 35%). If 35% of 
NK1 neurons expressed PH3S10, the possibility of PH3S10 in NK1 projection neurons 
would be substantially higher.  
Another previously suggested possibility (Torsney, 2011) is that the average lamina I 
NK1 population size observed and quantified in this chapter (6.5 ± 1.5) is not reflective 
of the 45% of all neurons reported to be NK1 positive in lamina I (Todd et al., 1998). 
The NK1 immunostaining presented in this chapter is most likely labelling projection 
neurons, which are known to exhibit the strongest NK1 staining (i.e. compared to 
interneurons).  
It has been more recently shown that NK1 projection and NK1 interneurons differ in 
terms of soma size and AMPA receptor subunit expression (Al Ghamdi et al., 2009; 
Polgár et al., 2010). 99% of NK1 cells with larger soma (˃200µm2) are known to colabel 
with retrograde tracer from the CVLM and LPb, conversely, only 10% of smaller 
(˂200µm2) soma colabelled with retrograde tracer suggesting an interneuron identity 
(Al Ghamdi et al., 2009). The two categories of morphology also have differential 
expression of AMPA subunits, which are known to influence forms of LTP, an event 
that is known to occur in lamina I NK1 neurons (Esteban et al., 2003; Ikeda et al., 2006, 
2003; Polgár et al., 2010).  The GluA4 subunit was found highly clustered on the large 
NK1 positive projection neurons, while the small area NK1 interneurons are positive for 
the GluA1 subunit (Polgár et al., 2010). The two groups also had no differences in ERK 
activation, suggesting that they are not activated by distinct types of noxious stimuli. In 
this chapter, the area of NK1 immunopositive cells was not measured and thus those 
that colocalised with PH3S10 cannot be classified by this method. However, it is 
possible that re-examination of staining using this classification would allow for 
categorisation of NK1 subtype expression PH3S10. 
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4.4.3 PH3S10 in NK1 laminae III-IV projection neurons 
NK1 positive projection neurons also exist in deeper laminae III and IV cells with 
dendrites extending to lamina II. The great majority of these cells (˃90%) project mainly 
to the LPb and lateral reticular nucleus (Todd et al., 2000), and selectively receive input 
from myelinated low threshold mechanoreceptors and local GABAergic NPY 
interneurons (Naim et al., 1998; Polgár et al., 1999). Lamina III-IV NK1 positive 
neurons also have dendrites extending dorsally into lamina I-II and receive dense 
innervation from C-fibre SP-containing primary afferents (Naim et al., 1997). 94% are 
activated by peripheral noxious stimulation (formalin, pinch, and heat) as indicated by 
colocalisation with PERK, and dendritic NK1 receptor internalisation (Polgár et al., 
2007; Todd et al., 2000). Importantly, the high percentage of NK1 positive projection 
neurons (˃90%) in laminae III-IV indicates statistically that at least 4% of the deeper 
laminae PH3S10 population did indeed occur in projection neurons (17% NK1 
expressing PH3S10) in the deep dorsal horn. However, the laminae III-IV NK1 
projection neuron population is small, at roughly only 20 on each side of the dorsal 
horn within L4 (Todd et al., 2000); therefore the number of PH3S10 labelled neurons is 
low.   
Finally, it is worth noting that evidence of NK1 receptor internalisation was not 
investigated here. NK1 endosome-mediated internalisation is an indication of agonist 
binding and primary afferent input in both acute and persistent pain states (Honor et al., 
1999; Mantyh et al., 1995).  Lamina I NK1 internalisation peaks 8 minutes post-formalin 
injection, and the majority (55-60%) of NK1 immunopositive staining at 1h is still known 
to express internalised NK1 (Honor et al., 1999). It should be noted that the NK1 
immunostaining presented in this chapter does not appear to exhibit receptor 
internalisation but is instead found on the cell surface. It is possible that during the 
quantification process there was a bias toward identification of NK1 staining that was 
cell surface in expression, and that some NK1 cells could have been over looked. 
4.4.4 PH3S10: presence in inhibitory or excitatory interneurons? 
Nearly all PH3S10 nuclei were seen to colocalise with the neuronal marker NeuN, and 
we endeavoured to find a distinctive neurochemical profile for PH3S10 indicative of 
neuronal function in the dorsal horn. 5% colocalisation of PH3S10 with NK1 indicated 
that at least some of the PH3S10 population occurred within excitatory neurons 
(Littlewood et al., 1995). 
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Subsequently, an additional attempt was made to determine the identity of PH3S10 
neurons using four functionally and neurochemically distinct populations of non-
overlapping GABAergic inhibitory interneurons: galanin, NPY, nNOS, and PV (Polgár et 
al., 2013). IHC staining for Galanin and NPY was unsuccessful; therefore no 
colocalisation was carried out with PH3S10. Furthermore, no colocalisation of PH3S10 
with PV and nNOS was observed. This was primarily due to the fact that the 
populations did not occur in the same region of the dorsal horn with PV and nNOS 
occurring more laterally in deeper laminae IIi. A study by Polgar et al. (2013) indicated 
that 8% of nNOS and 0% PV cells overlapped with PERK in the dorsal horn post-
formalin, it is not surprisingly that no colocalisation with nNOS or PV was observed in 
the experiments presented here. Moreover, the study by Polgar et al. indicated that 
galanin and NPY populations each had 68% and 66% overlap with PERK, respectively. 
Considering that experiments in this chapter reported 42% of PERK cells coexpressing 
PH3S10, it is possible that colocalisation of PH3S10 might have more likely been 
observed in galanin and NPY cells. 
GABA is present in 25 and 30% of lamina I and II neurons, respectively (Polgár et al., 
2003). However, achieving GABA or glycine immunolabelling of cell bodies is difficult 
and requires a glutaraldehyde fixation which would obscure the detection of other 
antigens (i.e. PH3S10). Admittedly, the investigation of PH3S10 with inhibitory 
interneuron markers in this chapter was not exhaustive, and therefore cannot be ruled 
out as a potential neuronal subtype. An additional technique to identify inhibitory 
interneurons could be to acquire genetically modified mice with a green fluorescent 
protein (GFP) reporter for GAD (GAD-GFP mice) to label GABAergic cells, and to 
double stain the spinal cord tissue with PH3S10. 
While it is probable that non GABA/glycinergic neurons in the dorsal horn are 
glutamatergic (Todd, 2010), it is similarly difficult to achieve cell body staining of 
glutamatergic neurons as most markers (i.e. vesicular glutamate transporters- 
VGLUTs) label axon terminals. In addition to low coexpression with excitatory NK1 
neurons, it is possible that PH3S10 is expressed in a larger percentage of excitatory 
glutamatergic interneurons; however, the only other investigation into this possibility 
was with glutamatergic neuronal marker, calbindin. Notably, it was low background 
levels of PH3S10 that were observed to colocalise with calbindin. Other neurochemical 
markers expressed in glutamatergic interneurons include calretinin, neurotensin, NKB, 
PKCɣ, substance P, and somatostatin (Todd, 2010). Calretinin is the next main 
candidate of interest as it is known to label whole cell bodies and is expressed in the 
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superficial dorsal horn. PKCɣ is most likely precluded as a colocalisation target for 
PH3S10 as its expression is too deep, in lamina IIi and III (E. Polgár et al., 1999). 
4.4.5 PH3S10 in glia 
It was rare to find colocalisation of formalin-induced PH3S10 with glial markers GFAP, 
APC CC1 and Iba1, although some colocalisation of background PH3S10 staining was 
noted. This was somewhat surprising as PH3S10 was originally identified in non-neural 
cells and additionally serves as a marker of mitotic cell division (Prigent and Dimitrov, 
2003). Notably, greater colocalisation of PH3S10 and glia may be observed following 
different types of noxious stimulation. Glial cells, particularly activated microglia 
labelled with Iba1 (Beggs and Salter, 2007), are involved in the spinal cord immune 
response to peripheral nerve injury. Thus, a different model might have been more 
appropriate to study colocalisation of PH3S10 with glial markers. However, it is not yet 
known if and when PH3S10 would be observed in the spinal cord following a 
neuropathic injury. 
4.4.6 Technical limitations 
The colocalisation data presented in this chapter are presented at time points chosen 
for maximal overlap of the populations of interest (see Discussion point 4.4.1 PERK 
and PH3S10, Figure 4.10). We were able to do this knowing the maximal expression 
for each population; however, the findings may not be indicative of the full overlap. 
Thus if anything, due to the constraints of analysing one point in time, the colocalisation 
values may indeed be higher than the values reported here (refer to Figure 4.10). 
It should also be noted that the colocalisation percentages presented in Table 4.2 
(columns 5 and 6) may not seem to reflect the presented values of respective 
population sizes (columns 2-4). A decision was made to present colocalisation values 
per each section, rather than across whole populations, as this was thought to be a 
more accurate representation of colocalisation (see Methods 4.2.5). The fact that the 
colocalisation percentages do not directly reflect colocalisation quantified across 
populations suggests that there is high variability of PH3S10 overlap with respective 
populations of interest between tissue regions/sections. 
4.4.7 Conclusions 
In summary, PH3S10 occurred in neurons of the dorsal horn that expressed markers of 
the pain pathway. More than half of the PH3S10 population colocalised with dorsal 
horn markers (PERK, c-Fos, and Zif268) indicating activation by noxious stimulation of 
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primary afferents. PH3S10 also colocalised partially with NK1 lamina III projection 
neurons, and potentially lamina I NK1 projection neurons.  
A substantial percentage of PH3S10 cells did not colocalise with PERK, which 
indicated that PH3S10 may be regulated by another kinase. Thus, one of the next aims 
was to determine a functional link between ERK/MAPK signalling on PH3S10 
expression by pharmacologically targeting PERK activity following inflammation 
(Chapter 6).  
Furthermore, as dorsal horn activity is under the regulation of descending input from 
the brain, a second aim was to investigate the role of descending controls on formalin-
induced PH3S10 expression (Chapter 5). 
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5.1 Introduction 
Top-down modulation of pain exists in the form of a number of descending circuits from 
the brain to the spinal cord, which have provided a pathway through which the brain 
can enhance or suppress dorsal horn activity and the overall pain response. 
Descending serotonergic release from fibres originating in the rostral ventromedial 
medulla (RVM) are known to regulate nociceptive activity in the spinal dorsal horn 
(Gebhart, 2004; Millan, 2002; Ossipov et al., 2010). Chapters 3 and 4 established the 
immediate upregulation of PH3S10 in the dorsal horn after intraplantar formalin 
stimulation, and this chapter describes experiments investigating the role of 
descending serotonin (5-HT) on PH3S10 expression. 
5.1.1 The rostral ventromedial medulla (RVM) 
The RVM receives input from the PAG and is the main origin of descending fibres 
projecting from the brain to the dorsal horn of the spinal cord. Importantly, descending 
activity from the RVM is known to have a modulatory influence upon spinal cord activity, 
which is overall inhibitory (Basbaum and Fields, 1979; Fields et al., 1977). In particular, 
the RVM has been implicated in the maintenance but not induction of neuropathic pain, 
and delivery of RVM lidocaine can temporarily reverse allodynia and hyperalgesia that 
results from nerve injury (Burgess et al., 2002; Pertovaara et al., 1996; Vera-
Portocarrero et al., 2006). Furthermore, more recently, it has been demonstrated that 
activation of descending inhibition may be an explanation for why certain subjects fail 
to develop chronic pain after nerve injury (De Felice et al., 2011). 
Crucially, however, the RVM can have bidirectional inhibitory and facilitatory 
descending influences on spinal nociception (Urban and Gebhart, 1999). Evidence 
suggests that the bidirectional effect of the RVM on descending activity is in part due to 
the role of serotonergic RVM neurons.  
5.1.2 Serotonin (5-HT) as a neurotransmitter in nociceptive processing  
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter that regulates 
a variety of CNS functions including sleep, mood, appetite, as well as cognitive 
processes. 5-HT also plays a significant role in pain processing; in particular, the 
regulation of nociceptive spinal cord excitability. Spinal 5-HT is derived mainly from 
supraspinal sources, specifically the RVM (Kwiat and Basbaum, 1992). Descending 
fibres containing 5-HT terminate most densely within dorsal horn laminae I-II and are 
known to synapse primarily onto projection neurons and interneurons, and less so onto 
primary afferent fibres (Li et al., 1997; Millan, 2002; Ruda, 1988; Wu and Wessendorf, 
1992).  There is a general acceptance that 5-HT can have bidirectional effects on 
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nociceptive activity, due to the fact that it can act on a diverse set of 5-HT receptor 
subtypes that are known to mediate either pro or anti-nociception (Millan, 2002).  
5.1.3 5-HT receptors in the CNS  
There are fifteen different 5-HT receptors that can be categorised into seven subtypes, 
5-HT1-5-HT7. All  seven 5-HT receptor subtypes are expressed in the spinal cord 
(Hamon and Bourgoin, 1999; Hannon and Hoyer, 2008) and function as G-protein 
coupled receptors with the exception of 5-HT3, which is a ligand-gated ion channel. 
While the majority of the subtypes have been studied to some extent, dorsal horn 5-
HT1, 5-HT2 and 5-HT3 have been implicated in mediating descending facilitation, while 
5-HT1 and 5-HT7 subtypes have been shown to have  inhibitory effects on nociceptive 
processing (Millan, 2002). Specifically, i.t. administration of a 5-HT2A antagonist is able 
to attenuate SNL and formalin-induced nociceptive behaviour (Nitanda et al., 2005; 
Obata et al., 2004), and 5-HT3 antagonists are similarly effective in producing anti-
nociceptive effects in hypersensitivity seen in inflammatory and neuropathic pain states 
(Dogrul et al., 2009; Lagraize et al., 2010; Oatway et al., 2004; Oyama et al., 1996; 
Silveira et al., 2010; Suzuki et al., 2002; Svensson et al., 2006; Zeitz et al., 2002). 5-
HT1 has also been shown to mediate descending facilitation of the nociceptive reflex, 
and is thought to act by inhibiting inhibitory interneurons (Wang et al., 2009). However, 
5-HT1 also has an overall inhibitory role in attenuating formalin-induced behaviour 
(Oyama et al., 1996) and it is thought that under these circumstances 5-HT1 directly 
inhibits the activity of projection neurons (Millan, 2002). 5-HT7 has been shown to 
mediate inhibitory effects, as spinal administration of 5-HT7 antagonists has been 
shown to reverse antinociception produced by morphine injection into the RVM (Dogrul 
et al., 2009).  
5.1.4 5-HT lesion studies in pain 
Studies have used i.t. delivery of the neurotoxin 5,7-dihydroxytryptamine creatinine 
sulphate (5,7-DHT) to lesion 5-HT-containing descending fibres from the RVM in order 
to investigate the role of 5-HT in nociception. The majority of studies using 5,7-DHT 
depletion of spinal 5-HT have concluded an overall facilitatory role for 5-HT in 
nociception. Specifically, these studies have shown an attenuation of the second phase 
of the formalin response after spinal depletion of 5-HT (Svensson et al., 2006), as well 
as attenuation of mechanical and thermal hypersensitivity induced by nerve injury or 
persistent hindpaw or ankle joint inflammation following CFA injection (Carr et al., 
2014; Géranton et al., 2008; Rahman et al., 2006).  Furthermore, molecular depletion 
of descending 5-HT activity from the RVM using RNAi to silence tryptophan 
hydroxylase 2 (TPH, rate-limiting enzyme involved in synthesis of 5-HT) has also been 
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shown to attenuate formalin, CFA, and SNL-induced hypersensitivity (Wei et al., 2010) 
without altering acute baseline responses to thermal or mechanical sensitivity.  
5.1.5 Aims 
Previous studies have shown reductions in dorsal horn molecular markers of 
nociception after 5,7-DHT ablation of descending serotonergic fibres from the RVM. 
PERK, PMeCP2, and the IEG protein products c-Fos and Zif268, all markers coupled 
with neural activation following noxious stimuli, are significantly reduced after i.t. 5,7-
DHT, indicating a net facilitatory role for descending 5-HT (Géranton et al., 2008; 
Svensson et al., 2006).  
Chapters 3 and 4 indicated that formalin-induced PH3S10 colocalised with PERK, c-
Fos, and Zif268, and provided a strong basis for the investigation of PH3S10 
expression after 5,7-DHT ablation.  
The aim of this chapter was to investigate the role of descending 5-HT activity from the 
RVM on spinal cord molecular activity, specifically the expression of formalin-
upregulated PERK and PH3S10 following i.t. ablation with 5,7-DHT. 
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5.2 Materials and Methods  
Please also see Chapter 2 for General Materials and Methods.  
5.2.1 Experimental design 
The aim of this Chapter was to investigate the role of descending serotonergic activity 
from the RVM on formalin-induced PH3S10 in the dorsal horn (Figure 5.1). An hour 
before i.t. surgery, all animals received i.p. desipramine (25mg/kg), a noradrenaline 
reuptake inhibitor, in order to prevent toxicity to noradrenergic neurons (Breese et al., 
1978). Animals subsequently underwent a surgical procedure and received either i.t. 
5,7-DHT to ablate serotonergic fibres or i.t. saline  (n=8 each group). 7 days after i.t. 
surgery, all animals underwent hindpaw stimulation with formalin, and 30 minutes later 
were sacrificed for perfusion (Figure 5.2).  Confirmation of the 5,7-DHT depletion was 
done using immunohistochemistry, and animals that did not show visible reductions in 
spinal 5-HT were discounted from further analysis (2 animals, leaving  an n=7 each 
group for further molecular analysis). 
 
 
Figure 5.1 Intrathecal delivery of 5,7-DHT chemically damages 5-HT-containing 
descending fibres from the RVM. Red ‘x’ indicates site of lesion. 
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Figure 5.2 Timeline of experimental procedures.  
 
5.2.2 Intrathecal surgery 
Intrathecal surgery was performed to deliver either 5,7-DHT or saline. Please see 2.3.1 
for full procedure details. 
5.2.3 Drugs 
5,7-DHT was given 60µg/10µl/0.9%saline (i.t.) and desipramine was given 
25mg/kg/0.9% saline (i.p.) (see Table 2.1). 
5.2.4 Formalin stimulation 
All animals were given intraplantar formalin, 50µl 2% under isoflurane anaesthesia (see 
2.2.1).  
5.2.5 Immunohistochemistry 
Please refer to section 2.5 for the full immunohistochemical protocol and antibody 
information. All stains done in this chapter were single stains for one antigen. 
Table 5.1 IHC experiments completed in Chapter 5 
Antibody Method of detection 
5-HT Biotin amplification  
GFAP Direct Alexa 488 
NeuN Direct Alexa 594 
PERK TSA 
PH3S10 DAB 
5.2.6 Immunohistochemistry- Image acquisition 
Images of fluorescent immunohistochemistry in this chapter were taken on a 
Hamamatsu CCD C4742 digital camera attached to a Leica DMR microscope using the 
OpenLab software (PerkinElmer, Waltham MA, USA). Images used for FIJI analysis 
were taken on the Leica TCS SPE laser scanning confocal microscope. 
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5.2.7 Immunohistochemistry- Quantification 
For manual quantification of PERK (n=3 each group) and PH3S10 (n=7 each group) 
immunopositive cells, all sections were counted in laminae I-II with experimenter blind 
to treatment using a Leica DMR microscope. Once all sections were counted, per 
animal, five sections with the maximum response (ipsilateral) were used and the 
average taken on the ipsilateral dorsal horn. The average of each treatment group was 
then calculated along with the standard error of each group mean (SEM). 
For PERK, an additional method was used to quantify immunostaining. FIJI (ImageJ) 
image analysis was performed on 3 tissue sections from each animal (n=4 each group). 
The sections were selected at random from five sections with the maximum response 
(ipsilateral). Two protocols were used: 
1. FIJI particle analysis 
Particle analysis was used to quantify the number of cell bodies using automatic 
particle counting. The number of cell bodies was averaged across the 3 
sections. 
2. FIJI intensity analysis  
Intensity analysis was used to quantify immunofluorescence from cell bodies in 
addition to other immunopositive staining such as dendritic processes. A pixel 
threshold of 11 was used and the sum of the weighted intensity particles greater 
than 11 was averaged across the 3 sections.  
Group data was presented as mean ± SEM. 
Gross visual analysis was performed on 5-HT, GFAP, and NeuN immunostains for all 
animals to confirm 5-HT depletion and no change in glial activation or neuronal death. 
5.2.8 Statistical analysis 
Please also see 2.7 for full details of statistical analysis. 
PH3S10 counts were compared in animals receiving i.t. saline and animals receiving i.t. 
5,7-DHT. Comparison was analysed using a univariate ANOVA, with ‘treatment’ (saline 
vs. 5,7-DHT) as the between-subjects factor, and ‘side’ (ipsilateral vs. contralateral) as 
the within-subjects factor. 
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5.3 Results 
5.3.1 Confirmation of 5-HT depletion 
Ablation of descending serotonergic neurons 7 days after i.t. 5,7-DHT was confirmed 
using immunohistochemical analysis. There was a clear lack of 5-HT immunostaining 
in the dorsal horn of animals receiving i.t. 5,7-DHT compared to a dense superficial 
expression of 5-HT in i.t. saline treated animals (Figure 5.3 A).  
5.3.2 No change in primary afferent activation of ERK in the dorsal horn 
following depletion of spinal 5-HT  
It was subsequently investigated whether ablation of descending serotonergic fibres 
had any effect on formalin-induced nociceptive primary afferent activity upon the dorsal 
horn as indicated by PERK. PERK expression was analysed using three methods: 
manual quantification, FIJI particle analysis, and FIJI intensity analysis. Contrary to the 
findings of Svensson et al., who found that i.t. 5,7-DHT blocked upregulation of PERK 
at 30 minutes (Svensson et al., 2006), manual quantification revealed no significant 
reduction in PERK expression in the dorsal horn 30 minutes post-formalin in 5,7-DHT 
vs. saline treated groups. There was however, a trend towards a reduction in PERK 
expression in the 5,7-DHT group (Figure 5.3 B). Further quantification using FIJI 
particle analysis and FIJI intensity analysis (Figure 5.3 C, D) confirmed no difference 
between groups, and no further attempt was made to increase n numbers. 
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Figure 5.3 Ablation of serotonergic fibres with 5,7-DHT leads to a reduction in 5-HT but 
does not prevent formalin-induced ERK activation in the dorsal horn when quantified 
using three different methods. A) Typical dorsal horn images of 5-HT and PERK-fluorescent 
staining in animals receiving i.t. saline or i.t. 5,7-DHT at 30 min post-formalin stimulation 
(rows=antigen of interest; columns=i.t. treatment). Scale bar upper, 50µm; lower, 30µm. B) 
Quantification of PERK cell bodies in the ipsilateral and contralateral dorsal horn using manual 
counts (n=3, 5 sections per animal). C) Quantification of ipsilateral PERK cell body counts using 
FIJI particle analysis. D) Intensity quantification of ipsilateral PERK positive staining using FIJI 
intensity analysis (C and D, n=4, 3 sections per animal).  Values presented as group mean (per 
40µm section) ± SEM. All graphs- no statistically significant differences.  
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5.3.3 Depletion of spinal 5-HT prevents full expression of formalin-induced 
PH3S10  
After confirmation of spinal 5-HT depletion, expression of PH3S10 was investigated. 
Although there was no difference in dorsal horn PERK expression between 5,7-DHT vs. 
saline treated groups, the same treatment revealed that there was nearly a 50% 
reduction in PH3S10 nuclei 30 minutes post-formalin. The data showed a main effect of 
treatment (F(1,24)=9.44, P˂0.01), and an interaction between side and treatment (F 
(1,24)=9.14, P˂0.01).  
 
Figure 5.4 Depletion of spinal serotonin prevents the full expression of formalin-induced 
PH3S10. A) Dorsal horn image of PH3S10-DAB staining 30 min after formalin in animals 
receiving i.t. saline or i.t. 5,7-DHT. Scale bar 30µm. B) Manual quantification of PH3S10 nuclei 
in ipsilateral and contralateral dorsal horn (n=7 each group, 5 sections per animal). Values 
presented as group mean ± SEM (per 40µm section).  **P˂0.01 
 
5.3.4 No gross indication of neuronal death or glial proliferation after depletion 
of descending 5-HT fibres caused by 5,7-DHT 
5,7-DHT caused a specific depletion of 5-HT in the spinal cord, and there were no 
indications of neuronal death or gliosis as shown by NeuN or GFAP immunostaining at 
30 minutes post-formalin in animals depleted of spinal 5-HT.  
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Figure 5.5 There were no changes in NeuN or GFAP expression after depletion of spinal 
5-HT. Typical dorsal horn images of NeuN and GFAP in animals receiving i.t. saline or i.t. 5,7-
DHT at 30 min post-formalin stimulation (rows=antigen of interest; columns=i.t. treatment). 
Scale bar 50µm. 
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5.4 Discussion 
RVM descending fibre release of spinal 5-HT can have facilitatory and inhibitory effects 
on nociception depending on the receptor subtype mediating its actions (Bardin, 2011; 
Millan, 2002; Ossipov et al., 2010). The experiments in this chapter showed no 
reduction in formalin-induced PERK and a significant reduction in the expression of 
PH3S10 after i.t. 5,7-DHT-mediated depletion of spinal 5-HT. 
5.4.1 No changes in PERK after i.t. 5,7-DHT 
Svensson et al. showed that loss of spinal 5-HT caused by i.t. 5,7-DHT attenuates 
formalin-induced nociceptive behaviour and PERK expression in the spinal cord 
(Svensson et al., 2006). In this chapter, although there was a trend toward a reduction 
in formalin-induced PERK expression after i.t. 5,7-DHT, it was not significant. The 
same 5,7-DHT induced depletion however, caused a significant reduction in dorsal 
horn PH3S10 expression. PH3S10 is a well-known downstream target of PERK in 
neurons (Crosio et al., 2003), and results from Chapter 4 indicated that at least 42% of 
formalin-induced PERK neurons colocalised with PH3S10. PERK and PH3S10 also 
share a similar time course of expression with PERK and PH3S10 levels, peaking at 5 
minutes and 5-60 minutes, respectively (Ji et al., 1999). It is therefore quite surprising 
that no reduction in PERK activation was observed despite attempts at various 
methods of quantification. 
The study by Svensson et al. (2006) and the experiment presented in this chapter both 
studies examined spinal PERK expression 30 minutes after i.pl. formalin stimulation; 
however, there were 2 apparent differences in protocol. Firstly, the investigators 
induced hindpaw inflammation with formalin 2 days after 5,7-DHT while the 
experiments here waited until day 7. It is possible that 2d was not long enough for a 
complete 5-HT depletion; however, the authors reported a 78-84% reduction in spinal 
5-HT levels, so this discrepancy cannot explain the difference in result. Secondly, 
Svensson et al. used western blot to analyse levels of PERK1 and PERK2 isoforms 
separately. Taking a similar approach, the FIJI intensity analysis was employed 
specifically to quantify all immunopositive PERK staining, including that observed in 
processes as well as cell bodies, which appeared to contribute to a dense plexus of 
positive staining in the superficial dorsal horn. All three methods of quantification 
shared the same result: a non-significant trend toward the reduction in dorsal horn 
PERK after 5,7-DHT. Thus, it does not appear that there are any major experimental 
differences between that of Svensson et al. and the experiments in this chapter. 
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Much of the evidence suggests that spinal cord activity is in fact reinforced by 
descending regulation from supraspinal structures (Ossipov et al., 2010; Svensson et 
al., 2006). Furthermore, ERK activation is seen in the RVM as early at 30 minutes after 
CFA-induced peripheral stimulation (Imbe et al., 2005). Imbe et al (2005) found that 
roughly 20% of the PERK positive cells in the RVM were serotonergic, thus suggesting 
that the RVM is engaged at early time points after noxious stimulation. And finally, 
attenuation of behavioural hypersensitivity due to 5,7-DHT has been observed as early 
as 1 hour after the induction of short-term inflammatory models such as CFA (i.pl.) or 
20 minutes post-formalin (i.pl.) (Géranton et al., 2008; Svensson et al., 2006). It should 
be noted however, that temporal correlations between behaviour and expression of 
molecular markers should be investigated with caution (discussed also in Chapter 6).  
Results from this chapter suggest that there may, in fact, be no effect of 5,7-DHT on 
ERK activation. One possible explanation for the lack of PERK reduction after 5,7-DHT 
is that the descending 5-HT system is not engaged until after the induction of PERK. 
PERK is largely indicative of primary afferent activity and peaks almost immediately 
within 5 minutes of noxious stimulation, primarily due to primary afferent activity and 
release of neurotransmitters SP and glutamate onto the spinal cord (Ji et al., 1999). 
Furthermore, when considering the effect of the 5,7-DHT ablation on nociceptive 
behaviour, significant attenuation of hypersensitivity is not observed until 1-2 days after 
the induction of hyperalgesia caused by persistent pain models such as SNI or CFA-
ankle joint inflammation (Carr et al., 2014; Rahman et al., 2006).  
5.4.2 Facilitatory role of 5-HT on PH3S10 expression 
The role of descending 5-HT is controversial, with earlier studies implicating mainly an 
inhibitory role for 5-HT on thermal and mechanical hypersensitivity in naïve animals 
(Bardin et al., 1997; Crisp et al., 1991; Xu et al., 1994; Yaksh and Wilson, 1979). 
However, an early study by Zhuo and Gebhart showed that bidirectional descending 
facilitation or inhibition occurred when the RVM was stimulated at low and high 
frequencies, respectively, and that the low frequency- induced pronociceptive activity 
was also  mediated by 5-HT (Zhuo and Gebhart, 1992, 1991). Subsequent studies 
have produced strong evidence to support descending facilitation of 5-HT from the 
hindbrain, and the majority of recent studies using the 5,7-DHT ablation  have 
supported a facilitatory role for descending 5-HT.  Depletion of spinal 5-HT using the i.t. 
5,7-DHT ablation has been previously shown to attenuate the second phase of the 
formalin response (Okamoto et al., 2004; Svensson et al., 2006), as well as mechanical 
and thermal hypersensitivity induced by nerve injury or persistent hindpaw or ankle 
joint inflammation with CFA (Carr et al., 2014; Géranton et al., 2008; Rahman et al., 
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2006).  Furthermore, RNAi silencing of TPH, and thus reduction in 5-HT in the RVM 
has also been shown to attenuate formalin, CFA, and SNL-induced hypersensitivity 
(Wei et al., 2010) without altering acute baseline responses to thermal or mechanical 
sensitivity.  
The reduction in formalin-induced PH3S10 after i.t. 5,7-DHT seen here indicates that 5-
HT is required for the full expression of PH3S10 and is reminiscent of other studies 
showing reductions in dorsal horn molecular markers of nociception after 5,7-DHT. 
Specifically, PERK, PMeCP2, and the IEGs c-Fos and Zif268 (Géranton et al., 2008), 
markers indicative of neural activation following noxious stimuli, are all significantly 
reduced after i.t. 5,7-DHT thus corroborating a net facilitatory role for descending 5-HT; 
although as previously noted no change in PERK was observed here (Svensson et al., 
2006). The role of PH3S10 in nociception is yet to be investigated (see Chapter 6), 
however, results from Chapter 4 indicated that PH3S10 is rapidly and robustly 
upregulated in the dorsal horn as early as 5 minutes after formalin stimulation and may 
contribute to spinal processing of nociceptive behaviour.  
5.4.3 A possible role for the 5-HT3 receptor? 
Numerous studies have implicated 5-HT3 in mediating descending facilitation and 
spinal cord excitability. 5-HT3 is highly expressed on axons of primary afferents, dorsal 
horn excitatory interneurons, and importantly contributes to regulation of spinal 
excitability of NK1-expressing projection neurons (Conte et al., 2005; Huang et al., 
2004; Maxwell et al., 2003; Suzuki et al., 2002; Zeitz et al., 2002). 5-HT3 is unique from 
the other 5-HT receptors in that it is a ligand-gated ion channel that, along with 5-HT2, 
enhances intracellular signalling via phospholipase C (PLC) after being activated 
(Maxwell et al., 2003). i.t. delivery of the 5-HT3 antagonist, ondansetron, has been 
shown to attenuate hypersensitivity generated by formalin, nerve injury, intraplantar 
CFA, CFA ankle joint inflammation, and post-operative pain (Dogrul et al., 2009; 
Lagraize et al., 2010; Oatway et al., 2004; Okamoto et al., 2004; Oyama et al., 1996; 
Silveira et al., 2010; Svensson et al., 2006; Zeitz et al., 2002) and when injected into 
the RVM produces analgesia and a conditioned place preference in SNL-ondansetron 
treated animals (Wang et al., 2013). Furthermore, 5-HT3A knockout mice also display 
attenuation in the second phase of the formalin response, without alterations in acute 
mechanical and thermal responses (Kayser et al., 2007). The expression of formalin-
induced PH3S10 after targeting of 5-HT3 was not investigated here. However, 
elimination of 5-HT3 activity using genetic targeting or i.t. ondansenton has been shown 
to lead to a reduction in noxious stimuli-induced c-Fos expression in the spinal cord 
and thus it is possible that PH3S10 expression would also be decreased under such 
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circumstances (Green et al., 2000; Suzuki et al., 2002; Zeitz et al., 2002). While the 
evidence seems to overwhelmingly implicate 5-HT3 in descending facilitation, some 
studies have reported anti-nociceptive roles, specifically utilising 5-HT3 agonists 
(Alhaider et al., 1991; Glaum et al., 1990; Paul et al., 2001). Although 5-HT3 is the most 
heavily investigated receptor underlying descending facilitation, other 5-HT receptors 
associated with facilitatory effects include 5-HT1a (Zhuo and Gebhart, 1991) and 5-HT2 
(Bardin 2011). 
5.4.4 Controversy over the 5,7-DHT depletion 
Utilisation of 5,7-DHT to investigate the role of descending 5-HT activity has attracted 
some criticism. The 5,7-DHT ablation targets and chemically damages 5-HT containing 
fibres which also consequently eliminates the activity of other functional 
neurotransmitters (such as GABA, SP, Dynorphin, Enkephalin) in the same fibres. 
Although the experiments in this chapter and others have reported no apparent change 
in neuronal death after 5,7-DHT, the complete elimination of fibre function leaves some 
to argue that 5,7-DHT is not a direct way of investigating the role of 5-HT function itself. 
Furthermore, it should be noted that experiments using the 5,7-DHT ablation have 
yielded contradicting effects on nociception, with some groups reporting attenuation of 
CFA-induced mechanical hyperalgesia after i.t. 5,7-DHT (Carr et al., 2014; Géranton et 
al., 2008; Rahman et al., 2006) and nerve injury-induced thermal hyperalgesia 
(Rahman et al., 2006), while other studies found that the treatment exacerbated 
thermal hypersensitivity after inflammation (Millan et al., 1997; Pertovaara et al., 2001; 
Wei et al., 1999; Zhao et al., 2007).  
A recent study by Wei et al. used a novel method to selectively deplete 5-HT from 
descending fibres originating in the RVM without chemically damaging 5-HT containing 
fibres. The method utilised plasmid-mediated RNAi (shRNA) silencing of TPH in the 
RVM, which kept descending fibres fully intact and preserved the contribution of non-5-
HT neurotransmitter activity thereby selectively isolating the effects of 5-HT in 
neurotransmission itself (Wei et al., 2010). Importantly, Wei et al. also found 5-HT to 
have a net facilitatory role upon spinal cord activity, with reported attenuation of 
inflammatory and neuropathic hypersensitivity but no changes to acute nociception 
following depletion. Interestingly, deletion of descending 5-HT did not affect descending 
inhibition produced by opioid analgesia using the synthetic mu receptor agonist, [D-
Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO), which supports studies indicating that 
5-HT signalling in the RVM is not necessary for RVM mu opioid-mediated analgesia. 
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It is worth noting that another recent study has used leading-edge optogenetic 
activation of tryptophan hydroxylase 2 (TPH2)- channelrhodopsin 2 (ChR2) transgenic 
mice to investigate the behavioural effects of activating 5-HT-expressing RVM neurons. 
The authors found that activation of 5-HT RVM neurons had an overall descending 
facilitatory pain effect. Activation of 5-HT RVM neurons in TPH2-ChR2 mice induced c-
Fos expression in TPH positive RVM neurons, and decreased both mechanical and 
thermal pain thresholds in an intensity-dependent manner, an effect not seen in wild-
type mice (Cai et al., 2014). 
5.4.5 Technical considerations 
It is worth mentioning that the significant reduction of spinal PH3S10 following 5,7-DHT 
utilised an n=7, while the non-significant trend toward a decrease in PERK expression 
used only an n=3 (both experiments, quantification by manual counts). Considering the 
difference in n numbers between the two experiments, it is possible that an increase in 
experimental subjects in the PERK study may have led to a significant reduction in 
PERK (i.e. using also n=7), but this approach was not utilised. Instead, the decision 
was made to employ two additional methods of immunohistochemical quantification to 
quantify PERK (FIJI particle analysis and FIJI Intensity analysis, n=4 each analysis), 
but both methods showed no reduction in PERK after 5,7-DHT. 
5.4.6 Conclusions 
The results from this chapter indicate that spinal depletion of 5-HT with i.t. 5,7-DHT 
after 7 days prevents the full expression of formalin-induced PH3S10. This result is 
further evidence that PH3S10 may be involved in nociceptive processing and that 
descending 5-HT has a net facilitatory effect on spinal activity, in particular PH3S10 
expression following noxious stimulation. Subsequently, the next aims were to 
investigate the specific contribution of PH3S10 in nociception.  
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6.1 Introduction 
Chapter 4 results indicated that 58% of formalin-induced PH3S10 in the dorsal horn 
colocalised with PERK, a marker of nociceptive activity. As previously mentioned in 
Chapter 4, ERK/MAPK regulation of PH3S10 has been demonstrated in various 
models of activity-induced synaptic plasticity such as memory formation 
(Chandramohan et al., 2008, 2007; Chwang et al., 2006). In the field of pain, numerous 
studies have used MEK inhibitors to show that PERK is essential to the full expression 
of pain states (Ji et al., 2009). The effect of MEK inhibition on PH3S10 expression, 
however, has never been investigated. The experiments in this chapter investigate the 
specific contribution of PH3S10 and its kinase, MSK1, in nociceptive processing and 
behaviour.  
6.1.1 ERK/MAPK signalling: MSK1 and PH3S10, downstream targets of PERK 
The role of ERK/MAPK signalling in nociceptive processing was discussed in 3.1.2.1. 
In addition, in vitro studies have shown that PERK is capable of translocation into the 
nuclear compartment where it phosphorylates the nuclear mitogen and stress-activated 
protein kinase (MSK). MSK is an intermediate kinase known to regulate gene 
transcription via downstream phosphorylation of histone H3, CREB, and other 
transcription factors (Schuck et al. 2003; Soloaga et al. 2003; Wiggin et al. 2002) 
(Figure 6.1), events which have been observed in the nervous system (Brami-Cherrier 
et al., 2005; Chandramohan et al., 2008; Chwang et al., 2007, 2006; Ciccarelli et al., 
2013; Correa et al., 2012; Crosio et al., 2003; Gräff et al., 2012; Gutièrrez-Mecinas et 
al., 2011; Karelina et al., 2012; Putignano et al., 2007; Rotllant and Armario, 2011). 
However, neither histone phosphorylation on H3 nor MSK have been investigated in 
nociception; a surprising finding considering the importance of ERK/MAPK signalling in 
nociceptive processing (Ji et al., 1999).  
 
Figure 6.1 The proposed signalling of ERK/MAPK following noxious stimulation involves 
activity of nuclear kinase MSK1 and PH3S10. It is known that PCREB is upregulated in the 
dorsal horn following noxious stimulation (Ji and Rupp, 1997) and is regulated by MSK1 in 
neurons (Arthur et al., 2004). MSK1 also phosphorylates ATF1, but this has only been shown in 
fibroblasts (Wiggin et al., 2002). 
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6.1.2 The mitogen and stress-activated protein kinase (MSK) 
The mitogen and stress-activated protein kinases (MSKs) are serine/threonine protein 
kinases, of which there are two isoforms: MSK1 and MSK2 (64% homology). MSK1 is 
the predominant isoform in the mammalian brain (Arthur et al., 2004; Frenguelli and 
Correa, 2013), and will therefore be referred to as MSK1 for the remainder of this 
thesis. A wide range of stimuli are known to activate MSK1, including neurotrophins 
BDNF/NGF/NT-3 and glutamate (Arthur et al., 2004; Brami-Cherrier et al., 2007; 
Frenguelli and Correa, 2013; Rakhit et al., 2005). MSKs are directly regulated by 
ERK/MAPK and p38 signalling. Specifically, PERK directly regulates MSK1 C-terminal 
kinase domain activity by phosphorylating S360, T581 and T700 (McCoy et al., 2005), 
and as already mentioned, MSK1 itself regulates phosphorylation of downstream 
targets implicated in neural plasticity: H3S10 and CREB (Arthur et al., 2004; Deak et al., 
1998; Soloaga et al., 2003; Wiggin et al., 2002). Indeed, MSK -/- striatal neurons 
display a lack of glutamate-induced expression of PH3S10 and show reduced 
expression of c-Fos (Brami-Cherrier et al., 2007). 
MSK1 itself is a novel protein of interest in nociception, and during this study it became 
increasingly apparent that MSK1 would be the best target for specifically investigating 
the role of PH3S10 in nociception particularly due to the availability of pharmacological 
inhibitors (Naqvi et al., 2012).  
 
6.1.3 Aims 
PERK is a widely used marker of neuronal activation by nociceptive stimuli in the spinal 
cord and brain, and pharmacological inhibition of its upstream kinase MEK has shown 
that PERK signalling is required for the full expression of pain states (Gao and Ji, 2009; 
Ji et al., 2009). Given the widely accepted importance of PERK in pain processing, it is 
somewhat surprising that neither MSK1 nor PH3S10, known downstream components 
of ERK signalling (Soloaga et al., 2003), have been investigated following noxious 
stimulation. Chapter 4 results showed that 58% of PH3S10 colocalise with PERK. 
Therefore, evidence of PH3S10 regulation by ERK (Chwang et al., 2006) and MSK1 
(Brami-Cherrier et al., 2009; Chwang et al., 2007) in other areas of the CNS suggest 
that inhibition of MEK and MSK1 kinases would reduce formalin-induced spinal 
PH3S10 expression and attenuate formalin-induced nocifensive behaviours.   
The aim of this chapter was to investigate the intracellular regulation of PH3S10 in 
nociceptive processing in order to determine the role of histone phosphorylation 
(PH3S10) on nociceptive behaviour. Specifically, to 
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1. Determine whether ERK/MAPK regulates formalin-induced PMSK1 (the kinase 
responsible for PH3S10) and PH3S10 by inhibition of MEK activity with i.p. 
SL327 
 
2. Determine whether PMSK1 regulates expression of formalin-induced PH3S10 
and c-Fos by inhibition of  MSK1 with i.t. SB747651A  
 
3. Determine whether PMSK1 regulates nociceptive behaviour by inhibiting MSK1 
with i.t. SB747651A  
Finally, for the majority of the experiments in this thesis, 2%, 50µl formalin was injected 
under general isoflurane anaesthesia. However, experiments in Chapter 6 required 5%, 
20µl formalin injections without general anaesthesia in order to assess nocifensive 
behaviour immediately following injection. Thus one final aim of this chapter was  
4. To determine whether there were any differences in spinal PERK expression 
between the two conditions of formalin injection (2%, 50µl injected under 
anaesthesia vs. 5%, 20µl injected without anaesthesia) 
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6.2 Materials and Methods 
6.2.1 Experimental design 
There are 3 main experiments in this chapter: 
6.2.1.1 Experiment 1: Does MEK inhibition block formalin-induced PMSK1 and 
PH3S10 expression? (Aim 1) 
 
 
Figure 6.2 Pharmacological blockade of MEK with SL327. Red boxes indicate main targets 
of interest. 
There were 2 treatment groups: 
1. SL327  
2. Vehicle (100% DMSO) 
The MEK inhibitor SL327 crosses the blood brain barrier and has been previously 
shown to block ERK activation and attenuate the first and second phase of the formalin 
response (Alter et al., 2010). SL327 or DMSO (n = 4 each group) was delivered i.p. 30 
minutes prior to i.pl. formalin stimulation and 30 minutes later animals were sacrificed 
for perfusion to investigate spinal expression of PERK, PMSK1, and PH3S10 using 
IHC (Figure 6.2, Figure 6.3).  
 
 
Figure 6.3 Timeline of experimental procedures (Experiment 1).  
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6.2.1.2 Experiment 2: Does inhibition of MSK1 activity block formalin-induced 
PH3S10 and c-Fos expression, and attenuate formalin behaviour? (Aims 
2 and 3) 
 
Figure 6.4 Pharmacological blockade of MSK1 with SB747651A. Red boxes indicate main 
targets of interest. 
There were 3 treatment groups: 
1. Vehicle (0.0086% EtOH/0.9% Saline) 
2. SB747651A (10µM) 
3. SB747651A (1µM) 
The MSK1 inhibitor SB747651A or Vehicle was delivered i.t (see 2.3.1 for description 
of surgical procedure) 30 minutes prior to i.pl. formalin stimulation. Animals were then 
perfused 30 minutes (investigation of PERK and PMSK1 for control measures) (n = 4) 
or 1h (investigation of PH3S10 and c-Fos) later for IHC (n =14/15/8; Vehicle/10µM/1µM 
groups) (Figure 6.4, Figure 6.5).  For the 1h survival, formalin behaviour was also 
recorded after stimulation (n = 11/16/6; Vehicle/10µM/1µM groups) (see 2.2.2). 
 
 
Figure 6.5 Timeline of experimental procedures (Experiment 2). 
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6.2.1.3 Experiment 3: Are there any differences in spinal PERK expression 
following two different conditions of i.pl. formalin injection? (Aim 4) 
In this thesis, with the exception of Chapter 6, Experiment 2, all animals were injected 
with i.pl. formalin (50µl, 2%) under isoflurane anaesthesia. Chapter 6, Experiment 2, 
Does inhibition of MSK1 activity block formalin-induced PH3S10 and c-Fos expression, 
and attenuate formalin behaviour? necessitated the injection of formalin without 
anaesthesia in order to investigate nocifensive behaviour. However, due to Home 
Office licence limitations, rats injected without anaesthesia could only receive a 
maximum i.pl. injection of 20µl. In order to deliver the same total amount of formalin as 
the 50µl, 2% dose given under isoflurane anaesthesia, a higher concentration was 
given (20µl, 5%). 
Thus, the aim of Experiment 3 was to serve as a control experiment to identify whether 
the two conditions of formalin injection induced the same amount of PERK activation in 
the dorsal horn.  
Sham animal groups were either given general anaesthesia only or light restraint only 
and no injection.  
There were 4 treatment groups:  
1. Formalin (50µl, 2%) with anaesthesia (Form-A) 
2. Formalin (20µl, 5%) without anaesthesia (Form-NA) 
3. Anaesthesia only (Sham-A) 
4. Handling/Restraint only (Sham-NA) 
All animals (n=3 each group) were sacrificed for perfusion 30min following stimulation 
and spinal cords processed for immunohistochemistry. 
 
Figure 6.6 Timeline of experimental procedures (Experiment 3) 
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6.2.2 Drugs 
For Experiment 1: SL327 (50mg/kg/DMSO) or Vehicle (100% DMSO) was given i.p. in 
0.5ml without anaesthesia.  
For Experiment 2: SB747651A (1 or 10µM/0.0086% EtOH in 0.9% saline) or Vehicle 
(0.0086% EtOH in 0.9% saline) was given i.t. in 10µl (see Table 2.1 for more drug 
information; see 2.3.1 for description of surgical procedure). 
6.2.3 Formalin stimulation 
For Experiment 1: All animals were given intraplantar formalin, 50µl, 2% under 
isoflurane anaesthesia (see 2.2.1). 
For Experiment 2: All animals were given intraplantar formalin, 20µl, 5% without 
anaesthesia, in order to immediately observe nociceptive behaviour after stimulation 
(see 2.2.1).  
For Experiment 3: One group of formalin stimulated animals was given intraplantar 
formalin, 50µl, 2% under isoflurane anaesthesia, while the other group was given 
intraplantar formalin, 20µl, 5% without anaesthesia. See 6.2.1.3 for an explanation 
behind the use of two different doses. 
6.2.4 Immunohistochemistry 
Please refer to section 2.5 for the full immunohistochemical protocol and antibody 
information.  
Table 6.1 Table of IHC experiments completed in Experiment 1 Where PH3S10 was applied 
as a second primary, acid pretreatment was used for antigen retrieval prior to blocking (see 
2.5.2).  
Immunostain 1
st
 primary Method of 
detection 
2
nd
 primary Method of 
detection 
Time 
point 
PH3S10/PERK PH3S10 TSA PERK Direct Alexa 
594 
30min 
PMSK1/PH3S10 PMSK1 TSA PH3S10 Direct Alexa 
594 
30min 
PMSK1/PERK PMSK1 TSA PERK Direct Alexa 
594 
30min 
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Table 6.2 Table of IHC experiments completed in Experiment 2 Please note that PERK 
staining in Experiment 3 also used DAB detection, at 30min time point. 
Immunostain Method of detection Time point 
PERK DAB 30min 
PMSK1 TSA 30min 
PH3S10 TSA 1h 
c-Fos DAB 1h 
 
6.2.5 Formalin behaviour- Scoring and quantification 
Formalin behaviours were scored and quantified in 5min bins across the 1h following 
injection. All scoring was done with the experimenter blind to treatment. 
1. Length of time spent licking and flinching 
 
2. Number of flinches  
6.2.6 Immunohistochemistry- Quantification 
Immunopositive cells for all sections were counted manually with experimenter blind to 
treatment using a Leica DMR microscope. Immunopositive cells bodies (PERK) or 
nuclei (PMSK1, PH3S10, c-Fos) were counted in laminae I-II in the ipsilateral dorsal 
horn of all tissue sections. Once all sections were counted, per animal, five sections 
with the maximum response (ipsilateral) were used and the average taken on the 
ipsilateral side of the dorsal horn. The average of the treatment group was then 
calculated along with the standard error of each group mean (SEM). Data from Chapter 
3 showed that PH3S10 nuclei in sham and contralateral tissue was virtually inexistent 
and showed such low expression that only ipsilateral PH3S10 expression was 
quantified for the experiments done in this chapter.  
6.2.7 Immunohistochemistry- Image acquisition 
Images of fluorescent immunohistochemistry in this chapter were taken on the Leica 
TCS SPE laser scanning confocal microscope, or a Hamamatsu CCD C4742 digital 
camera attached to a Leica DMR microscope using the software Volocity (PerkinElmer, 
Waltham MA, USA). All images for colocalisation were taken in a single focal plane. 
6.2.8 Statistical analysis 
Please also see 2.7 for full details of statistical analysis. 
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6.2.8.1 Formalin behaviour 
Formalin-induced nociceptive behaviour (see 6.2.5) in Experiment 2 was compared in 
animals receiving Vehicle and animals receiving Drug (SB747651A; 2 doses 10µM or 
1µM in 10µl). Data was analysed using a repeated measures ANOVA, with ‘treatment’ 
as the between-subjects factor, and ‘time’ as the within-subjects factor. A significant 
main effect of treatment or significant treatment-time interaction led to post-hoc 
analysis by LSD or Bonferroni tests. To determine the effectiveness of drug treatment, 
percentage reductions in formalin-induced nocifensive behaviour were calculated using 
the area under the curve (AUC) for the two formalin phases (first phase 0-10 minutes, 
second phase 15-60 minutes). 
6.2.8.2 Immunohistochemistry 
For Experiment 1, group means were analysed by univariate ANOVA, with treatment 
(vehicle or SL327, see 6.2.1.1) as a between-subjects factor.  
For Experiment 2, group means (vehicle and 10µM dose) were analysed by 
independent t-test. 
For Experiment 3, group means for PERK counts were analysed by univariate ANOVA, 
with treatment (4 groups- see 6.2.1.3) as a between-subjects factor, and side 
(ipsilateral or contralateral) as a within-subjects factor. A significant main effect of the 
independent variable or interaction of factors led to post-hoc analysis of treatment. 
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6.3 Results 
6.3.1 PMSK1, the activated kinase responsible for PH3S10, is expressed 30 
minutes post-formalin and requires ERK activation  
The role of MEK inhibitors, specifically SL327, in nociceptive formalin behaviour has 
already been investigated. Specifically, it has been shown that SL327 attenuates both 
first and second phase of the formalin response (Alter et al., 2010). In this chapter, 
SL327 was utilised to assess the functional role of novel molecular targets downstream 
of ERK. Results from Chapter 4 indicated that 58% of PH3S10 in the dorsal horn 
colocalised with PERK after formalin, and this information suggested that PH3S10 was 
at least partially dependent on ERK/MAPK signalling. PMSK1 is part of the ERK/MAPK 
pathway and an intermediate kinase linking PERK and PH3S10 activity, and was 
therefore also a target of interest.  
Both PERK and PMSK1 populations were quantified from a double stain of 
PERK/PMSK1. Specifically, the number of both double-labelled and single-labelled 
cells was noted. Formalin stimulation induced expression of PERK and PMSK1 in 
laminae I-II of the ipsilateral dorsal horn at 30 minutes (Figure 6.7 A, DMSO-control, 
first row). To quantify the magnitude of MEK inhibition, the number of PERK 
immunopositive cells in laminae I-II was compared in DMSO and SL327 groups. There 
was a 68% reduction of downstream target PERK after systemic SL327, which was 
significant (F(1, 7) = 13.39, P<0.05) (Figure 6.7 B).  
Although no time course investigation into PMSK1 expression was completed, it is 
worth referring back to results from Chapter 4 which indicated that PH3S10 peaked 30 
minutes post-formalin. PMSK1 lies downstream of PERK (5 minute peak post-formalin) 
and upstream of PH3S10, suggesting that it is likely to have a peak expression 
between 5 and 30 minutes; thus, an investigation into PERK/PMSK1 colocalisation at 
30 minutes seemed appropriate. Even when considering that the 30 minute time point 
for PMSK1 expression might not be optimal, the great majority of PMSK1 colocalised 
with PERK in DMSO-control animals (87%) (Figure 6.7 B).  
SL327 caused a significant reduction (77%) in total PMSK1 nuclei in laminae I-II of the 
ipsilateral dorsal horn (F(1, 7) = 13.19, P<0.05) (Figure 6.7 B). Specifically, there were 
significant reductions post-SL327 in PMSK1 Only cells and double labelled cells (PERK 
+ PMSK1) (F(1, 7) = 6.42, P<0.05 and F(1, 7) = 12.24, P<0.05) (Figure 6.7 C, D). Following 
SL327, the majority of PMSK1 nuclei (63%) still colocalised with PERK (Figure 6.7 B). 
It is of note that the formalin-induced upregulation of PERK in DMSO-controls was 
similar to the magnitude of PERK upregulation seen in Chapter 4 at the same 30 
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minute time point (23.1 ± 7.3 cells vs. 30.7 ± 3.7 cells, respectively), therefore 
indicating that there was no presumed effect of DMSO on nociceptive activation in the 
dorsal horn (Figure 6.7 B). 
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Figure 6.7 Formalin-induced PMSK1 expression in the dorsal horn is prevented by MEK 
inhibitor SL327. A) Images are examples of double labelling of PERK and PMSK1 taken from a 
single focal plane 30 min after formalin stimulation in animals receiving i.p. DMSO or SL327. 
Images in the final column show a merge of first two images; colocalisation appears yellow; 
arrowheads indicate examples of colocalisation. White line indicates medial border between 
lamina I and white matter. Scale bar, 50µm. B) Quantification of PERK and PMSK1 populations 
(yellow = double labelled; red = PERK only, blue = PMSK1 only, n = 4 each treatment group, 5 
sections per animal). C) Single- labelled populations (PERK Only or PMSK1 Only) taken from 
graph B for ease of visualisation and further comparison. D) Population of double labelled 
(PERK + PMSK1) cells. All values presented as group mean ± SEM (per 40µm section). *P < 
0.05, versus DMSO control.  
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6.3.2 The majority of formalin-induced PH3S10 nuclei are downstream of ERK 
signalling  
The next step was to determine the functional link between ERK activation and 
PH3S10 expression investigating a double stain of PERK/ PH3S10. Again, inhibition of 
MEK activity with SL327 was confirmed with a 63% reduction of PERK immunopositive 
cells, which was significant (F(1, 7) = 22.46, P< 0.01) (Figure 6.8 B). [NB: The reduction 
in PERK is different from that in 6.3.1 because the counts were obtained from a 
different set of tissue.] 
Importantly, it was found that 73% of PH3S10 neurons colabelled with PERK in DMSO-
control animals (Figure 6.8 B). SL327 caused a 69% reduction in total PH3S10 nuclei 
in laminae I-II of the ipsilateral dorsal horn, which was significant (F(1,7) =36.39, 
P<0.001) (Figure 6.8 B). Specifically, there was a significant reduction post-SL327 in 
double labelled cells (PERK+ PH3S10) (F(1, 7) = 138.22, P<0.0001), but not PH3S10 
Only cells (Figure 6.8 D, C). 46% of the PH3S10 population still colocalised with PERK 
after SL327 (Figure 6.8 B). 
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Figure 6.8 Formalin-induced PH3S10 expression in the dorsal horn is prevented by MEK 
inhibitor SL327. A) Images are examples of double labelling of PERK and PH3S10 taken from 
a single focal plane 30 min after formalin stimulation in animals receiving i.p. DMSO or SL327. 
Images in the final column show a merge of first two images; colocalisation appears yellow; 
arrowheads indicate examples of colocalisation. White line indicates medial border between 
lamina I and white matter. Scale bar, 50µm. B) Quantification of PERK and PH3S10 populations 
(yellow = double labelled; red = PERK only, green = PH3S10 only, n = 4 each treatment group, 
5 sections per animal). C) Single- labelled populations (PERK Only or PH3S10 Only) taken from 
graph B for ease of visualisation and further comparison. D) Population of double labelled 
(PERK + PH3S10) cells. All values presented as group mean ± SEM (per 40µm section). *P < 
0.05, **P < 0.01, ***P< 0.001, ****P< 0.0001 versus DMSO control.  
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6.3.3 The majority of PH3S10 nuclei colocalise with PMSK1 
The overlap of PH3S10 and PMSK1 after SL327 was then investigated using a double 
stain directly comparing the two populations. The results indicated that the total number 
of PMSK1 cells was similar to, if not slightly larger than that of PH3S10 (10.8 ± 2.5 vs. 
6.9 ± 0.8 nuclei/40µm section, DMSO-control treated tissue). The total number of 
PMSK1 and PH3S10 cells were more similar in number with each other than to that of 
PERK (which was consistently >20 cells in DMSO-controls) (Figure 6.9 B). 87% of 
PH3S10 nuclei coexpressed PMSK1 in contrast to 56% of the PMSK1 population 
coexpressing PH3S10 (Figure 6.9 B). SL327 produced a 69% reduction in PMSK1 
expression and a 49% reduction in PH3S10 (F(1, 7)  = 8.09, P<0.05 and F (1,7) = 9.16, 
P<0.05) (Figure 6.9 B).  There was a significant reduction in double labelled cells 
(PMSK1 + PH3S10) post-SL327 (F(1,7) = 11.28, P<0.05) (Figure 6.8 D). Interestingly, 
there were no reductions in both PMSK1 Only and PH3S10 Only cells, after SL327 
(Figure 6.9 C) (see also PH3S10, Figure 6.8 C). 
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Figure 6.9 The majority of PH3S10 nuclei coexpress PMSK1 A) Typical images of PMSK1 
and PH3S10 double labelling taken from a single focal plane 30 min after formalin stimulation in 
animals receiving i.p. DMSO or SL327. Images in the final column show a merge of first two 
images; colocalisation appears yellow; arrowheads indicate examples of colocalisation. White 
line indicates medial border between lamina I and white matter. Scale bar, 50µm. B) 
Quantification of PMSK1 and PH3S10 populations (yellow = double labelled; blue = PMSK1 
only, green = PH3S10 only, n = 4 each treatment group, 5 sections per animal). C) Single- 
labelled populations (PMSK1 Only or PH3S10 Only) taken from graph B for ease of 
visualisation and further comparison. D) Population of double labelled (PMSK1 + PH3S10) cells. 
All values presented as group mean ± SEM (per 40µm section). *P< 0.05, **P<0.01, versus 
DMSO control. 
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6.3.4 Inhibition of MSK1 with SB727651A reduces formalin-induced PH3S10 
expression but has no effect on c-Fos in the dorsal horn 
The previous experiments indicated that the majority the PH3S10 population colabelled 
with the PMSK1 population (86%) (Figure 6.9 B), and that PMSK1 and PH3S10 
populations were of similar size. Therefore, PMSK1 seemed an ideal pharmacological 
target to manipulate PH3S10 expression. The novel MSK1 inhibitor, SB747651A, was 
delivered i.t. at two different doses 30 minutes prior to formalin stimulation in order to 
investigate the role of PH3S10 in nociceptive behaviour. 
Expectedly, treatment with i.t. SB747651A (10µM dose) yielded a significant reduction 
(42%) in superficial dorsal horn expression of PH3S10 1h post-formalin (independent t-
test, P<0.05). There was no effect of i.t. SB747651A (1µM) on spinal PH3S10 
expression. 
Furthermore, no reductions were observed in spinal expression of IEG product c-Fos 
1h post-formalin following i.t. SB747651A (10µM dose) (Figure 6.10). 
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Figure 6.10 SB747651A causes a significant reduction in formalin-induced PH3S10 but 
not c-Fos. A) Typical images of PH3S10 and c-Fos in the dorsal horn in Vehicle and 
SB747651A (10µM) treated animals. Scale bar, 100µm; white line indicates medial border of 
lamina I and white matter. B) Quantification of PH3S10 (n = 11/13 each group, 5 sections per 
animal) and C) c-Fos (n = 13/15, 5 sections per animal). There was a significant reduction in 
formalin-induced PH3S10 but not c-Fos after i.t. SB747651A (10µM). Values presented as 
group mean ± SEM (per 40µm section). *P<0.05 
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6.3.5 Inhibition of MSK1 activity using SB747651A prevents the full expression 
of formalin-induced nocifensive behaviour without affecting PERK or 
PMSK1 expression in the dorsal horn 
The final aim was to determine whether inhibition of MSK1 could modify nociceptive 
behaviour. Two different formalin response behaviours were scored for 1h following 
stimulation in all animals. There was a significant main effect of treatment at 35-60 
minutes on the time spent licking and flinching (F(2,30) = 5.13, P<0.01). SB747651A 
(10µM dose) attenuated the formalin response compared to the Vehicle-treated group 
(Bonferroni post-hoc test, P<0.01). Calculation of area under the curve (AUC) indicated 
a 30% reduction of time spent licking/flinching in SB747651A (10µM) treated animals 
during the second phase (15-60 minutes) of the formalin response. There was no 
difference between the Vehicle and 1µM dose groups (Figure 6.11 A). 
Interestingly, SB747651A significantly attenuated both the first and second phase of 
the formalin response when quantified by total number of flinches. There was a main 
effect of treatment (F(2,21) = 4.939, P<0.05), specifically a difference between Vehicle 
and SB747651A (10µM dose) groups (Bonferroni post-hoc test, P<0.01). AUC 
calculation indicated a 43% reduction of flinch behaviour during the first phase (0-10 
minutes) and 37% reduction during the second phase (15-60 minutes) in SB747651A 
(10µM) treated animals. 
 Analysis across the 15-30 minute time points also indicated a main effect of treatment 
(F(2,21) = 4.263, P<0.05) and differences between Vehicle and SB747651A (10µM dose) 
groups, as well as Vehicle and SB747651A (1µM dose) groups (LSD post-hoc test, 
P<0.05, each comparison) (Figure 6.11 B). 
Importantly, specificity of SB747651A as an MSK1 inhibitor was demonstrated by no 
change in the activation of upstream PERK expression between Vehicle and 
SB747651A (10µM dose) groups 30 minutes post- formalin (Figure 6.12). There was 
also no difference in PMSK1 expression between the two groups. 
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Figure 6.11 Inhibition of MSK1 reduces nociceptive behaviour. A) SB747651A attenuated 
the second phase of the formalin response 35-60 minutes post-formalin **P<0.01, between 
Vehicle and 10µM groups (n = 11/16/6; Vehicle/10µM/1µM)  B) SB747651A reduces formalin-
induced flinching during the first and second phase of the formalin response. **P<0.01, between 
Vehicle and 10 µM; +P<0.05, between Vehicle and 10 µM; $P<0.05 between Vehicle and 1µM; 
*P<0.05, between Vehicle and 10µM (n = 10/8/6; Vehicle/10µM/1µM). 
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Figure 6.12 i.t. delivery of SB747651A does not alter nociceptive primary afferent input to 
the dorsal horn as indicated by PERK expression. A) Typical images of PERK and PMSK1 
in the dorsal horn in Vehicle and SB747651A (10µM) treated animals. Scale bar, 100µm. B) 
Quantification of PERK and C) PMSK1 (n = 4 each group, 5 sections per animal). There was no 
change in PERK or PMSK1 expression 30 minutes after formalin stimulation in Vehicle or 
SB747651A (10µM) treated groups.  Values presented as group mean ± SEM (per 40µm 
section). 
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6.3.6 50µl, 2% formalin injected under general isoflurane anaesthesia and 20µl, 
5% formalin injected without anaesthesia caused the same degree of 
spinal PERK activation at 30 minutes 
Finally, the investigation of MSK1 inhibition with SB747651A on formalin behaviour 
(see 6.3.5 and Figure 6.11) in this chapter required the injection of formalin without 
anaesthesia. Due to Home Office regulations, this meant that the formalin injection had 
to be given in a smaller volume at a higher concentration (20µl, 5% formalin). This dose 
importantly delivered the same total amount of formalin into the hindpaw but in a 
different volume. Therefore, as the rest of the experiments in this thesis delivered 
formalin under anaesthesia at 50µl, 2% as a stimulus, we decided to investigate the 
effect of the two formalin treatments on nociceptive primary afferent activity as 
indicated by PERK expression in the dorsal horn. 
There was a main effect of treatment (ANOVA F(3,8)=9.92, p<0.01); however, 
importantly there was no difference in PERK activation between the two different doses 
and conditions of formalin stimulation (Form-A and Form-NA groups, NS) (Figure 6.13 
A, B). There was also no difference between sham groups (Sham-A and Sham-NA, 
NS). 
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Figure 6.13 No difference in formalin-induced spinal PERK between two formalin 
treatments at 30min (50µl, 2% formalin injected under general isoflurane anaesthesia vs. 
20µl, 5% formalin injected without anaesthesia) A) Typical PERK expression in the ipsilateral 
superficial dorsal horn for each treatment group. Scale bar 50µm. B) No difference between 
Form-A and Form-NA, LSD post-hoc p=0.71, NS. *P<0.05, **P<0.01, ***P<0.001, Formalin vs. 
Sham groups. Data presented as means ± SEM (n=3 each group, 5 sections per animal). 
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6.4 Discussion 
PERK is required for the full expression of pain states and is used as a marker of 
neuronal activation by nociceptive stimulation in the spinal cord (Gao and Ji, 2009; Ji et 
al., 2009, 1999). It is widely known that PERK regulates nociceptive behaviour, but less 
is known about the specific molecular events downstream of PERK that lead to gene 
regulation. The results from this chapter are the first to indicate that PERK signalling 
engages downstream targets MSK1 and PH3S10 to regulate nociceptive behaviour. 
6.4.1 ERK/MAPK regulation of PMSK1 and PH3S10 expression 
Chapter 4 results indicated that the majority of PH3S10 nuclei colocalised with PERK 
30 minutes post-formalin, and results from this chapter (Experiment 1: Does MEK 
inhibition block formalin-induced PMSK1 and PH3S10 expression?) found that 73% of 
the PH3S10 population and 87% of the PMSK1 population colabelled with PERK 
(DMSO-control treated animals) (Figure 6.8 B, Figure 6.9 B). It should be noted that no 
time course was completed for PMSK1 expression, although knowing the peak 
expression times of PERK and PH3S10 in the dorsal horn (5 and 30 minutes, 
respectively, post-formalin) would suggest that PMSK1 would be somewhere in 
between, considering its position in ERK/MAPK pathway. It is worth noting that the 
induction of PMSK1 observed at 30 minutes post-stimulation is in agreement with a 
previous study which showed neuronal induction of PMSK1 after 15 and 30 minutes of 
glutamate stimulation in vitro (Brami-Cherrier et al., 2007). 
In animals given SL327, 46% of PH3S10 and 63% of PMSK1 colocalised with PERK. 
Within each population, the reduction in colocalisation percentage with PERK 
(73%/46% DMSO/SL327 for PH3S10; 87%/63% DMSO/SL327 for PMSK1) indicated a 
requirement of upstream ERK signalling on the activity of PMSK1 and PH3S10 (Figure 
6.7 C, PMSK1; Figure 6.8 B, PH3S10). Interestingly, the PH3S10 Only population was 
the only subpopulation that never exhibited a reduction after SL327 treatment (Figure 
6.8 C, PH3S10; Figure 6.9 C, PH3S10), which indicates that there could be a 
population of PH3S10 occurring independently from ERK/MAPK signalling.  
If indeed there is an ERK/MAPK-independent kinase leading to PH3S10 expression, 
this population would be small in number (1-2 per 40µm section). The possibility of a 
separately occurring PH3S10 population seems highly likely, and therefore a key 
question would be to identify another kinase which might be responsible for PH3S10. 
One example could be a non-ERK/MAPK kinase or cascade that converges onto 
MSK1, such as p38 MAPK. The only other kinase which has been suggested to 
activate PH3S10 is p70 ribosomal s6 kinase (RSK2), which also lies downstream of 
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ERK (Ciccarelli and Giustetto, 2014). No other candidates responsible for PH3S10 
have been suggested (Davie, 2003).  
Importantly, the technical limitation of choosing one time point to investigate the 
maximum overlap of two populations in Chapter 4 was eliminated in Experiment 1 of 
this chapter. Specifically, blocking PERK with SL327 allowed us to focus on the optimal 
time point to investigate the downstream PH3S10 reduction. However, to conclusively 
establish whether an independent, non-ERK/MAPK PH3S10 population existed would 
have required the complete elimination of PERK expression- a condition which was not 
met in Experiment 1. The dose of SL327 (50mg/kg) was chosen because it has been 
shown to significantly attenuate the second phase of the formalin response, although it 
does not prevent it completely (Alter et al., 2010). Furthermore, Experiment 1 (Figure 
6.7 – 6.9, B) and the study by Alter et al. (2010) indicated that PERK was significantly 
reduced following SL327 (50mg/kg), but not prevented entirely at this particular dose. It 
is likely that higher doses causing the entire elimination of PERK activity might have led 
to undesired behavioural side effects. 
Despite similar issues regarding experimental limitations regarding the complete 
blockade of ERK activation, other models of neural plasticity have also been able to 
show that PH3S10 is partially dependent on PERK signalling. In particular, the MEK 
inhibitor U0126 blocked PKC and PKA pharmacological activation of hippocampal 
PH3S10 in vitro (Chwang et al., 2006). Furthermore, pre-emptive delivery of i.p. SL327 
caused reduced expression of PH3S10 1h after memory acquisition (memory formation 
by contextual fear conditioning), and a reduction in freezing behaviour 24h after 
memory acquisition (Chwang et al., 2006). The use of i.p. SL327 also demonstrated 
that inhibition of MEK regulated the activity-induced joint histone mark PH3S10-
AcH3K14 in the hippocampus 2h after the forced swim test (Chandramohan et al., 
2008, 2007); it has also shown regulation of synaptic activity-induced PH3S10 by ERK 
in visual cortical plasticity, striatal plasticity induced by drug addiction, and naloxone-
precipitated morphine withdrawal (Brami-Cherrier et al., 2009; Ciccarelli et al., 2013; 
Putignano et al., 2007). 
6.4.2 Targeting PH3S10 via MSK1- the best option 
The investigation into MSK1 was interesting in itself as a novel target never before 
explored within the context of nociception.  Additionally, being upstream of PH3S10, 
MSK1 was an ideal target for interfering with PH3S10 expression in Experiment 2: 
Does inhibition of MSK1 activity attenuate formalin behaviour and block formalin-
induced PH3S10 and c-Fos expression? 
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In general, studies investigating the role of histone modifications in neuronal function 
and behaviour have pharmacologically targeted the enzymes responsible for either 
imparting or removing the histone marks. In particular, these studies have used HAT or 
HDAC inhibitors to examine the effects of manipulating histone acetylation levels in a 
relatively non-specific manner (Barrett and Wood, 2008; Gräff and Tsai, 2013; Peixoto 
and Abel, 2013). In order to manipulate PH3S10, there were two options: MSK1, the 
kinase responsible for PH3S10, or protein serine/threonine phosphatase 1 (PP1) the 
kinase responsible for H3S10 dephosphorylation (for discussion of PP1 refer to 6.4.3.5).  
In order to choose an appropriate target, we investigated the distribution of PMSK1 in 
the dorsal horn after noxious stimulation. The results in this chapter (Experiment 1) 
indicated that PMSK1 and PH3S10 populations had similar distributions within the 
superficial dorsal horn. The majority of PH3S10 colabelled with PMSK1 (86%), and 
conversely the majority of PMSK1 colabelled with PH3S10 (59%) (Figure 6.9 B). While 
the number of PH3S10 nuclei coexpressing PMSK1 was very high, the reverse figure 
for the PMSK1 population indicated a substantial but not complete amount of 
population overlap (59%). However, this again could have been an issue of timing as 
30 minutes may not have been optimal for PMSK1 expression. Additionally, PH3S10 is 
not the only downstream target of MSK1, as MSK1 is also known to phosphorylate 
transcription factors CREB and activating transcription factor 1 (ATF1) in vitro (Arthur et 
al., 2004; Soloaga et al., 2003; Wiggin et al., 2002), so perhaps a complete 
colocalisation between PMSK1 and PH3S10 should not be expected. Nonetheless, the 
substantial overlap between PH3S10 and PMSK1 populations suggested that MSK1 
would be a good target for interfering with PH3S10 expression.  
Many studies have investigated the role of MSK1 using genetically modified mice 
(Brami-Cherrier et al., 2005; Chandramohan et al., 2008; Chwang et al., 2007; Correa 
et al., 2012; Karelina et al., 2012). Recently however, a new MSK1 inhibitor, 
SB747651A has become available (Tocris, UK). Prior to the release of SB747651A, 
studies attempting to pharmacologically target MSK either utilised upstream inhibition 
of MEK (using inhibitors PD98059, SL327, U0126), Ro 31-8220 or H89- the latter two 
being non-selective MSK1 inhibitors also known to inhibit PKC and PKA, respectively, 
as well as other kinases. In contrast, using SB747651A causes less interference with 
other cell signalling activity, and allows for a refinement of MSK1 inhibition. Currently, 
no published work has used SB747651A in vivo, but recent evidence has conclusively 
shown that it has improved selectivity of MSK1 compared to Ro 31-8220 and H89 in 
vitro (Naqvi et al., 2012).  
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The use of global MSK1-/- mice has shown that MSK1 itself regulates a variety of 
forms of neural plasticity. In particular, MSK1 regulates memory formation (as shown 
by contextual fear conditioning, the forced swim test, and spatial and object- 
recognition tasks), environmental enrichment-induced cognitive enhancement, visual 
cortical plasticity, cocaine addiction, and neurodegeneration (Brami-Cherrier et al., 
2005; Chandramohan et al., 2008; Chwang et al., 2007; Karelina et al., 2012; 
Putignano et al., 2007; Roze et al., 2007). MSK1 has also been shown to modulate 
dendritic morphology and synaptic plasticity involved in hippocampal environmental 
enrichment and homeostatic synaptic scaling, and is thought to do so by regulation of 
AMPA subunit GluR1 expression via the IEG arc/arg3.1, which is also known to be 
upregulated in the spinal dorsal horn by noxious stimulation (Correa et al., 2012; 
Hossaini et al., 2010).  
Control experiments in this chapter indicated there were no upstream changes in 
PERK activation after i.t. delivery of SB747651A (10µM), which would support the 
targeted specificity of MSK1 inhibition within L4/5 of the superficial dorsal horn (Figure 
6.12). However, it should be carefully noted that there was a trend toward a PERK 
reduction in the SB747651A-treated group, with only an n=4 (Figure 6.12, P=0.06). The 
significant reduction in formalin-induced PH3S10 observed following i.t. SB747651A 
(10µM) required an n=11/13 (Figure 6.10), a value much higher than the n=4 used in 
the control PERK experiment. Furthermore, i.t. SB747651A (10µM) caused a 
significant attenuation of flinching behaviour in the first phase of the formalin response 
(Figure 6.11); thus, if spinal PERK was directly indicative of nociceptor activity it would 
not be surprising to observe a significant reduction in PERK in SB747651A-treated 
animals with a higher n number. 
Quantification of IHC indicated that there were also no changes in PMSK1 expression 
following SB747651A. However, this was expected- SB747651A is a specific inhibitor 
of the MSK1 N-terminal kinase, the domain which is reportedly essential for the 
phosphorylation of downstream MSK1 substrates (McCoy et al., 2005). The antibody 
used to detect PMSK1 was specific to phosphorylation at Threonine 581 in the C-
terminal kinase domain, activity which precedes N-terminal activity. It is worth noting 
that SB747651A can inhibit ribosomal s6-kinase (RSK) and PKA at low levels (Naqvi et 
al., 2012).  Non-specific inhibition of PKA could have potentially had an effect on the 
expression of PH3S10, as MEK is known to integrate upstream PKA and PKC activity 
in dorsal horn signalling (Hu et al., 2003). However, the fact that no changes in PERK 
were observed eliminates this potential confounding factor. RSK2 occurs downstream 
of ERK and therefore may be a factor requiring consideration. 
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6.4.3 MSK1 contributes to PH3S10 and nociceptive behaviour 
6.4.3.1 The formalin response 
I.t. inhibition of MSK1 significantly attenuated formalin-induced nociceptive behaviour 
when analysed by two criteria: 1) Time spent licking and flinching and 2) Total number 
of flinches; attenuation of nociceptive behaviour was accompanied by a reduction in 
PH3S10 nuclei at 30 minutes. Although opinion remains controversial (Abbott et al., 
1995), it has been reported that scoring formalin behaviour using spontaneous 
behaviours such as flinch is a more robust measure than measuring time spent paw-
licking in rats, whereas in mice it is the opposite (Bannon and Malmberg, 2007; Mogil, 
2009). Indeed, there seems to be a variety of behavioural measures used to report 
formalin behaviour which include the aforementioned criteria, as well as weighting of 
behaviours to produce a formalin response ‘score’ (Dubuisson and Dennis, 1977). 
Results from this chapter showed that SB747651A (10µM) produced a significant 
reduction in time spent licking/flinching and total number of flinches during the second 
phase (15-60 minutes), which is attributed to central sensitisation (Fischer et al., 2014; 
Puig and Sorkin, 1996; Tjølsen et al., 1992). There was also a significant reduction in 
the quantification of flinch behaviour during the first phase. A significant effect was also 
seen for the 1µM dose with the flinch response, perhaps due to the fact that flinch was 
a more robust measure of quantification.  
It has been reported that the formalin test is an ideal behavioural paradigm to 
understand the mechanisms generating persistent nociception (Dubuisson and Dennis, 
1977; Ren and Dubner, 1999). Hindpaw formalin stimulation is known to induce a 
biphasic response across nociceptive behaviour, cardiac activity, and underlying dorsal 
horn electrical discharge (Dickenson and Sullivan, 1987a, 1987b; Taylor et al., 1995; 
Tjølsen et al., 1992). It is of general agreement that the first phase (first 5-10min) of the 
response results from chemical activation of all peripheral nociceptors (Puig and Sorkin, 
1996). This phase is followed by a short period (5-10min) of quiescence, followed by a 
second phase response (20-60min) mediated by central sensitisation in spinal cord 
circuits following on from peripheral nociceptor sensitisation maintained by sustained 
Aδ and C-fibre activity (Dubuisson and Dennis, 1977; Puig and Sorkin, 1996; Tjølsen et 
al., 1992). However, it has been suggested that Aδ activity is sufficient for the full 
expression of the formalin response, as ablation of the majority of C-fibres only 
changed latency to onset but not total nocifensive behaviour (Shields et al., 2010). 
Furthermore, studies have indicated the role of the NMDA and NK1 receptors in the 
second phase of the formalin response (Haley et al., 1990; Henry et al., 1999).  
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The majority of the formalin studies have utilised the delivery of pharmacological 
agents before or after the first phase response and investigated the outcome of the 
second phase responses. Crucially, i.t. delivery of local anaesthetics or opioid agonists 
given prior to formalin injection have been shown to reduce or prevent nociceptive 
behaviour and neuronal activity accompanying the second phase of the response, 
indicating that dorsal horn sensitisation during the first phase is required for the full 
expression of the second phase (Abram and Yaksh, 1993; Coderre et al., 1990; 
Dickenson and Sullivan, 1987a; O’Connor and Abram, 1994; Sullivan et al., 1989; 
Yashpal et al., 1998). Other evidence however, suggests that the second phase 
response necessitates ongoing primary afferent activity, as local anaesthetic (QX-314) 
given at the site of injection after the first phase was sufficient to eliminate the second 
phase response (Taylor et al., 1997, 1995). The behavioural results in Experiment 2 
indicated that when analysed by Time spent licking and scratching, SB747651A had no 
effect on the first phase formalin response, but caused a reduction in the second phase 
response, suggesting that MSK1 plays a role in the development of central 
sensitisation.   
6.4.3.2 Linking underlying molecular targets to formalin behaviour 
Referring to colocalisation studies performed in this chapter and Chapter 4, it was 
expected that inhibition of MSK1 would reduce expression of downstream targets 
PH3S10 and c-Fos, as well as attenuate formalin-induced behaviour. Indeed 
SB747651A was found to have a significant effect on PH3S10 reduction, however, no 
change was observed with c-Fos. The reduction of PH3S10 expression suggests that 
MSK1 may act via PH3S10 to promote the full expression of formalin-induced 
nociceptive behaviour.  
No change in c-Fos 
Despite any controversy linking c-Fos expression and nociceptive behaviour (Gao and 
Ji, 2009), it was still surprising to find no reduction in c-Fos expression after MSK1 
inhibition. MSK1 is required for c-Fos induction by lysophosphatidic acid in embryonic 
stem cells in vitro (Schuck et al., 2003), via phosphorylation of CREB (PCREB) 
(Shimada et al., 2010; Wiggin et al., 2002). MSK1 -/- striatal neurons showed no 
PH3S10 in response to glutamate, and c-Fos expression was reduced (Brami-Cherrier 
et al., 2007). Furthermore, in vivo models of synaptic plasticity show that the 
upregulation of c-Fos in the dentate gyrus caused by the forced swim test (a learning 
paradigm measuring behavioural immobility) was entirely prevented in MSK-/- mice 
(Chandramohan et al., 2008). This effect was specific to the hippocampus as no 
changes in c-Fos expression were seen in other brain regions.   
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Results from Chapter 4 indicated that 17% (only 6.2 ± 1.2 nuclei) of the formalin-
induced c-Fos population colocalised with PH3S10 at 1h. Considering the size of the c-
Fos population quantified in this chapter (>50 nuclei/40µm section), the reduction of a 
maximum of 6.2 ± 1.2 nuclei would be very difficult to detect using IHC. Other studies 
have successfully used a more sensitive technique, chromatin immunoprecipitation 
(ChIP), to identify links between histone modifications and transcription of specific 
genes. In particular, ChIP has revealed enrichment of the joint histone mark PH3S10-
AcH3K14 at the c-Fos promoter in striatal tissue following chronic cocaine 
administration in rats, indicating that PH3S10-AcH3K14 modulated activity-induced 
c-Fos (Kumar et al., 2005). ChIP would have been a more sensitive and thus better 
method for the purposes of quantifying small changes in spinal cord c-Fos expression, 
and would have allowed for the quantification of PH3S10-associated c-Fos expression 
that was undetectable with IHC. This method would also have expedited the probing of 
additional candidate genes associated with PH3S10 regulation. 
Correlating molecular targets and behaviour: c-Fos 
It is tempting to correlate molecular targets involved in pain processing with nociceptive 
behaviour; however, the picture is not always straightforward. For example, studies 
investigating c-Fos expression within the context of formalin behaviour have suggested 
that c-Fos is indicative of the second phase of the formalin response (Abbadie et al., 
1997). Abbadie et al (1997) used remifentanil, a short acting opioid agonist 
administered during the first phase of the formalin response to show that reduction in c-
Fos expression (laminae I-II) occurred to the same degree as when lidocaine was 
administered during the second phase alone (27% reduction). Interestingly, utilisation 
of both remifentanil and lidocaine during first and second phases, respectively, reduced 
c-Fos to a greater degree (51% reduction), indicating that the second phase of the 
formalin response was necessary for the full expression of c-Fos in the dorsal horn.  
Contrastingly, other studies have implicated that c-Fos expression is not closely linked 
with nociceptive behaviour, in particular because of its delayed expression (Gao and Ji, 
2009). While nocifensive behaviour is immediately observed following formalin injection 
and other noxious stimuli, the c-Fos protein product does not appear until at least one 
hour after noxious stimulation, with expression peaking 2h after formalin stimulation (Ji 
and Rupp, 1997). Delayed upregulation c-Fos expression makes it difficult to interpret 
its correlation within the 60 minute biphasic behavioural response period to formalin. 
Moreover, it has been reported that i.t. lidocaine given after formalin stimulation can 
cause a reduction in c-Fos nuclei, but have no effect on formalin-induced nociceptive 
behaviour, which suggests that c-Fos does not correlate with nociceptive behaviour 
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(Yashpal et al., 1998). Furthermore, c-Fos can still be present in the superficial dorsal 
horn despite a complete opioid-induced blockade of second phase behaviour (Gogas 
et al., 1991; Jasmin et al., 1994; Presley et al., 1990). It is difficult to investigate the role 
of c-Fos in nociceptive behaviour by pharmacological intervention studies, and 
antisense mRNA knockdown of c-Fos has proven controversial. A few studies have 
shown reductions in c-Fos expression and increased formalin behaviour and 
hypersensitivity (Hunter et al., 1995; Ibrahim et al., 2001), although attenuation of 
formalin behaviour has been documented (Hou et al., 1997).  
Correlating molecular targets and behaviour: PERK 
It has been suggested that PERK could be a better molecular correlate of nociceptive 
behaviour, and its role in nociception has been investigated with pharmacological 
agents (Gao and Ji, 2009). Following formalin injection, PERK appears in the 
superficial dorsal horn within 3 minutes of injection and peaks at 5 minutes, which 
appears to correlate well with the onset of the behavioural response (Ji et al., 1999).  
Interestingly, Ji et al (1999) showed that pre-emptive i.t. inhibition of MEK did not alter 
the first phase of the formalin response, and it is therefore surprising to have seen a 
reduction in first phase flinching after inhibition of MSK1. It is possible that the diffusion 
drug (i.t. SB747651A) to peripheral DRG sites could explain the reduction in first phase 
flinch data, although previous experiments in this lab suggest this is unlikely within the 
time frame of the experiment (Géranton et al., 2008). As motor control experiments are 
yet to be carried out, a first phase reduction caused by motor deficit cannot be ruled out. 
It is worth stressing however, that no differences in licking and flinching duration were 
observed between Vehicle and Drug treated groups during the same period of 
observation (Figure 6.11 A, B). 
6.4.3.3 Inhibiting a population of limited size: Behavioural effects 
Perhaps one surprising feature of attenuating nociceptive behaviour following MSK1 
inhibition is the effect of inhibiting such a small population of cells within the dorsal horn. 
Indeed, the PH3S10 population rarely exceeded 20 cells/ 40µm section at peak 
expression, which is limited in comparison to classical markers PERK (roughly 30 
cells/40µm section) and c-Fos (roughly 50 cells/40µm section). However, previous 
work has shown that another epigenetic regulator implicated in nociceptive processing, 
phospho-MeCP2 (PMeCP2), is similar in quantity and distribution within the superficial 
dorsal horn, and plays a key role in nociceptive behaviour (Géranton et al., 2008). In 
particular, Géranton et al. (2008) found that RNAi knockdown of a downstream target 
of MeCP2 activity, the serum- and glucocorticoid-regulated kinase-1 (SGK1), delayed 
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the onset of hypersensitivity caused by CFA ankle joint injection. In this chapter, i.t. 
inhibition of MSK1 by SB747651A (10µM) led to a 42% reduction in formalin-induced 
PH3S10 at 60 minutes, which related to a 30% reduction of time spent licking/flinching 
during the second phase (15-60 minutes) of the formalin response, and a 43% and 
37% reduction of total flinches during the first (0-10 minutes) and second phases (15-
60 minutes) of the response, respectively. Importantly, it cannot be said whether the 
behavioural effects of the MSK1 inhibitor SB747651A are strictly due to the reduction in 
formalin-induced PH3S10. MSK1 has other downstream targets that could also be 
affected following MSK1 inhibition (see below 6.4.3.4). 
The wider implications of the restricted pattern of PH3S10 will be addressed in the 
General Discussion. 
6.4.3.4 Other targets of MSK1 and PH3S10 signalling in nociceptive behaviour 
Due to its importance in nociception (Hunt et al., 1987), c-Fos was an obvious target to 
investigate as a gene under the regulation of PH3S10. However, there could be other 
gene targets under the regulation of PH3S10. Furthermore, there are known targets of 
MSK1 other than PH3S10. 
Candidate genes under the regulation of PH3S10 
Candidate genes under the regulation of PH3S10 activity are most likely plasticity-
related genes, and potentially genes related to nociceptive processing. In particular, 
Zif268, is known to regulate nociceptive processing (Rygh et al., 2006). Chapter 4 
results showed that 12% of the Zif268 population coexpressed PH3S10. Indeed, ChIP 
experiments have shown that Zif268, under the regulation of PH3S10, is upregulated in 
the hippocampus during recent memory consolidation (1d), as well as in the prefrontal 
cortex during remote memory formation (7d) in an object recognition task (Gräff et al., 
2012). Notably, a number of known genes under the regulation of the transcription 
factor, CREB, could also be under the regulation of PH3S10 (see below). As the 
general function of PH3S10 is to aid in the relaxation of chromatin, it is possible that 
PH3S10 and CREB (both via phosphorylation by MSK1) could act together to permit 
transcription. 
Downstream targets of MSK1 
MSK1 additionally phosphorylates cAMP response element-binding protein (PCREB), a 
transcriptional regulator which binds to regulatory CRE-binding sites embedded within 
specific genes. It is therefore possible that changes may have been observed in the 
expression of PCREB had it been investigated.  
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CREB is known to be activated by PKA, PKC, ERK/MAPK, and p38 MAPK, and plays a 
major role in neuronal signalling in response to neurotrophic factors such as NGF and 
BDNF (Finkbeiner et al., 1997; Ying et al., 2002), and PCREB is known to mediate 
NGF-induced c-Fos expression (Ginty et al., 1994).  Furthermore, CREB activity 
regulates gene expression accompanying hippocampal LTP (Impey et al., 1996). It has 
been reported that PCREB activity does not always lead to activation of IEG 
transcription, which may also provide an explanation as to why no changes were 
observed in c-Fos expression after MSK1 inhibition, if indeed this is a downstream 
mechanism of MSK1 in nociceptive processing (Bonni et al., 1995; Tao et al., 1998). 
Other relevant genes under the regulation of CREB include Cox-2, Zif268, NK1, 
prodynorphin, TrkB and nNOS; genes which have been reported to play a role in pain 
processing (Lonze and Ginty, 2002). 
 
MSK1 is also known to regulate the IEG arc/arg3.1 via CREB in models of plasticity, 
specifically homeostatic synaptic scaling in dissociated hippocampal cultures (Correa 
et al., 2012). Arc/arg3.1 itself is known to regulate LTP, LTD, and homeostatic synaptic 
scaling (Bramham et al. 2008) and does so by regulating trafficking and endocytosis of 
AMPAR subunits at the synapse (Correa et al., 2012; Shepherd et al., 2006). 
Furthermore, arc/arg3.1 is essential for memory consolidation and while knockout mice 
have normal short-term memory, they fail to exhibit long-term memory formation (Plath 
et al., 2006). In nociception, intensity dependent Arc/Arg3.1 upregulation in the 
superficial dorsal horn occurs after peripheral stimulation by capsaicin, CFA, or 
mustard oil, or i.t. delivery of BDNF (Hossaini et al., 2010). The authors found that 90% 
of Arc/Arg3.1 colocalised with c-Fos, and 68% colocalised with preproenkephalin. 
Arc/Arg3.1 knockout mice showed no deficits in nociceptive behaviour as demonstrated 
by the formalin response or mechanical and thermal response after CFA hindpaw 
inflammation. The behavioural results combined with high expression of Arc/Arg3.1 in 
preproenkephalin-expressing neurons led the authors to conclude that Arc/Arg3.1 plays 
a role in the anti-nociceptive response to noxious stimuli, which is particularly 
interesting considering the results of Correa et al, who propose upstream regulator of 
Arc/Arg3.1, MSK1, as a key homeostat in activity dependent synaptic plasticity.  
It seems likely that MSK1 is actively contributing to the regulation of gene expression 
via direct manipulation of PH3S10 following noxious stimulation. Dynamic geometric 
remodelling of the nucleus, an indicator of active gene transcription and chromatin 
remodelling, has been shown to increase with neuronal activity (Wittmann et al., 2009). 
This is specifically caused by NMDA-mediated action potential bursting, which leads to 
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a high degree of nuclear infolding and small compartment formations- a process which 
required ERK/MAPK signalling and correlated with the degree of PMSK1 and PH3S10 
expression. These correlations suggest a functional link between nuclear geometry and 
transcriptional regulation, in part dynamically regulated by histone modifications (such 
as PH3S10) which serve to make signalling-induced transcription gene more efficient. 
This could also be the case for the events occurring in the spinal cord following noxious 
stimulation. 
6.4.3.5 PP1 
Finally, we cannot eliminate protein phosphatase 1 (PP1) as an alternative regulator of 
PH3S10. PP1 is well-known to regulate synaptic plasticity and molecular mechanisms 
of learning and memory (Genoux et al., 2002; Munton et al., 2004), and use of PP1 
genetically modified mice has demonstrated that PP1 is a negative regulator of 
memory formation (Koshibu et al., 2009). Inhibition of PP1 has been found to enhance 
long-term memory formation as shown by fear conditioning, object recognition learning, 
and spatial learning using the Morris Water Maze (Koshibu et al., 2011, 2009). 
Somewhat surprisingly, PP1 has been shown to have specificity for PH3S10 in the 
hippocampus. In particular, the use of doxycycline-inducible PP1 null mice indicated 
that PP1 was specific to histone proteins as phosphorylation of other nuclear enzymes 
MSK1, CREB, HDAC1, and MeCP2 did not occur (Koshibu et al., 2009). Remarkably, 
PP1 null mice displayed increases in PH3S10 without affecting phosphorylation at 
residues serine 28, threonine 3 or 11 (Koshibu et al., 2009). Furthermore, 
phosphorylation of non-nuclear targets GluR1 and GluR2 subunits were also 
unaffected in PP1 null mice. However, the picture becomes more complicated as 
Koshibu and colleagues showed that PP1 additionally regulates hippocampal histone 
acetylation and methylation at specific genes, in particular NFκB and CREB. These 
events act via an enzyme complex with Jumonji domain 2 demethylase (JMJD2A) and 
HDAC1. These additional histone modifying effects make PP1 a slightly less desirable 
enzyme candidate for targeting PH3S10. 
While it would have indeed been interesting to explore the effects of targeting PP1, the 
availability of enhanced specificity with SB747651A and the ability to specifically inhibit 
MSK1 in the superficial dorsal horn (versus a global knockout), targeting MSK1 with 
SB747651A was the most appropriate and economical option for investigating the role 
of PH3S10 in nociceptive processing and behaviour. 
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6.4.4 No difference in spinal cord activation of PERK between two conditions of 
i.pl. formalin injection 
Experiment 3: Are there any differences in spinal PERK expression following two 
different conditions of i.pl. formalin injection?, was a control experiment to identify 
whether two formalin injections of a slightly different nature (50µl, 2% with general 
anaesthesia vs. 20µl, 5% no anaesthesia) used in this thesis induced the same amount 
of PERK activation in the dorsal horn.  
Importantly, the two conditions of formalin stimulation led to the same degree of PERK 
induction in the dorsal horn. It is difficult to unequivocally make conclusions about the 
effect of anaesthesia on spinal ERK activation due to the variability of formalin dose (i.e. 
formalin concentration, volume of injection). It is important to note however, that the 
two doses of formalin delivered the same total amount of formalin. 
Previous studies have shown the ability of general anaesthetics to alter spinal dorsal 
horn neural activity and output as a result of noxious stimuli (Antognini et al., 2000a, 
2000b). Although the effect of anaesthesia cannot be directly deduced from this 
experiment, isoflurane is thought to have an inhibitory effect on neural activity 
(Grasshoff and Antkowiak, 2006; Patel et al., 1999; Winegar and MacIver, 2006; Zaugg 
et al., 2003). While no study has directly investigated the effect of isoflurane 
anaesthesia on nociceptive spinal PERK activity, numerous studies have investigated 
the effect of general anaesthetic on spinal nociceptive c-Fos expression. The studies 
indicate that injectable anaesthetics such as propofol, fentanyl, and pentobarbital 
(Gilron et al., 1999; Sommers et al., 2008; Takasusuki et al., 2013) as well as 
inhalational anaesthetics such as nitrous oxide and isoflurane (Jinks et al., 2002) 
reduce c-Fos expression in the spinal cord. Furthermore, brief halothane has been 
shown to reduce expression of spinal PCREB and c-Fos induced by formalin, but these 
levels are still significantly higher than non-anaesthetised controls (Ji and Rupp, 1997). 
The anaesthetic used in our experiments, isoflurane, is known to enhance activity of 
two-P-domain potassium channels, TASK and TREK-1, leading to membrane 
hyperpolarisation (Patel et al., 1999).  While isoflurane reduces c-Fos expression, it 
does not alter primary afferent peptide release into the spinal cord as investigated by 
internalisation of the NK1 receptor for SP (Takasusuki et al., 2013). Takasusuki et al. 
suggested that while this result could implicate a role for non-peptidergic primary 
afferent activity accounting for the effects of general anaesthesia, it is more likely that 
general anaesthetics play a role in post-synaptic suppression of molecular nociceptive 
targets. Indeed, PERK is more rapidly activated than c-Fos mRNA and protein, peaking 
within 3 minutes following noxious stimulation in contrast to a 30min and 2h peak for c-
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Fos mRNA and protein respectively (Ji et al., 1999), a consideration which may be a 
factor for susceptibility to anaesthetic modulation.  
A study investigating the duration of isoflurane anaesthesia in the cerebral cortex 
showed significant differences in PERK activity in rats treated with short (2-5min) vs. 
long (>10min) anaesthesia (Takamura et al., 2008). Animals under anaesthetic for 
more than 10 minutes exhibited a reduced expression of PERK compared to those 
subject to the shorter duration. It is therefore of crucial note that in our experiments 
animals receiving formalin with anaesthesia were never subject to anaesthetic for 
longer than 10 minutes. The experiments by Takasusuki et al. (2013) indicate that rats 
received formalin stimulation after 10 minutes of inhalation anaesthetic which may 
explain the reduction of c-Fos nuclei that we did not see with PERK, implicating factors 
of depth and duration of anaesthesia on c-Fos expression which have been previously 
investigated (Sommers et al., 2008). However, if isoflurane anaesthesia did have an 
inhibitory effect on spinal PERK in Experiment 3, it would suggest that the 50µl, 2% 
dose of formalin caused a greater induction of PERK than the 20µl, 5% dose injected 
without anaesthesia, which would be a logical explanation for the equal activation of 
spinal PERK caused by the two conditions. 
Additional evidence from work in this lab has indicated that the two conditions of 
formalin stimulation presented in this chapter, while causing equal activation of spinal 
PERK, cause differential activation of PERK in the rostral anterior cingulate cortex 
(rACC) (Tochiki KK, unpublished observations). 
6.4.5 Future experiments required 
In Experiment 2, the inhibition of MSK1 on formalin behaviour requires a control study 
confirm that SB747651A does not impair motor function which could have interfered 
with the nocifensive behaviours measured (1. Time spent licking and flinching, and 2. 
Number of flinches). A few possible protocols are being considered, including the 
measurement of locomotor activity (i.e. open field experiment or home cage activity 
monitoring), motor coordination (i.e. rotarod), or motor function (i.e. 
suspension/gripping, stepping, or pulling tests).  
6.4.6 Conclusion 
In summary, the results in this chapter are the first to elucidate, at least in part, the key 
downstream players contributing to ERK/MAPK regulation of the nociceptive 
behavioural response to injury, PMSK1 and PH3S10.  
Specifically, results from this chapter indicate that: 
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 Formalin-induced PMSK1 and PH3S10 are downstream of PERK, and can be 
reduced by the MEK inhibitor, SL327 
 
 MSK1 activity blocked by SB747651A contributes to the development of central 
sensitisation and full expression of formalin-induced nocifensive behaviour, 
possibly via direct manipulation of PH3S10 and other downstream targets  
 
 The administration of formalin in two varying conditions (50µl, 2% with general 
anaesthesia vs. 20µl, 5% no anaesthesia) shows no difference in spinal cord 
activation of molecular targets, specifically PERK expression 
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7.1 Introduction 
Chronic pain remains a major clinical problem, with nearly 1 in 5 adults in Europe 
having experienced moderate to severe chronic pain in their lifetime, and a further 40% 
reporting inadequate pain management (Breivik et al., 2006). The statistics 
undoubtedly illustrate that identification of novel pharmacological targets for the 
treatment of chronic pain remains essential, and raises the possibility of targeting 
epigenetic mechanisms as a valid option.  
The aim of this thesis was to investigate the role of histone modifications, specifically 
histone phosphorylation, in nociceptive processing. Phosphorylation of histone H3 at 
serine 10 (PH3S10), is known to be specifically engaged by ERK/MAPK signalling 
during memory formation, a process which requires similar cellular activity to that seen 
in sensitised states following injury (Ji et al., 2003). PH3S10 was therefore a particular 
modification of interest given the importance of ERK/MAPK signalling in nociceptive 
processing (Ji et al., 1999). Using a combination of molecular and behavioural 
techniques, in addition to pharmacological blocking of signalling pathway components, 
I have demonstrated that MSK1 regulates the nociceptive response, and may do so 
through chromatin remodelling induced by PH3S10. 
Deregulation of histone acetylation in human disease states such as cancer cells has 
long been known, and therapeutic treatment with HDAC inhibitors has attracted much 
attention in clinical practice (Wee et al., 2014). Deregulation of epigenetic processes 
are now associated with a broad spectrum of neurological disorders and activity 
induced-changes in neural plasticity, including schizophrenia, depression, addiction, 
neurodevelopmental disorders, and neurodegenerative disease (Deutsch et al., 2008; 
Qureshi and Mehler, 2010). Moreover, epigenetic processes are engaged in and 
essential to normal cognitive functions including the formation of short and long-term 
memories, and can even be targeted to enhance such processes (Barrett and Wood, 
2008; Day and Sweatt, 2011, 2010; Gräff and Tsai, 2013; Peixoto and Abel, 2013). 
Furthermore, evidence from identical twins studies has clearly demonstrated that 
epigenetic mechanisms are responsible for activity or experience-dependent responses 
of the nervous system, as individuals with identical sets of DNA can have vastly 
different phenotypical outcomes with regard to disease (Nielsen et al., 2012). 
Consequently, it seems highly likely that environmental experience (such as prior injury, 
stress) in addition to genetic vulnerability, would contribute to lasting alterations in 
sensory processing and more specifically susceptibility to the development of chronic 
pain (Géranton and Tochiki, In press). 
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To date, only a handful of pain studies have shown that nociceptive processing 
engages epigenetic processes such as histone modification and DNA methylation in 
various structures along the pain pathways including the DRG, dorsal horn, and RVM, 
primarily using animal models (Figure 7.1, Figure 7.2). However, recent work in human 
subjects has demonstrated that altered responses to thermal stimuli correlated with 
gene-specific DNA methylation levels of TRPA1 in the blood (Bell et al., 2014). The 
growing body of evidence for a key role of epigenetic mechanisms in nociceptive 
processing has pointed to the possibility of therapeutically targeting these mechanisms 
for clinical pain management (Doehring et al., 2011). Furthermore, the necessity of fully 
functioning epigenetic mechanisms for long-term synaptic plasticity and modulation of 
gene expression indicates a potential key role for epigenetic mechanisms underlying 
long-term pain states. 
The few studies investigating histone modifications in nociceptive processing are 
similar to studies of learning and memory in that they have largely focused on histone 
acetylation due to the wide availability of HDAC inhibitors. The literature indicates 
strongly through the use of HDAC inhibitors that histone acetylation plays a functional 
role in nociception, but outcomes are not entirely straightforward and vary according to 
pain model and method of drug administration (Figure 7.1). Generally, when given pre-
emptively, HDAC inhibitors have successfully attenuated hypersensitivity associated 
with both inflammatory and neuropathic pain; however, reversibility of hypersensitivity 
remains limited (Bai et al., 2010; Denk et al., 2013). The hindpaw plantar incision 
model is one exception not under the same influence of HDAC inhibitors, as 
administration has no effect on thermal hypersensitivity, and has actually been found to 
exacerbate mechanical hypersensitivity (Sun et al., 2013). It is important to note that 
the aforementioned studies tested the behavioural effects of HDAC inhibition in 
inflammatory and neuropathic pain models without first identifying injury-induced 
changes to the epigenome. While these studies showed that global or locus-specific 
histone acetylation levels expectedly increased after delivery of HDACi (Bai et al., 
2010; Chiechio et al., 2009; Denk et al., 2013; Matsushita et al., 2013; Sun et al., 2013; 
Zhang et al., 2011), other studies have initially focused on injury-induced deregulation 
of the epigenome itself by looking at histone modification and DNA methylation pattern 
changes post-injury, or altered levels of enzymatic machinery (Figure 7.2). Indeed, 
histone acetylation levels have been found to be deregulated after plantar incision, CCI, 
and chronic morphine-induced sensitivity (Liang et al., 2013; Sun et al., 2013; Zhu et al., 
2014), and studies have also found that HDAC and HAT expression levels are altered 
following SNI, CFA-ankle joint inflammation, and CCI (Tochiki et al., 2012; Zhu et al., 
2012). In some studies, pharmacological targeting of these marks was only attempted 
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after alterations in the epigenome were identified, and this was the particular approach 
taken in this thesis.  
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Figure 7.1 Pharmacological targeting of histone modifications to modify pain states. Various studies have investigated the effects of drugs targeting 
HDACs, HATs and DNMTs in the treatment of pain states. Source: Géranton and Tochiki (In press).
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Figure 7.2 Epigenetic marks and machinery modified after injury. A handful of studies have 
investigated changes in the epigenome and epigenome modifying enzymes following injury. 
Source: Géranton and Tochiki (In press). 
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7.2 Summary of Findings 
For a concise summary of the main findings in this thesis, please see Figure 7.3. 
7.2.1 Peripheral noxious stimulation induces histone phosphorylation in the 
spinal cord 
Previous studies have indicated aberrant histone acetylation in the dorsal horn 
following injury (Figure 7.2). Profiling of the dorsal horn for alterations in histone 
modifications in Chapter 3 indicated that formalin stimulation did not change histone 
acetylation levels in the dorsal horn at 1h in contrast to a clear ipsilateral upregulation 
of a small number of cells expressing histone phosphorylation (PH3S10). Interestingly, 
expression of histone acetylation (various residues on H3, H4) appeared to be more 
ubiquitous in spinal cord distribution compared to histone phosphorylation which 
followed a very restricted pattern of expression.  Positive staining of PH3S10 nuclei 
was upregulated in the ipsilateral superficial dorsal horn following formalin stimulation. 
Because PH3S10 is a globally expressed histone mark which presumably contributes 
to the regulation of chromatin structure at many loci, there were indeed low levels of 
PH3S10 immunolabelling within dorsal horn nuclei which were not quantified and 
considered here as background staining. It should be noted that this does not mean 
that background levels of PH3S10 should be ignored; in fact, techniques such as ChIP 
would enable the detection of PH3S10 associated genes (for example, c-Fos) that 
might not have been visible using IHC colabelling with candidate targets.  
Notably, the experiments in this thesis are not the first to implicate the importance of 
histone phosphorylation in acute activity-generated CNS responses. A study by Kumar 
et al. (2005) found that acute cocaine administration induced increases in H4 
acetylation as well as H3 phospho-acetylation (PH3S10-AcH3K14) at the c-Fos 
promoter in striatum. When H3 acetylation (K14) was investigated alone without the 
presence of H3 phosphorylation (S10), acute cocaine-induced increases at c-Fos were 
not observed. Interestingly however, a switch in histone upregulation occurred during 
chronic cocaine administration, which was associated with an upregulation of H3, and 
not H4 acetylation (at FosB, BDNF, and CdK5). Acute upregulation of H4 acetylation 
and H3 phospho-acetylation, and chronic upregulation of H3 acetylation has similarly 
been observed in acute and chronic seizure (Tsankova et al., 2004). 
Importantly, the ipsilateral upregulation of PH3S10 following injury is reminiscent of 
other molecular markers crucial to nociceptive processing that are unilaterally 
upregulated post-injury, such as PERK (Ji et al., 1999), c-Fos (Hunt et al., 1987), and 
PMeCP2 (Géranton et al., 2007). Similar to MeCP2, PH3S10 contributes to global 
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regulation of gene transcription (Crosio et al., 2003), and therefore the results 
described in Chapter 3 suggested that PH3S10 might be contributing to the regulation 
of a set of gene programmes essential to the development of pain states. 
7.2.2 Cellular characterisation of PH3S10 in the dorsal horn following noxious 
stimulation 
Chapter 4 experiments confirmed the presence of PH3S10 in neurons of the pain 
pathways as shown by colocalisation with PERK, NK1, c-Fos and Zif268, results which 
further implicated a role for PH3S10 in nociceptive processing. The immediate 
expression of PH3S10 within 5-10 minutes following formalin injection was very similar 
to the induction of PERK which is immediately present after noxious stimulation. 
However, in contrast to the maximal expression of PERK at 5 minutes (Ji et al., 1999), 
PH3S10 levels were found to peak around 30 minutes after injury. As it is well-known 
that PH3S10 lies downstream of PERK (Soloaga et al., 2003), the peak expression of 
PH3S10 fits in well with this sequence of signalling events. Furthermore, expression of 
c-Fos protein is known to peak at 2 hours post-injury (Hunt et al., 1987), again 
evidence suggesting that PH3S10 could regulate downstream gene programmes 
crucial to the nociceptive response, including c-Fos.  
The time course of formalin-induced PH3S10 showed the sustained expression of 
PH3S10 after injury. This prolonged upregulation indicated that PH3S10 has a unique 
role in nociceptive processing. While PERK expression largely disappears by 1h, 
PH3S10 levels are robust for at least 2h. The main function of PERK is presumably 
signal integration and relay of extracellular events (Kelleher et al., 2004; Kelleher et al., 
2004), while downstream PH3S10 expression may be more indicative of long-lasting 
post-synaptic changes (changes in gene expression). In the nucleus, histone 
modifications are known to play a pivotal role in the long-term effects of neural plasticity 
by modifying chromatin structure and enhancing or obscuring the accessibility of 
transcriptional machinery to DNA, acting together with other epigenetic factors to 
promote or silence transcription at key gene loci (Borrelli et al., 2008; Zocchi and 
Sassone-Corsi, 2010). These epigenetic factors can include other histone modifications, 
DNA methylation, and epigenetic readers such as bromodomains, which bind to 
monoacetylated lysine residues on histone tails, and DNA binding complexes such as 
MeCP2. 
Importantly, experiments in Chapter 4 allowed for the direct comparison of the PH3S10 
population size relative to PERK, c-Fos, and Zif268 populations after injury. The 
PH3S10 population was notably smaller and had a more limited distribution than PERK, 
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c-Fos, and Zif268 populations. Similar observations have been drawn by Rotllant and 
Armario (2011), who found that amphetamine administration induced more restricted 
patterns of PH3S10 expression  in areas of the brain key to addiction (nucleus 
accumbens, dorsal striatum) compared to c-Fos, which was more widely expressed 
throughout additional brain structures. The authors suggest that a restricted population 
of PH3S10 labelled neurons may indicate a unique and more specific role for PH3S10 
positive cells in amphetamine-induced neural activity. It is possible that this may also 
be the case for PH3S10 in the dorsal horn, and that the restricted pattern of PH3S10 
expression following injury may label neurons important in the response to noxious 
stimulation. 
Finally, Chapter 4 results also indicated that while noxious stimuli-induced upregulation 
of PH3S10 nuclei indeed appeared to be entirely neuronal, background levels of 
PH3S10 did colocalise minimally with glial markers APC CC1 and Iba1. This is not 
surprising as PH3S10 is also a well-known marker of mitotic cell division (Hsu et al., 
2000). Furthermore, it is entirely possible that injury-induced PH3S10 may be found to 
colocalise with glial markers if investigated using different pain models known to induce 
activation of the glial population, such as microglia in neuropathic injury (Tsuda et al., 
2013). Interestingly, formalin has been shown to cause an ipsilateral activation of 
phospho-p38 MAPK (pp38) in the dorsal horn as early as 30 minutes, and pp38 largely 
occurs in microglia (Li et al., 2010). However, no unilateral increase of Iba1 expression 
was seen, and colocalisation of PH3S10 with pp38 was not investigated. 
7.2.3 Descending serotonergic regulation of PH3S10 in nociceptive processing 
It was found in Chapter 5 that PH3S10 in the dorsal horn was reduced after depletion 
of descending serotonergic fibres from the RVM. 5,7-DHT-induced depletion of 
descending 5-HT has been shown to lead to a reduction in spinal formalin-induced 
PERK, Zif268, and PMeCP2 (Géranton et al., 2008; Svensson et al., 2006) and has 
implicated descending 5-HT as having an overall pronociceptive role onto dorsal horn 
activity. Taking these results into consideration, a reduction in PH3S10 further 
suggested a key role in nociception. 
7.2.4 Intracellular regulation of PH3S10 in nociceptive processing 
Crucially, experiments from Chapter 6 proved a role for MSK1 in nociception, and 
suggested that MSK1 may act via PH3S10 to modulate the development of central 
sensitisation, reflected by attenuation of nocifensive behaviour in the second phase of 
the formalin response (Fischer et al., 2014), following i.t. inhibition by SB747651A. The 
experiments firstly confirmed that both formalin-induced PMSK1 and PH3S10 were 
  Chapter 7 General Discussion 
183 
 
downstream of PERK, and secondly showed that inhibition of MSK1 led to a reduction 
in both PH3S10 expression and nociceptive behaviour caused by formalin. 
Although it is a well-known fact that ERK regulates nociceptive behaviour, ERK is 
known to have multiple downstream targets. Importantly, the experiments in Chapter 6 
managed to dissect out one of the downstream ERK/MAPK signalling cascades which 
significantly contribute to nociception, particularly via inhibition of MSK1.  
Similar to PH3S10 (and as mentioned in 7.2.2), the PMSK1 population was limited in 
size compared to PERK when investigated at 30 minutes. The PERK population was 
considerably larger than PMSK1, and there were many PERK positive cells that did not 
coexpress PMSK1 (Chapter 6, Experiment 1) suggesting a refinement of the signalling 
cascade at this particular step. However, experimental limitations regarding the time 
point investigating overlap should be noted, and other downstream targets of ERK not 
investigated here obviously cannot be ignored (i.e. Elk, Myc, RSK2).  
The expression of PERK in dorsal horn neurons does not necessarily indicate 
outcomes of activity-induced gene transcription, as PERK is also involved in many 
early activity-induced intracellular events such as post-translational modification of 
receptors (Slack et al., 2004; Zou et al., 2000). It is not known if there are specific 
factors determining whether extracellular stimulation is sufficient to induce lasting 
changes in gene transcription and protein synthesis post-synaptically. However, MSK1 
is the only kinase in the ERK/MAPK cascade that appears solely in the nucleus, and its 
positioning downstream of ERK could indicate that PMSK1 expression represents 
primary afferent activation of intracellular signalling sufficient to drive long-term nuclear 
changes contributing to nociceptive behaviour, and therefore potentially the 
development of chronic pain. The suggestion that PMSK1 may indicate a lasting 
outcome/consequence of extracellular activity is a striking one, as other studies have 
implicated MSK1 as having a key role in BDNF/MAPK signaling. Specifically, Correa et 
al (2012) suggest that MSK1 is the ‘apex’ of BDNF/MAPK signalling which is a 
molecular control determining the direction of neuronal output, and that MSK1 is a key 
homeostatic regulator of neural activity, implications which will be discussed in 7.4.  
Surprisingly, Chapter 6 results showed that MSK1 inhibition did not lead to a reduction 
in c-Fos expression in the dorsal horn. However, only a small reduction was expected, 
and it is entirely possible that IHC was insufficient at detecting a small reduction in c-
Fos following MSK1 inhibition with SB747651A. A more sensitive technique such as 
ChIP might have indicated a change in PH3S10 mediated c-Fos transcription after 
formalin stimulation. ChIP experiments in other studies have proven that there is a 
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functional link between PH3S10 and the c-Fos expression, in particular cocaine-
induced enrichment of PH3S10 at the c-Fos promoter has been observed in the brain 
(Brami-Cherrier et al., 2009). Investigating PH3S10-c-Fos associations using ChIP 
would be an important study contributing to the results in Chapter 6; it would also 
provide an important insight into other gene targets partially mediated by PH3S10 
activity. Please see 7.5 Future directions. 
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Figure 7.3 Summary of main findings in this thesis Box A) Expression of molecular targets investigated in the dorsal horn under naïve, injured, and injured-5-
HT-ablated conditions. Red box indicates area of investigation. Box B) Percentage colocalisation of formalin-induced PH3S10 population with markers of the pain 
pathways. Box C) Pharmacological inhibition of ERK/MAPK signalling by SL327 led to a reduction in formalin-induced PERK, PMSK1, and PH3S10. In a 
separate experiment, inhibition of MSK1 by SB747651A reduced PH3S10 and prevented the full expression of pain states. Horizontal arrows indicate no change 
in injury-induced expression of molecular targets following drug treatment. Black inhibitory symbols indicate reduction in injury- induced expression of target 
following 5,7-DHT ablation or drug treatment.
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7.3 MSK1: a key signalling molecule governing the post- synaptic 
structural plasticity underlying hyperalgesia and allodynia 
The induction and maintenance of central sensitisation requires a number of structural 
and functional changes post-synaptically, which can be separated into short-term post-
translational events, such as receptor subunit phosphorylation or trafficking (Carvalho 
et al., 2000; Chen and Roche, 2007; Lau and Zukin, 2007), as well as longer-term 
events which require gene transcription and synthesis of new protein, the same way 
that LTP can be distinguished by early- and late- LTP phases. Considering the 
importance of intracellular signalling in activity-dependent neural function, there 
appears to be a clear functional distinction between early signalling events responsible 
for immediate post-translational consequences of Ca2+ entry, such as PKA, PKC, and 
CaMKII signalling, which are known to converge upon ERK (Hu et al., 2003; Ji et al., 
2009), and further downstream signalling inclusive of ERK and MSK1. ERK and MSK1 
therefore integrate a number of signalling events, regulating the transduction of cell 
surface-to-nucleus communication and thus long-term translational consequences of 
plasticity  (Kelleher et al., 2004; Kelleher et al., 2004).  
The findings in this thesis suggest that MSK1 could be a regulator of the long-term 
events involved in central sensitisation. Studies have shown that at early time points 
after acute inflammation (Fang et al., 2002; Fang et al., 2003; Fang et al., 2003; 
Larsson and Broman, 2008), phosphorylation of the AMPAR GluR1 subunit is 
increased, indicating a preferential switch from GluR2 to GluR1 subunit expression, 
which results in Ca2+ permeability of AMPAR. The preferential expression for calcium 
permeable GluR1 AMPAR subunits has also been observed at later time points (3d) of 
longer-term persistent pain states induced by i.pl. CFA (Vikman et al., 2008) which 
suggests a role for MSK1 regulating gene expression and translation of the GluR1 
subunit. As previously discussed (Chapter 6), MSK1 has been shown to regulate the 
cell surface expression of AMPAR GluR1 and dendritic spine volume in the 
hippocampus, which has been suggested to occur via regulation of downstream target 
Arc/Arg3.1, a CREB-mediated IEG (Bramham et al., 2008; Chowdhury et al., 2006; 
Correa et al., 2012; Shepherd and Bear, 2011). Notably, it has been shown that 
Arc/Arg3.1 is acutely upregulated in the dorsal horn following inflammation or i.t. 
delivery of BDNF, and 70% of these cells were found to express enkephalin. 
Furthermore, Arc/Arg3.1 was observed in a small percentage of NK1 positive neurons 
(Hossaini et al., 2010).  
Finally, the literature indicates that MSK1 regulates nuclear epigenetic signalling events 
such as PH3S10 and CREB phosphorylation in other models of plasticity (Chwang et al. 
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2007 OTHERS). Studies have shown that CREB is, in fact, an effector of central 
sensitisation (Latremoliere and Woolf, 2009). CREB is phosphorylated by a variety of 
signalling events in the dorsal horn post-injury, and leads to the transcription of several 
genes including c-Fos, NK1, and TrkB (Ji et al., 2009; Kawasaki et al., 2004). Although 
the interpretations for the role of MSK1 are speculative, the evidence likely points to the 
fact that MSK1 is a key signalling molecule mediating the events occurring at the cell 
surface down to the nuclear level to regulate gene expression.   
7.4 MSK1: a key role in experience-dependent synaptic scaling?  
A few studies have implicated MSK1 in the long-term synaptic adaptation to prolonged 
neural activity caused by exposure to environmental enrichment (EE) (Correa et al., 
2012; Karelina et al., 2012). MSK1-/- mice fail to exhibit the upregulation of synaptic 
strength in response to EE. Specifically, MSK1-/- mice fail to demonstrate 
enhancements in EE-induced spine density, a process which is also known to occur in 
the dorsal horn following persistent activity induced by intraplantar CFA injury and is 
associated with hypersensitivity, albeit via a different signalling mechanism (Simonetti 
et al., 2013). The role of MSK1 as an adaptive response in the face of prevailing 
activity has important implications for MSK1 signalling in long-term pain states and 
chronic pain, although without conclusively testing this function in an appropriate model 
such as a model of persistent or neuropathic pain, is merely speculative (Figure 7.4). 
Others have also shown that MSK1 is necessary for adjustments in synaptic strength in 
models of homeostatic synaptic plasticity. Correa et al. (2012) used cultures from 
MSK1-/- mice to elucidate a role for MSK1 in a paradigm which demonstrates the 
ability of neurons to regulate firing activity either via network activity (circuit activity),  or 
intrinsically, such as via insertion of ion channels that would cause changes in neural 
excitability (Correa et al., 2012; Turrigiano, 2011). Specifically, the role of homeostatic 
synaptic plasticity is to prevent runaway excitation or enhance neural activity in 
prevailing Hebbian synaptic activity such as LTP or LTD (Turrigiano, 2011). The 
experiments in this thesis focused on the induction phase of central sensitisation, and 
MSK1 was not investigated during the maintenance phase. Therefore, the role of 
MSK1 as a key homeostat requires further investigation in inflammatory pain states. 
However, it might be interesting to consider the role of MSK1 as a homeostatic 
regulator within dorsal horn circuits during the recovery phase from inflammatory 
responses, or in long-term pain states. Homeostatic compensatory activity has usually 
been demonstrated as occurring several hours or longer after activity enhancement or 
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deprivation, and MSK1 may have wider implications in the long- term response to 
chronic pain states within dorsal horn circuits.  
Finally, although we could not confirm that c-Fos was under the control of MSK1 
signalling following injury, if the main function of MSK1 in dorsal horn signaling is as a 
homeostatic regulator (albeit not in the induction phase of inflammation), it is also 
possible that MSK1 could also control late response gene programmes crucial to the 
homeostatic response at the circuit-wide level. A recent publication by Spiegel et al. 
(2014) has identified an immediate early gene, Npas4, which is upregulated in both 
excitatory and inhibitory cortical neurons following neuronal activity. Crucially however, 
Npas4 differentially activates non-overlapping late-response gene programmes in 
inhibitory and excitatory neurons such that excitatory synapses are expressed on a 
specific set of inhibitory neurons (SST positive), thereby promoting GABAergic release, 
while regulating inhibitory synapses on excitatory neurons (Lin et al., 2008). Overall, 
the differential activation of late-response gene programmes work to balance overall 
network activity. Interestingly, Spiegel et al. (2014) suggest that epigenetic 
mechanisms, including histone modifications, could be responsible for the cell-type 
specific distinct activation of gene programmes downstream of global Npas4 
upregulation, which may have interesting implications for PH3S10. Preliminary 
experiments indicate that Npas4 is colocalised within dorsal horn superficial laminae 
following noxious stimulation (Hunt SP and Lammertse H, personal communication). 
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Figure 7.4 MSK1 could play a role in short and long-term pain states.  
7.5 Future directions 
7.5.1 Investigation into MSK1 targets and PH3S10-associated genes 
Experiments in this thesis indicated that MSK1 regulates nociceptive behaviour, 
potentially via PH3S10. Chapter 6 results showed that reducing PH3S10 by MSK1 
inhibition did not lead to a reduction in c-Fos nuclei, as was expected following a 60% 
colocalisation of PH3S10 with c-Fos (Chapter 4). The lack of significant change in c-
Fos expression in this case does not necessarily eliminate the possibility that c-Fos is 
regulated by MSK1, and could have been a limitation of the IHC technique used for this 
analysis to detect the expected small changes in c-Fos expression. Furthermore, IHC 
could have only indicated correlative results for the relationship of c-Fos to that of 
PH3S10. In order to determine whether PH3S10 may functionally contribute to c-Fos 
gene regulation, it would be necessary to investigate locus specific enrichment of the c-
Fos gene with PH3S10 following peripheral formalin stimulation using a chromatin 
immunoprecipitation experiment (ChIP). 
A ChIP experiment could reveal PH3S10/c-Fos associations that would have gone 
unseen with the limited analysis provided by IHC. Incidentally, if PH3S10 was specific 
to the regulation of c-Fos, this would possibly remain unidentified using IHC as 
PH3S10 would be upregulated only at the c-Fos locus. As there is only one copy of the 
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c-Fos gene within each neuronal nucleus, PH3S10 might not appear strongly enough 
to label the entire nucleus, as was the appearance of the nuclei quantified/counted in 
this thesis. In fact, it is quite possible that the PH3S10 population described in this 
thesis could actually indicate that PH3S10 in these neurons is less specific to the 
nociceptive response, in that PH3S10 could be aiding transcription of a multitude of 
genes, not all of which may be specifically related to nociception. However, the set of 
gene programmes activated by PH3S10 could be specific to the nociceptive response. 
It is therefore worth considering deep sequencing techniques such as ChIP-sequencing 
(ChIP-seq) which could identify the main gene targets of PH3S10 regulation following 
injury. The other option would be to use ChIP followed by qPCR to investigate the 
association of PH3S10 and other candidate genes in addition to c-Fos. Discussions 
arising from the results in this thesis suggest that Arc/Arg3.1, CREB, FKBP5, Npas4, 
and Zif268 could all be worthy targets of investigation (Géranton et al., 2007; Hossaini 
et al., 2010; Ji and Rupp, 1997; Soloaga et al., 2003; Spiegel et al., 2014). 
7.5.2 Inhibitory/excitatory interneuron populations 
The identification of a neuronal subtype for PH3S10 is another approach that could 
have helped to understand its function in nociception within the dorsal horn circuit. 
There are a number of glutamatergic excitatory markers that could be tested for 
colocalisation with PH3S10, including neuropeptides somatostatin (SST), neurotensin, 
calretinin, SP, NKB, and calretinin, provided they label cell bodies (Todd, 2010). 
Glutaraldehyde perfusion to optimise staining for GABAergic interneurons is another 
possibility. An additional technique to identify inhibitory interneurons would be to 
acquire genetically modified mice with a green fluorescent protein (GFP) reporter for 
GAD (GAD-GFP mice) to label GABAergic cells, and to double stain the spinal cord 
tissue with PH3S10 following noxious stimulation. This approach however, would 
require re-characterisation of formalin-induced PH3S10 expression in mice (e.g. cell 
specificity, colocalisation with markers of the pain pathway, time course expression). 
7.5.3 Investigation of MSK1 as a regulator of homeostasis using hyperalgesic 
priming models 
Animal models of hyperalgesic priming have been suggested to reproduce events 
responsible for the transition from acute to chronic pain, specifically due to the fact that 
an initial injury can lead to a state of sensitisation which resembles clinical situations for 
human increased risk of developing chronic pain (Reichling and Levine, 2009). After full 
behavioural recovery to a minor insult (typically peripheral inflammation with IL-6, 
carrageenan, or surgical incision), animals become ‘primed’ and maintain a lasting 
latent hyper-responsiveness to any subsequent injury (PGE2, carrageenan, or another 
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surgical insult) (Aley et al., 2001; Bogen et al., 2012; Dina et al., 2008; Parada et al., 
2005, 2003; Sun et al., 2013). As MSK1 has been implicated as a key homeostat in 
models of lasting plasticity (hours to days) (Correa et al., 2012), it would be interesting 
to use MSK1-/- mice in a model of hyperalgesic priming to investigate the role of MSK1 
in a long-term sensitised state. The hypothesis would be that MSK-/- animals would fail 
to exhibit a typical response seen with primed animals; if MSK1 is to maintain balance 
of a sensitised state the MSK-/- mice could either exhibit more sensitivity than a normal 
primed response, or conversely could be hyposensitive. 
7.6 General Conclusions 
A growing body of evidence exists, not just within the pain field, to support the role of 
epigenetic mechanisms as potential targets for pain management. Human twin and 
animal studies have clearly indicated that epigenetic mechanisms can be differentially 
engaged by environmental experience, such as that experienced in early life (stress), 
or in adulthood (learning, addiction) (Borrelli et al., 2008; Renthal and Nestler, 2008; 
Weaver et al., 2004), and are even robust e250nough to encode behavioural 
information across generations (Dias and Ressler, 2013; Heard and Martienssen, 
2014). The unique feature of epigenetic mechanisms is the ability to bridge the genome 
and the environment, and the ability to imprint a variety of activity-dependent 
experiences onto the genome (the epigenome) (Day and Sweatt, 2011; Lester et al., 
2011; Sweatt, 2013). Specifically, epigenetic mechanisms refine neural networks 
according to experience and can allow the environment to elicit life-long biological 
changes in both gene expression and behaviour. The potential diversity of behavioural 
manifestations due to the same epigenetic processes easily highlights the fine balance 
that is required of these marks on the epigenome to maintain normal neural function. 
Epigenetic processes have been shown, in part by experiments in this thesis and by 
others, to be engaged in both the induction phase as well as the maintenance phase of 
persistent pain states. In states of chronic pain, spinal cord nociceptive networks 
remain sensitised with long- lasting changes in gene expression and synaptic strength 
(Kuner, 2010), and could be regarded as a form of nociceptive memory (Sandkühler 
and Lee, 2013). It is therefore plausible that chronic pain states- in particular the events 
responsible for the transition from acute to chronic pain states- involve a specific 
epigenetic code, or possibly a contribution of epigenetic processes (Géranton and 
Tochiki, In press). Targeting epigenetic mechanisms could be a promising approach for 
the treatment of pain states; however, identifying the defining specific epigenetic events 
leading to, or involved in chronicity are key. Furthermore, as global regulators of gene 
transcription, pharmacological inhibition of epigenetic mechanisms may benefit from 
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refinement in the form of enzyme subtype inhibitors, or target specificity, particularly at 
the level of the genome. The targeting of epigenetic mechanisms should also be 
considered contextually, as they are sure to act in concert with a multitude of molecular 
events to regulate neural function. The findings in this thesis demonstrate that histone 
phosphorylation and histone modifying enzymes can be targeted pharmacologically to 
alter nociceptive behaviour and indicate a potential for epigenetic mechanisms as 
targets of reversibility. Furthermore, the outcomes of this thesis continue to justify the 
investigation into a relatively new research area which continues to increasingly gain 
crucial attention. 
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Appendix 
Solutions 
Immunohistochemistry 
 
TTBS (1L) (All Sigma, UK) 
0.05M (v/v) Tris HCl  
0.3% (v/v) Triton X-100 
0.9% (w/v) NaCl 
 
Western Blot 
 
TX Homogenisation Buffer (All Sigma, UK) 
50 mM Tris HCl        
150 mM NaCl        
2 mM EDTA         
1% (v/v) Triton X100 
 
TX Resuspension/Lysis Buffer  
TX Buffer + 0.2M HCl 
 
CHAPS Buffer (All Sigma, UK) 
10mM Tris pH 8.0 
5mM Magnesium Acetate 
8M urea 
4% CHAPS 
 
Loading Buffer 
0.267M DTT  
66.6% (v/v) NuPage LDS 4X loading buffer (Life Technologies, UK) 
 
MOPS Running Buffer (All Sigma, UK) 
0.05M 3-(N-Morpholino) propane sulphonic acid (MOPS)  
0.05M Tris Base  
3.5mM SDS  
1mM EDTA 
 
Transfer Buffer (All Sigma except methanol) 
48mM Tris Base 
39mM Glycine 
0.037% (v/v) SDS 
10% (v/v) Methanol (VWR, UK) 
 
iBlock  
0.24% (w/v) iblock (Tropix/Applied Biosystems, UK) 
1% Tris HCl (v/v) 
0.15M NaCl 
0.05% (v/v) Tween 20 
 
 
PBS-Tween 
0.1% (v/v) Tween 20 
0.1M PBS 
